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Due to their rising popularity, herbal supplements have created a specific niche 
for themselves between the food and the drug industry.  Due to their categorization as 
dietary supplements, they lack scientific seriousness where as on the other hand they act 
like unregulated drugs with potential effects.  Finding scientific data of questionable 
accuracy for herbal supplements is not uncommon, which is usually designed to sell 
products rather then provide unbiased information.  Hence, development of performance 
standards based on the bioavailability of the active components of herbal extracts 
promises to be an attractive solution towards regulating the inflow of meaningful 
products in the herbal supplement market.  Solubility, partition coefficient and 
permeability are the fundamental properties for studying drug absorption.  Top selling 
herbal extracts from the United States that included Kava, Ginkgo biloba, Milk thistle, 
Ginseng, Black cohosh, Garlic, Valerian, and Echinacea were selected and in silico 
descriptors such as CLogP, minimal cross-sectional area, polar surface area and in vitro 
 vii
permeability using the Caco-2 cell model and SimBioDAS® of their active components, 
determined.  Based on the interparameter relationships between the minimal cross 
sectional area, CLogP, polar surface area and the in vitro permeability of the active 
components, bioavailability/bioequivalence markers were predicted for Kava, Ginkgo 
biloba and Milk thistle.  Kawain was predicted as a marker for Kava, Ginkgolide B for 
the ginkgo terpenes and quercetin for the flavonol glycosides in Ginkgo biloba and 
silycristin as a marker for Milk thistle (silymarin).  Silymarin comprising of isomers 
silycristin, silydianin, silybin A, silybin B, isosilybin A and isosilybin B was selected as a 
representative extract for further confirmation of marker prediction.  Equilibrium 
solubility, experimental octanol-water partition coefficient values, and assay and in vitro 
dissolution profiles were determined for each of the active isomers in extract and market 
products respectively.  The pharmacokinetics and absolute bioavailability of each of the 
active isomers was determined in male Sprague Dawley rats following intravenous and 
oral administration of the silymarin extract.  Equilibrium solubility values indicated that 
all the silymarin isomers were practically insoluble, and silycristin and silydianin had 
relatively higher solubility values as compared to the other isomers.  Experimental 
partition coefficient values correlated with the predicted partition coefficient (CLogP) 
with an r2 of 0.834.  Based on their equilibrium solubility and the partition coefficient 
(experimental and predicted) the active isomers were classified according to the 
Biopharmaceutic Classification System (BCS).  Thus, isomers silybin A, silybin B, 
isosilybin A and isosilybin B were classified as Class II compounds (High Permeability-
Low Solubility) where as silydianin was classified as a Class IV compound (Low 
Permeability-Low Solubility).  Silycristin was classified as a intermediate between Class 
II and Class IV.  Absolute bioavailability (F) for silycristin was found to be the lowest 
(0.15±0.1), followed by silybin A (0.20±0.04) followed by silybin B (0.62±0.08).  
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Silycristin being one of the least permeable and bioavailable component, was selected as 
a marker for silymarin, further confirming its prediction based on the correlations 
between the in silico descriptors and in vitro permeability.  Pharmacokinetic parameters 
such as area under the curve, half life, volume of distribution, clearance and F for the 
components suggest significant differences between not only the silymarin isomers but 
also diastereomers of silybin (A and B) and isosilybin (A and B).  Selection of 
bioavailability-bioequivalence markers, based on their least permeability/bioavailability, 
proves to be the most conservative and meaningful approach towards standardization of 
complex mixtures such as herbal extracts and supplements. 
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STATEMENT OF OBJECTIVES AND SIGNIFICANCE OF 
RESEARCH 
 
This dissertation is a result of an effort to establish the inter-relationships between 
in silico-in vitro -in vivo parameters that may help predict and select bioavailability and 
bioequivalence markers for herbal supplements.  
The study was initiated with the following specific aims: 
1. Selection of herbal extracts based on highest retail sales in the United States, 
whose active components would collectively span a wide range of molecular 
weight and show structural diversity. 
2. Estimation of molecular descriptors such as the polar surface area, minimal cross 
sectional area and predicted octanol water partition coefficient for each of the 
active components in the selected herbal extracts. 
3. Determination of in vitro permeability of the active components using the Caco-2 
cell model or SimBioDAS,® both of which are epithelial cell based permeability 
assays. 
4. To qualitatively predict markers for select herbal extracts (Kava, Ginkgo biloba, 
Milk thistle), that could have the least intestinal permeability by studying the inter 
parameter relationships between the in silico descriptors and the in vitro 
permeability of all the active compounds.  Selection of a representative extract 
(Milk thistle) for the verification of marker prediction by in vitro and in vivo 
experiments. 
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5. To determine the solubility, apparent octanol-water partition coefficient and assay 
for content uniformity , in vitro dissolution profile of the active isomers in Milk 
thistle extract and select market formulations, respectively. 
6. To determine the pharmacokinetic parameters and absolute bioavailability of the 
isomers after intravenous and oral administration of the extract in male Sprague 
Dawley rats. 
7. To select the least bioavailable compound as a bioavailability and bioequivalence 
marker for that herbal extract, in an effort to verify the prediction obtained from 
the inter parameter relationships between the in silico descriptors and in vitro 
permeability. 
 
The steady increase in sales on one side, and new reports, and experiments 
questioning their safety, efficacy and regulation on the other side, herbal extracts and 
supplements now demand scientific attention similar to synthetic drugs.  Herbal extracts 
are complex mixtures with more than one active component, the pharmacologic effect of 
which is usually synergistic in nature.  This is further complicated by large variations in 
the amounts of active components present in market formulations of the same extract 
having the same label claim.  Therapeutic efficacy is proportional to the amount of drug 
at the action site within the therapeutic index, and drug reaching the systemic circulation 
(bioavailability) is an estimate of the amount of drug reaching the action site.  
Conducting routine bioavailability/bioequivalence tests for each active compound in a 
herbal extract is a tedious or a near impossible task.  Thus, selection of a marker that 
represents the bioavailability of its extract is necessary for the biopharmaceutic 
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characterization of any herbal extract.  Solubility, partition coefficient and intestinal 
permeability are the fundamentals of oral absorption and use of in silico and in vitro 
methods to predict intestinal permeability gives a certain directional focus in the process 
of marker selection.  Selection of a compound that has the least intestinal permeability or 
bioavailability assures bioavailability of the rest of the active compounds in the extract 
and hence is the most conservative approach towards the biopharmaceutical 
characterization of herbal supplements.  If implemented in practicality by Federal Law, 
bioequivalence studies based on marker selection can make a significant impact on the 
inflow of safe and biopharmaceutically relevant  herbal supplements in to the American 
market. 
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CHAPTER 1:  HERBAL SUPPLEMENTS: A Brief Background 
1.1:  HISTORY 
 
“Life is short, the art long, the opportunity fleeting, the experiments 
treacherous, and judgment difficult.”  
                                                                      –Aphorisms i.1, Hippocratic Corpus 
Hippocrates (460-377 B.C) 
The above quote by Hippocrates holds so much meaning when we think of 
standardization of herbal extracts and herbal drug products.  According to the Hippocratic 
Corpus, Hippocrates himself is known to have worked on nearly 200 herbs in his life 
time.  Herbal medicine or herbalism dates back over 5,000 years to the Sumerians, who 
described well established medicinal uses for plants such as laurel, caraway, and thyme.  
The first known Chinese herb book, dating back to about 2700 B.C., lists 365 medicinal 
plants and their uses, including ma-Huang, the shrub that introduced the drug ephedrine 
to modern medicine.  There is evidence from the Shanidar Caves in Iraq that suggests 
Neanderthals living 60,000 years ago used medicinal plants. A body unearthed there had 
been buried with eight species of plants that are still widely used in ethno-medicine 
around the world. [1, 2]  Medicinal herbs found amongst the personal effects of an "Ice 
man" whose body was frozen in the Swiss Alps for more than 5,300 years, appear to have 
been used to treat the parasites found in his intestines. [3] 
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Herbal remedies have become a major component of individual health care, and 
botanicals like Ginseng, Ma-Huang, Ginkgo, St. John’s Wort, and many more have 
become household names throughout the world.  Herbalism is a significant category in 
alternative medicine which includes other treatments such as acupuncture, folk 
medicines, mind-body techniques, homeopathy, psychic healing, and many more.  The 
use of herbs to treat disease is almost universal among non-industrialized societies.  
Millions of people in the third world have used and will continue using herbal medicines 
because they believe in them and regard them as “their” medicine in contrast to allopathy, 
introduced to them from the outside world.  These beliefs are further strengthened by the 
notion that herbs are natural and thus safe, and without any adverse effects.  They are 
usually available locally and prescribed by traditional practitioners of medicine who are 
part of the community and in whose presence the patient feels comfortable.  On the 
European and American side, use of herbal medicines is increasing rapidly mainly 
because of a belief that powerful synthetic agents can exert unwanted side effects, and are 
often used indiscriminately and irrationally.   
 
1.1.1:  Complimentary and Alternative Medicine 
The National Centre for Complimentary and Alternative Medicine (NCCAM), a 
part of the National Institutes of Health (NIH), classifies complimentary and alternative 
therapies into five different categories or domains:  
1. Alternative Medical Systems 
2. Mind-Body intervention 
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3. Biologically Based Therapy 
4. Manipulative and Body Based Methods 
5. Energy Therapy 
Aside from being more educated and more likely to report their health status, a 
majority of alternative medicine users appear to turn to it not so much because they feel 
dissatisfied with conventional medicine, but largely because they find these health care 
alternatives more congruent with their own values, beliefs, and philosophical orientations 
toward health and life.  
According to a survey by Eisenberg et al. [4] and Barnes et al. [5] published in 
1998 and 2002 respectively, the following are the most commonly used complementary 
therapies: 
Table 1.1: Most commonly Used Complimentary Therapies in the United States 
1997-98 2002 
Prayer Prayer 
Mind-Body Techniques Herbs and Supplements 
Herbs and Supplements Mind-Body Techniques 
Massage Chiropractic 
Chiropractic Yoga 
Diet Therapies Massage 
Energy Healing Diet Therapies 
Acupuncture Acupuncture 
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The survey conducted by Barnes et al. involved 31,044 adult participants (>18 
years of age) and they reported that 36% of these participants used one or more than one 
complimentary and alternative medicine (CAM) therapy (prayer excluded) and 62% used 
one or more than one CAM therapy prayer included. [5] 
 
The following is a brief description of the various therapies mentioned above: 
Mind-Body Techniques:  Mind-body techniques or medicine focuses on the 
interactions between the brain, mind, body, and behavior, and on the powerful ways in 
which emotional, mental, social, spiritual, and behavioral factors can directly affect 
health. [3] It regards as fundamental an approach that respects and enhances each person's 
capacity for self-knowledge and self-care, and it emphasizes techniques that are grounded 
in this approach.  Mind-body medicine focuses on intervention strategies that are thought 
to promote health, and typically include techniques such as:  
• Relaxation 
• Hypnosis and Visual Imagery  
• Meditation:  A conscious mental process using techniques, such as 
focusing attention or maintaining a specific posture, to suspend the stream 
of thoughts and relax the body and mind.   
• Yoga: A practice from Ayurvedic medicine that combining breathing 
exercises, physical postures, and meditation that is intended to calm the 
nervous system and balance the body, mind, and spirit.  
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• Biofeedback:  Use of electronic devices to help people learn to control 
normally subconscious body functions, such as breathing or heart rate with 
the intent of promoting relaxation and health improvement.  
• Tai-chi, Qi-Gong: A component of traditional Chinese medicine that 
combines movement, meditation, and controlled breathing. The intent is to 
improve blood flow and the flow of qi.  
• Cognitive-behavioral therapies, Group support, Autogenic training, Prayer 
and Spirituality  
 
Mind-body interventions constitute a major portion of the overall use of 
Complimentary Alternative Medicine (CAM) by the public. In 2002, mind-body 
techniques, including relaxation techniques, meditation, biofeedback, and hypnosis, were 
deemed to be used by about 17 percent of the adult U.S. population. Prayer was deemed 
to be used by 45 percent of the population for health reasons. [5] 
 
Acupuncture:  There are over 350 acupoints on the meridians of the body.  
Selected points are stimulated by inserting fine acupuncture needles to improve the flow 
of chi in the meridians and to restore balance and healthy functioning to the internal 
functioning of the body.  Treatment points are selected on the basis of pulse and tongue 
diagnosis, examination and questioning and categorized according their effects on 
specific body systems and organs.  The insertion of needles is quick and virtually painless 
and often a comfortable and relaxed feeling follows. [6]  
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Chiropractic Medicine:  Chiropractic, derived from two ancient Greek words 
meaning “manually effective” is technically defined as the diagnosis, treatment and 
rehabilitation of conditions that affect the neuromusculoskeletal system.  The technique 
was invented by Daniel Palmer in 1895, when he treated his office janitor for deafness, 
by realigning some small bones in his spine.  Through a series of special examination and 
manipulative techniques, chiropractors can diagnose and treat disorders associated with 
nerves, muscles, bones and joints of the body. [6] 
Diet Therapies:  Diet therapy has been practiced for centuries dating back to 
Hippocrates, who wrote extensively about the therapeutic use of diet.  Most alternative 
therapists believe that everybody can benefit from dietary self help for both prevention 
and treatment of disease.  Diet-based therapy uses a variety of diets in order to improve 
health and longevity, to control weight, and to treat specific health conditions such as 
high cholesterol.  Some different types of diet therapies are: Breatherian, Fruitarianism, 
Vegan, Ovo-lacto-vegetarian, Low-fat diet, Low-carb diet, Okinawa diet etc. [6] 
Energy Healing:  Energy healing or energy therapies are alternative treatments 
that involve the use of purported energy fields. Some examples of this therapy are: 
Magnet therapy, Medical Qigong, Reiki, Shiatsu, Therapeutic Touch, and The W.I.S.E. 




1.1.2:  Dietary supplements  
In the United States, a dietary supplement is a product taken by mouth that 
contains a "dietary ingredient" intended to supplement the diet. The "dietary ingredients" 
in these products may include: vitamins, minerals, herbs or other botanicals, amino acids, 
and substances such as enzymes, organ tissues, glandulars, and metabolites. Dietary 
supplements can also be extracts or concentrates, and may be found in many forms such 
as tablets, capsules, softgels, gelcaps, liquids, or powders. They can also be in other 
forms, such as a bar, but if they are, information on their label must not represent the 
product as a conventional food or a sole item of a meal or diet. Whatever their form may 
be, DSHEA places dietary supplements in a special category under the general umbrella 
of "foods," not drugs, and requires that every supplement be labeled a dietary 
supplement. [6, 7] 
The European Union has a similar definition for dietary supplements, but with the 
implementation of the food supplements directive, the European Union Directive on 
dietary supplements now reclassifies vitamin supplements as medical drugs and mandates 
low dosage levels of certain vitamins which are essential only in small quantities (eg. 
Vitamin A).  Consequently, only those supplements that have been proven to be safe may 
be sold without prescription. [8] 
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1.2:  HERBAL SUPPLEMENTS 
1.2.1:  Definition and Overview 
According to Congress, a herbal supplement is considered as a dietary supplement 
consisting of an herb, or concentrate, constituent, extract, or combination of any botanical 
intended for ingestion as a tablet, capsule or liquid and is not represented for use as 
conventional food or as a sole item for a meal or diet and is labeled as a dietary 
supplement. [7] Scientifically, herbal supplements are crude extracts or semi-purified 
extracts manufactured to contain a definite amount of a particular constituent or a group 
of constituents, which are called marker compound(s).   
According to the European pharmacopoeia, herbal drugs are mainly whole, 
fragmented or cut plants or parts of plants, algae, fungi, lichen in an unprocessed state, 
usually in a dried form but sometimes fresh.  Certain exudates that have not been 
subjected to a particular treatment are also considered to be a herbal drug.  Herbal drugs 
are precisely defined by their botanical scientific name according to the binomial system. 
[9] 
In Germany, there are two reasons pytopharmaceuticals are of a high standard and 
are classified primarily as conventional drugs by law.  One reason being that during the 
last 50 years traditional medicine has been kept alive by both medicinal practitioners and 
the increasing interest of patients in herbal drugs.  The other reason is that the German 
pharmaceutical industry, shortly after World War II, specialized in and relied on herbal 
drugs.  It also developed and supported projects aimed at optimizing the quality of herbal 
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drugs by standardization and basic scientific research.  This development was paralleled 
by an intensified evaluation of herbal drugs and a search for the active principles of 
phyto-preparations.[8]   
In the United States, one hundred years ago, herbal drugs were very well 
established as medicines. [10] They were widely listed in the United States 
Pharmacopoeia and herbal tinctures and extracts were materia medica of the day.  Then 
in 1938 the Food and Drug Administration was given the authority to set regulations and 
enforce drug safety standards.  The passage of Food, Drug and Cosmetic Act gave the 
FDA the responsibility to prosecute the adulteration or misbranding of foods, drugs and 
cosmetics.  Herbal preparations soon gave way to single entity chemical drugs.  World 
War II created a demand for more powerful drugs of all kinds particularly antibiotics and 
trauma treatment agents.  The federal government urged companies then largely botanical 
crude drug houses, such as Merck, Lily and Parke-Davis to invest in new synthetic 
chemistry based research.  Single entity chemicals were more consistent, easier to 
measure and judged more specific in their therapeutic focus than botanical preparations. 
[10]  
In Germany, between 1970 and 1985, the first phase of herbal drug investigations 
was completed which involved proving the quality of these phytopreparations and a 
thorough search for the various active principles.  This phase was followed by clinical 
trials that initially focused on 10 herbal drugs or preparations that were already on the 
market good clinical data.  This wave of clinical trials provided new findings that can be 
summarized below: 
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• Phytopreparations are applicable primarily for the treatment of moderate 
or moderately severe diseases.  They can also be used as adjuvants in 
combination with a strongly acting chemosynthetic drug. (This finding 
would later on be checked for herb-drug interaction) 
• Clinical trials indicated that several phytopreparations showed full 
therapeutic equivalence with chemotherapeutics and had no adverse 
effects. 
• Many phytopreparations exihibit no immediate pharmacologic or 
therapeutic effects and achieve their optimal efficacy only after long term 
treatment.    
Even though these claims were made, the new findings needed a scientific 
explanation for the mechanism of action and possible interactions involved with other 
drugs. [8] 
  In the United States, during the 1970’s the FDA began to apply the food additive 
provisions of the Food, Drug and Cosmetic Act to botanicals.  Under these provisions, 
food additives already on the market in 1958 were accepted without FDA review.  
However substances added to the food supply after this date were required to gain FDA 
approval prior to marketing, unless they were considered GRAS (generally regarded as 
safe).  A fair number of herbs that were included on the list of GRAS food additives that 
had been prepared by the Flavor and Extract Manufacturers Association as flavorings for 
alcoholic beverages.  However, the FDA viewed several other commonly used herbs as 
unapproved food additives and therefore subject to FDA approval prior to marketing.  
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This interpretation led to a series of bitterly fought court cases and several herbs being 
taken off the market.   
Congress passed the Nutrition Labeling Education Act of 1990 (NLEA) to reform 
food labeling and to allow for the first time, a new class of health claims based on 
disease-nutrient relationships.  For the most part his legislation did not apply to botanicals 
because of the way it was written and the way it was interpreted by the FDA.  With 
lawsuits between herbal manufacturers and FDA common place, a group of leading herb 
companies met with Senator Orrin G. Hatch (R-Utah) and Congressman Bill Richardson 
(D-New Mexico) who drafted a legislation that became the Dietary Supplement Health 
and Education Act of 1994.  This law was passed by Congress and signed into law by 
President Clinton on October 25, 1994.  This was the first time a U.S law defined the 
term herb or botanical. [10] 
The most extensive surveys on the use of complimentary and alternative medicine 
in the United States revealed that approximately 12% of the population used herbal 
medications in 1997, representing a 380% increase since 1990. [11]  Patients who 
undergo surgery appear to use herbal supplements more frequently than the general 
population.  A study conducted by Moss et al. on the relation between herbal medicines 
and perioperative care, reported that more than 70% of the patients failed to disclose their 
herbal medicine use during routine preoperative assessment.  Explanations for this lack of 
disclosure included patient held beliefs that physicians are not knowledgeable about 
herbal medications or are prejudiced against their use.  Some patients may fear admitting 
to their physicians their use of unconventional therapies.  Others possibly neglect to 
mention that they are taking herbal medications when they are using them for reasons 
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perceived as unrelated to their medical care.  Still other patients do not consider these 
substances as medications do not report them during preoperative questioning.  Thus, for 
these reasons it becomes necessary for physicians to specifically seek out a history of 
herbal medicine use in presurgical investigations. [11] In a survey conducted by Blendon 
et al. in 2001, on Americans’ view on the use and regulation of dietary supplements 
(n>1000), it was found that 48% of the participants used at least one or more than one 
dietary supplement regularly while 44% of the users believed that their physician knows 
“little” or “not much at all” about the dietary supplements products used by their patients. 
[12] The study also revealed that 81% of the users would require evidence of efficacy, 
safety and FDA approval prior to allowing the sale of that product, but 72% of the users 
would continue using their dietary supplement, even if a government scientific study 
showed negative results for that product. [12]      
Surveys reveal the fraction of the U.S population using some kind of herbal 
therapy for a continuous of 12 months or more, increased from 2.5% in 1990 to 12.1% in 
1997, to 14% in 2000 and to 18% in 2002. [4, 5, 13, 14] Table 1.2 shows the Global 
Dietary Supplement Market estimates for 2005 (Source: Nutrition Business Journal, 
Chart 73 c. 2005 Penton Media Inc) 
Table 1.2:  Global Dietary Supplement Market Estimates for 2005 
Product Category Estimate 
Vitamins and Minerals $27.5 Billion 
Herbs/Botanicals $19.7 Billion 
Nutritionals $19.4 Billion 
Total $66.6 Billion 
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1.2.2:  Dietary Supplement Health and Education Act (DSHEA) 
With reference to herbal supplements, the DSHEA defines the term dietary 
supplement as a herb or other botanical concentrate, constituent, extract, or combination 
of any botanical that is intended for ingestion as a tablet, capsule or liquid, is not 
represented for use as conventional food or as a sole item for a meal or diet and is labeled 
as a dietary supplement.  This includes new drugs that were marketed as botanicals prior 
to 1994; it does not include a botanical approved as a new drug or authorized for 
investigation as a new drug and not previously marketed as a dietary supplement.  
Botanicals are thus not classified as food additives.    
The DSHEA amends the Food, Drug and Cosmetic act of 1938 and alters the way 
dietary supplements are regulated and labeled.  DSHEA was enacted by the Congress 
based on 15 findings, one of which was “improving the health status of United States 
citizens ranked at the top of the national priorities of the Federal government.” Other 
Congressional findings supporting the adoption of DSHEA included the increasing 
reliance of the use of “unconventional” health care providers to avoid the increasing costs 
of conventional medical treatments and the belief that consumers should be able to make 
choices about preventive health programs based on information obtained from scientific 
studies of health benefits related to particular dietary supplements. [15] The DSHEA 
influences the FDA’s regulatory practice in four primary areas by: 
i. Placing the burden of proof of safety on the FDA in actions against the 
manufacturer of dietary supplements. 
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ii. Limiting the FDA’s ability to require pre marketing information about 
product safety and efficacy. 
iii. Establishing a minimal pre-marketing notification for certain new dietary 
ingredients not marketed in the United States before October 15, 1994. 
iv. Specifying acceptable claims that could be made without triggering 
requirements for classification as drugs. 
1.2.2.1:  Lack of Pre Market Controls 
One of the most misunderstood aspects of DSHEA is the issue of FDA’s ability to 
protect the public from unsafe dietary supplements.  Once the supplement is on the 
market, the FDA must prove that it is unsafe before imposing restrictions on its use.  The 
burden of proof has thus shifted from the manufacturer to the FDA to prove that a 
substance poses an imminent health hazard.  This issue of regulation, herb safety and the 
impact on general public can often be mischaracterized and exaggerated in the media to 
the extent that even the FDA officials have misstated the agency’s authority.   
Consumer and professional confidence in herbal preparations and other dietary 
supplements underwent a considerable degree of erosion during the late 1990’s as various 
news organizations and independent groups reported that many of these products failed to 
meet a variety of label claims related to content of certain ingredients, standardization 
markers, or other elements.  Thus, lack of pre market controls leads to:  
i. Undeclared toxic contaminants 
ii. Undeclared or high level of impurities 
iii. Incorrect label amounts 
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iv. Microbial contamination 
v. Lack of bioavailability    
1.2.3:  Role of the U.S Pharmacopoeia 
Not surprisingly, herbs have had a long history of use as medicines in North 
America.  Native Americans had medicinal uses for at least 2,582 species of plants 
including such uses as analgesics, contraceptive, laxative, sedatives, remedies for cold, 
tuberculosis and cancer.  Until about 1930, herbs and herbal products constituted a 
significant portion of the materia medica of North America during the 17th, 18th, 19th 
and early 20th centuries.  The first edition of the United States Pharmacopoeia (USP) in 
1820 contained 425 botanical substances (67%) of all entries.  Herb and herb product 
monographs reached their peak of 636 botanical substances (66%) in USP V in 1870, but 
by the time USP X was published in 1926, the total number of botanically related 
monographs had dropped down to 203 botanical substances (36%).  This reflected the 
trend that botanical medicine was widely used in the United States until about 1920 when 
herbs began to be replaced with pharmaceutical drugs, not because they were determined 
to be unsafe and ineffective, but because their actions were generally not as 
pharmacologically dramatic and they were not as economically profitable as the new 
synthetic drugs.  In 1888, the American Pharmaceutical Association published the 
National Formulary (NF), a compendium of formulae of primarily herb based medicines.  
In 1975 the publication of the NF was taken over by the USP and combined with the USP 
to create the USP-NF in 1980.  In the 1990’s the USP renewed its efforts to address the 
issue of establishing quality standards for conventional dietary supplements and in 1995, 
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after the passage of the DSHEA, USP began the development of monographs defining 
identity and purity standards for many of the best selling herbs in the U.S market.  From 
1995 to 2002, the USP has published 86 standard monographs on 25 herbs. [16]  
This dissertation, in part, is also a result of the USP’s efforts to develop 
meaningful bioavailability and quality control performance standards for herbal 
supplements. 
1.2.4:  European (Germany) Regulatory Status 
In the countries of the European Union, especially Germany which accounts for 
nearly 50% of the total OTC sales, herbal medicines enjoy relative parity with 
conventional medicines.  Herbal medicines are generally sold in pharmacies as licensed 
non prescription or prescription medicines.  According to the EU directive, 65/65/EEC 
(European Economic Community) all phytomedicines are treated as drugs.  Registrations 
based on quality, efficacy and safety are required.  Exceptions include the Netherlands 
and the United Kingdom where botanicals are still sold as food supplements or dietary 
supplements. [17]  
In the European Union herbal medicinal products are “medicinal products 
containing as active ingredients exclusively plant material and/or vegetable drug 
preparations.”  An herbal drug or preparation is thereof regarded as “one active ingredient 
in its entirety whether or not the constituents with therapeutic activity are known.  
However chemically defined isolated constituents or their mixtures are not considered 
herbal medicinal products.  Other substances such as solvents, diluents, or preservatives 
may form part of the vegetable drug preparation.  These substances must be indicated”.     
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One of the driving forces that has resulted in mainstream acceptance of 
phytomedicines in Germany is the inclusion of phytotherapy in the medical and 
pharmacy school curricula.  In the opinion of several medical groups, “modern 
phytotheraly is not perceived as alternative medicine, but as a part of so called traditional 
medicine.”  Since 1993 all medical school students in Germany must successfully 
complete a portion of their board examination in phytotherapy as a precondition for 
practicing medicine.   
Rational phytotherapy in Germany is based on four basic rules for 
phytomedicines also known as the phytopharmaca: 
i. Dose-Response relationship:  Phytomedicines in the therapeutic arena can be 
applied in a dose effective manner.  Possible dose dependent reversals of effects 
should not be interpreted as homeopathic effects- a reference to the observation 
that homeopathic medicines produce symptoms at higher potencies in healthy 
individuals.  This means, sometimes a variation in the dosage of a phytomedicine 
can produce a different effect than a higher or a lower dose of the same herbal 
drug and this cannot be dismissed as homeopathic.  
ii. Efficacy-Constituent relationship:  Efficacy or effectiveness can be deduced from 
specific ingredients.  They are codetermined for effectiveness, which means, in 
most cases not one but more than one different plant constituents are responsible 
for the observed effectiveness. For example: St. John’s Wort used  in the 
treatment of mild to moderate depression, is believed to be attributable to at least 
three types of substances: hypericins, hyperforins, and flavonoids. 
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iii. Total extracts vs. isolated constituents:  Typically phytomedicines that are 
standardized extracts consisting of primary active components, secondary 
components and accompanying compounds manifest better effects and a greater 
therapeutic range of activity than indivisual isolated compounds.   
iv. Pharmaceutical Quality:  Phytomedicines with a high level of pharmaceutical and 
medical quality are the basic requirement for successful phytotherapy.  
 
   An interesting study conducted in Germany (Table 1.3), comparing the use of 
phytomedicines by German consumers for curing common ailments in 1970 and 1997 
revealed that even after so many new drugs are being available in the market, the use of 
phytomedicines for common ailments has either remained constant or increased during 
the years 1970 to 1997. 
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Table 1.3:  Phytomedicine Use Among German Consumers. 
Condition 1970 Poll (% users) 1997 Poll (% users) 
Common cold 41 66 
Flu 31 38 
Digestive complaints 24 25 
Headache 13 25 
Insomnia 13 25 
Stomach ulcer 21 24 
Nervousness 12 21 
Circulatory Disorders 15 17 
Bronchitis 12 15 
Skin diseases 8 12 
Fatigue & Exhaustion 8 12 
Table reproduced from [17] 
 
1.2.5:  WHO: Regulatory Status 
The World Health Organization (WHO) in 1991 published its “Guidelines for the 
Assessment of Herbal Medicines” in recognition of world wide growth in the usage of 
herbs in both official and unofficial medicine.  Its main purpose was to aid member 
nations in establishing appropriate regulatory criteria and procedures to evaluate the 
quality, safety and efficacy of herbal medicines.  These guidelines call for recognition of 
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the fact that long term historical use of a botanical in traditional medicine constitutes a 
presumption of safety unless contradicted by modern scientific research. [18] 
1.4:  SAFETY AND EFFICACY  
1.4.1:  Safety:  Risks and Benefits 
In general it would appear that there are fewer adverse event reports (AERs) in 
the United States, on a per capita basis, for herbs than for conventional pharmaceutical 
drugs.  On the other hand it is also possible that lower incidence of AERs for herbs are a 
result of poor reporting mechanisms or because many herb users simply do not report 
minor events such as a gastrointestinal upset or a headache or because many herb users 
consider themselves outside the medical mainstream and may have a bias against making 
a report.  All these explanations are equally plausible; i.e. most commercially available 
herbs are gentler and safer than conventional drugs, and there needs to be a better 
reporting mechanisms for herb-related adverse events. [19] 
There are several voluntary reporting systems for herb and dietary supplement 
related AERs in the U.S.  One is the American Association of Poison Control Centers in 
Washington D.C, whose results are available on a fee for service basis, usually for 
companies who check reports on their specific products.  Another is the FDA’s 
MedWatch system for drugs that is used primarily by health professionals, it is however 
considered controversial, on account of incomplete documentation and inadequate 
information.  A new improved system at the FDA for documenting AERs related to 
dietary and herbal supplements is managed by the Centre for Food Safety and Nutrition 
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(CFSAN) and is known as CFSAN-Adverse Event Reporting System (CAER). [20] 
CAER replaces the older and less reliable Special Nutritional/Adverse Event Monitoring 
System (SN/AEMS) that was created in 1998.   
The German Commission E review process is only slightly comparable to the 
OTC review process of old drugs conducted by the FDA.  When lacking controlled 
studies, the safety and efficacy of known substances can be determined on the basis of 
well documented review articles, older clinical trials and sound knowledge of their 
traditional use. According to the Commission E monographs, approved and unapproved 
herbs are divided into separate sections into positive and negative monographs.  Positive 
monographs always show the approved use and dosage.  If no approved uses are given, if 
there is no dosage listed, and if the efficacy of the plant has not been efficiently proven, 
or there are risks that outweigh the documented benefits, the assessment becomes a 
negative monograph.   
As mentioned earlier, the U.S. FDA deals mostly with mild acting herbs and 
herbal supplements. Unlike the FDA, Commission E approves relatively powerful, 
pharmacologically active and also potentially toxic herbs such as Hyoscyamus niger 
[Henbane], Rauvolfia serpentina [Indian Snakeroot] and Urginea maritima [Squill] all of 
which are treated as ‘prescription only’ drugs.  Thus, the existence of a positive 
Commission E monograph does not imply that the herbal drug is sufficiently harmless to 
be treated as an OTC drug. [17, 21] With amendments in the risk-benefit assessment, if a 
certain herbal drug emerges with new data that deems it toxic, the existing positive 
monograph is not revised, but replaced with a negative monograph. [17] Thus, new data 
indicating potential risks that outweigh possible benefits attests to the rationality of the 
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Commission E process.  This constant vigilance by Commission members regarding what 
has been termed the “doctrine of absolute proof” to assess safety is a significant 
characteristic of the Commission E evaluation process.     
 
1.4.2:  Standardization and Quality Control 
1.4.2.1:  Standardization   
Standardization is probably one of the most controversial terms used to describe 
herbal supplements.  Most people would agree that the goal of standardizing herbal 
products is to provide product consistency and thus a reliable health benefits.  But 
standardization can also mean establishment of consistent biological effect, a consistent 
chemical profile or simply a quality assurance program for production and 
manufacturing. [10, 22, 23] The process of standardization depends partly on whether the 
active constituents in an herbal extract are well established.  This can be done by 
classifying a botanical product into three categories:  
(i) those containing constituents (single compound or a family of compounds) with 
known and acknowledged therapeutic activity that are solely responsible for the 
efficacy of the extract;  
(ii) those containing chemically defined constituents possessing relevant 
pharmacological properties which are likely to contribute to clinical efficacy;  
(iii) those in which no constituents have been identified as being responsible for the 
therapeutic activity.     
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Standardization of Therapeutic Activity:  Standardization of a botanical extract 
based on therapeutic activity has been followed for over a century.  Before sophisticated 
chemical analytical methods were available, and the active principles of an extract 
unknown, herbal extracts were standardized based on biological activity measurements in 
animals or animal tissues.  As the active components were profiled with the advent of 
new analytical techniques, bioassays were replaced first by the measurement of 
representative chemical constituents of an extract (e.g silybin as a measure of silymarin in 
milk thistle) and then by measurement of each of the active components in the extract 
(measurement of all six isomers in silymarin). 
Standardization of a botanical product can also be established by adjusting the 
preparation to contain a defined level of an active component or group of components in 
a single dosage form.  For example Milk thistle preparations contain silymarin, the active 
group of components comprising of six isomers.  Hence, the dosage form can be 
standardized to contain a certain variable amount of dried extract containing a fixed 
amount of silymarin (e.g. “X” mg of extract containing 140 mg of silymarin) or fixed 
amount of extract containing a fixed amount of silymarin (e.g. 175 mg of extract 
containing 140 mg of silymarin). 
The standardization method in the above example is not complete. It states that 
the dose/extract contains 140 mg of silymarin; but silymarin itself comprises of six active 
isomers, wherein the proportion of each isomer can vary from extract to extract.  Thus, it 
is necessary to quantify the composition of each isomer in the extract regardless of 
whether the isomer does or does not exhibit a pharmacologic effect.  Standardization 
based on therapeutically active components can ensure consistency between lots from the 
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same manufacturer, but in a larger scenario, it is just a small step forward when it comes 
to comparing proprietary preparations from different manufacturers for the same 
botanical.  Even if the claimed level of constituents is accurate, the inherent variability in 
the undefined portion of the extract must be considered.  Thus, different formulations or 
routes of administration are bound to give variable results and affect bioavailability 
studies, which in itself is a completely different paradigm. 
 
Standardization Based on Chemical Characterization: Botanical products can be 
standardized to a norm that may or may not relate to the expected biological activity of 
the product.  This norm is a level of a constituent chemical or group of chemicals called 
marker compounds.  The concept of determining levels of marker compounds was 
developed because it was not feasible to test for all compounds in an extract and finalize 
a formula for content and consistency.  This gave rise to ‘Markers’ which are chemically 
defined components of an herbal extract, ideally characteristic to the herb, of interest for 
quality control purposes, and independent of whether they have any therapeutic activity.  
By providing product characterization marker compounds can be used to facilitate 
botanical identification and detection of adulteration.  They can also be used as indicators 
of consistency throughout the manufacturing, handling, and storage process.  Thus, 
setting minimum limits for marker compounds can be a useful indicator of quality in 
preparations in which there is little or conflicting knowledge regarding the active 
constituents.  Thus, determinations of marker consistency in finished products should be 
done using specific and sensitive validation methods.  Analytical methods can be used to 
measure either individual compounds or a collective class of compounds.  It is important 
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to realize that no global consensus has yet been made regarding standards or test methods 
for herbal products although attempts are being made in this direction.  
 
1.4.2.2:  Quality Control 
Standardization based on quality control is best described as a quality assurance 
program.  It is well established that intrinsic and extrinsic factors including plant species 
differences, organ specificity, diurnal and seasonal variation, environment, field 
collection and cultivation methods, contamination, substitution, adulteration, processing, 
and manufacturing practices greatly affect botanical quality. [23-27] Plants are inherently 
dynamic living organisms, each of which is capable of being genetically influenced to 
differ slightly in their physical and chemical characteristics.  For example a study on the 
accumulation of hypericin in H. perforatum showed that narrow leafed populations have 
greater concentrations than the broader leaf variety. [28, 29] Such variations can be due 
to diurnal, seasonal and other intrinsic factors as well as extrinsic factors such as soil, 
light, water, temperature and nutrients.  For e.g., silymarin content in milk thistle was 
found to be highest in the fruits of plants grown under 60% water/field capacity (1.39%) 
and nitrogen level of 100 (1.46%) per acre. [18] Contamination by microbial and 
chemical agents (pesticides, herbicides and heavy metals) as well as by insects, animals, 
animal parts, and animal excreta during any of the stages of source plant material 
production and collection can lead to lower quality and unsafe source material. [30] 
Heavy metal contamination can occur at cultivation, post harvest treatment, or product 
manufacturing stages.  Lead and thallium contaminations have been reported in multi-
 29
component botanical mixtures and cases of lead, thallium, mercury, arsenic, gold and 
cadmium poisoning from the consumption of contaminated products has been 
documented. [31, 32] 
Botanical product quality and safety can also be influenced by regulatory status, 
which varies from country to country.  As discussed earlier, in countries like Germany 
botanicals are regulated as medicines and are subjected to mandated standards of quality, 
where as in the United States a majority of botanicals are marketed as dietary 
supplements.  Good manufacturing practices (GMP’s) are required in the production of 
prescription and OTC drugs, but regulatory provisions under DSHEA provide little 
assurance of identity, quality or purity for botanical supplements.  Hence, these products 
have not been subjected to mandated QA/QC standards as in the case of prescription and 
OTC drugs. Although the FDA is taking steps in the direction of implementing strict 
GMP’s in the labeling and manufacturing of botanical supplements, such rules have yet 
to be imposed. [33]  
 
1.4.3:  Bioavailability 
Many consumers use botanical products in a holistic manner, due to obvious 
reasons implying to empirical and traditional applications.  Evidence based use of 
botanical products, known as ‘rational phytotherapy’ is in complete contrast to the 
holistic traditional medical herbalism.  Hence, in order to bring this contrast to a 
minimum, all botanical products must meet acceptable standards of quality, safety and 
efficacy.  The topic of safety and efficacy brings along with it the pharmacologic effect of 
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herbals which can be further divided into pharmacodynamic (PD) and pharmacokinetics 
(PK).  Comparing the PK with the PD of botanicals, it is seen that, there is sufficient and 
steadily increasing PD data for botanicals as compared to PK studies being undertaken.  
This is mainly because the study of herbal PK is extraordinarily complicated due to the 
complex nature of herbal extracts.  Herbal extracts are multicomponent complex mixtures 
containing several chemical constituents in a vegetative matrix.  Most botanical products 
are formulated after a certain extraction-purification process in order to guarantee 
sufficient efficacy.  PK profiling of a certain herbal extract would require the analysis of 
each of the active component present in the extract.  As a consequence, analytical 
methods determining bioavailability and PK of herbal products have to be sufficiently 
sensitive.  To further complicate the matter, in many of the herbal extracts the active 
constituent is often unknown, implying that the compound being detected in body fluids 
may not necessarily be the active constituent.  Natural compounds are often prodrugs that 
are metabolized in the digestive tract.  Sometimes, herbal extracts may contain polar 
molecules that might be expected to have poor or highly variable/unpredictable 
bioavailability. [26]  
Bioavailability of a substance depends on several factors like the type of 
formulation, solubility, permeability, partition coefficient of the molecule, 
gastrointestinal factors, first pass effect, interaction with food and individual factors in 
the patient such as pathological conditions.  Besides these factors, bioavailability of 
components in an herbal extract can also be influenced by other components of the 
extract, which are not active themselves but play a major part in positively influencing 
the stability, solubility, bioavailability or half life time of the active compounds.  A good 
 31
example is the concentration of Kawain and Yangonin (active components of the herb 
Kava) in mouse brain samples is higher after administration of the Kava extract (Piper 
methysticum) than after administration of the purified single compound in the same 
amount. [34] Similarly the oral bioavailability of Kawain from the kava extract is 10 
times higher than pure Kawain. [26] 
Factors influencing the ease and importance of conducting bioavailability studies 
include the type of therapeutic activity and the extent to which the active constituents 
have been identified.  Thus, bioavailability and bioequivalence studies are important for 
botanicals with immediate and strong activity.  Bioequivalence is important when one 
product is being substituted for another and hence should be performed for all immediate 
release products intended for systemic action unless there is sufficient in vitro data.  This 
concept originally developed for synthetic drugs can be transferred to herbal extract 
formulations without modifications.  In principle two parameters from the in vitro data 
are essential in this context: Solubility (predicted by in vitro dissolution) and permeability 
through the intestinal wall (as predicted by the Biopharmaceutic Classification System-
BCS) [35] If both the solubility and permeability of a substance are good, the probability 
of bioavailability problems diminishes.  However if one or the other is poor, 
bioavailability can be compromised.  Hence, if solubility is good and permeability is 
poor, absorption from the gastrointestinal tract becomes the rate limiting step.  On the 
other hand, if the permeability is good and the solubility is poor, the bioavailability will 
depend on the in vitro dissolution of the drug making dissolution the rate limiting step for 
bioavailability.  Excepients can impact both the solubility and permeability of the active 
components impacting their bioavailability. 
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For extracts where the active components are not defined clearly and the 
pharmacologic effect is a result of the presence of a group of undefined components, 
chemical assays would not predict the pharmacological activity of the extract.  In such 
cases bioassays that measure biological activity may be more suitable endpoints.  
Recently biochemical assays have been proposed for several herbal extracts like St. 
John’s Wort, Ginkgo, Ginseng, Echinacea and Saw Palmetto. [33] An ideal bioassay 
would be a measurement that correlated with the therapeutic activity of the extract.  This 
ideal is very difficult to achieve and in most cases bioassays do not reflect therapeutic 
effect as a whole but only selected pharmacological aspects caused by individual active 
markers.  A disadvantage of bioassays is that they are generally not as reproducible as 
chemical assays and hence variability in results may complicate the evaluation of 
bioavailability studies.  Even then, bioassays may play an important role for future 
pharmacokinetic approaches if new intelligent strategies are developed. 
Although the study of herbal pharmacokinetics appears to be difficult, the 
information derived from such investigations will become an important issue to link 
pharmacological/chemical assays to clinical effects.  In particular, a better understanding 
of pharmacokinetics and bioavailability of natural compounds can help in designing 
rational dosage regimen and it can help to predict potential botanical product-drug 
interactions.   
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1.4.4:  Herb-Drug Interactions     
The body cannot discern between a natural chemical emanating from a garden and 
a synthetic chemical generated from a laboratory and consequently deals with both in the 
same way.  The body thinks of these chemicals as foreign (xenobiotics) as they cannot be 
exploited beneficially by the body and hence tries to eliminate them.  A large number of 
drugs that reach the systemic circulation tend to be lipophilic and hence difficult to 
excrete, as a result of which the body converts them into hydrophilic analogs by 
metabolism to ease excretion and eliminate them through the biliary route.  A series of 
enzyme systems that are efficient in breaking down drugs to excretable polar metabolites 
are present throughout the body, but principally found in the liver, and are intracellulary 
localized on the endoplasmic reticulum and in the cytosol. [36] In order for a 
pharmacologic response to occur, the drug must be able to gain access or interact with the 
specific receptor, but when a drug is metabolized the biological activity in most of the 
cases is terminated.  The most popular and well studied enzyme system involved in drug 
metabolism is the cytochromes P450 (CYP450). This enzyme system displays 
unprecedented substrate specificity being able to metabolize a wide range of structurally 
dissimilar drugs.  This system of enzymes is also responsible for the metabolism of 
herbal components.  Thus, potential herbal-drug interactions should be studied to prevent 
therapeutic failures. 
Herb drug interactions leading to changes in CYP450 activity become crucial 
when drugs with a low therapeutic index are concerned and plasma levels have to be 
maintained within a narrow concentration range to obtain optimum benefit with 
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minimum adverse effects.  Elevated CYP450 activity translates into higher metabolic 
rates which may result in decreased blood plasma concentrations leading to sub 
therapeutic levels and loss of pharmacological effect.  Conversely, suppression of 
CYP450 may trigger a rise in drug plasma concentrations leading to undesirable and 
elevated pharmacologic effect leading to toxicity.  
The best researched clinically relevant interaction between diet and drugs 
involves grapefruit juice.  Simultaneous consumption of grapefruit juice with drugs that 
are subject to first pass effect, results in elevated plasma levels of that drug leading to 
unwanted high bioavailability potentially resulting in adverse therapeutic events. [37] 
The effect becomes more pronounced with repeated intake of grapefruit juice, but of 
particular concern is that this effect is observed for at least three days following the last 
consumption of grapefruit juice.  Grapefruit juice contains furanocoumarins which have 
been shown to inhibit intestinal CYP3A4 activity, which is responsible for the 
presystemic metabolism of these drugs, thus allowing higher than desired concentrations 
of the drug to reach systemic circulation leading to toxicity.   
Herbal supplements are taken not only by healthy people, but also by those 
suffering from life threatening diseases, those about to undergo surgery or post surgery, a 
situation in which they are most likely to receive more than one medicinal drug. [11, 37] 
Herbal medicines may interact with a drug at the absorption site, modifying the 
pharmacologic profile of the drug.  Herbal components may interact with the ATP 
dependent transporter proteins such as the intestinal P-glycoprotein (P-gp) and other 
multi-drug resistance proteins that facilitate the efflux of drugs.  Phytochemicals thus 
have the potential to compete with traditional drugs for transporter proteins.  Several 
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cases have been reported where a number of herbal products (Chamomile, Feverfew, 
Ginger, Garlic, Ginkgo, Ginseng, St. John’s Wort) have known to interact with anti 
coagulants such as warfarin, though it is not clear whether the underlying mechanisms are 
competitive based or pharmacokinetic in nature.  [37, 38] Warfarin is a highly protein 
bound drug and the displacement from its binding site may cause an undesired increase in 
its anticoagulant effect.   
In essence, interactions between herbals and drugs involve the same 
pharmacokinetic and pharmacodynamic mechanisms as drug-drug interactions.  
Pharmacokinetic interactions may involve alteration in absorption, distribution, 
metabolism or excretion of the affected drug or herbal compound.  Pharmacodynamic 
interactions on the other hand alter the relationship between drug concentration and the 
pharmacological response for a drug or herbal product.  Though most research has been 
focused on the adverse effect of herb-drug interaction, not all such types of interactions 
have a negative effect.  Animal studies have shown that the combination of the Chinese 
medicinal plant Tripteriygium wilfordi and cyclosporine, significantly increased the heart 
and kidney allograft survival compared to cyclosporine alone.  The effective cyclosporine 
dose required for 100% kidney allograft survival was reduced by 50% to 75% in the 
presence of the herbal extract. [39]  
Garlic-Drug Interactions:  Garlic is promoted for its antiplatelet activity, 
lowering cholesterol and hypertension, delay artherosclerotic processes and improve 
circulation.  Reports suggest that concomitant use of warfarin and garlic was followed by 
an increase in the INR (International Normalized Ratio) leading to increased plasma 
levels of warfarin in the systemic circulation increasing the risk of bleeding, especially 
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during post surgical recovery period.  An isolated clinical trial suggested that garlic 
changes some pharmacokinetic variables of acetaminophen after 1-3 months of garlic 
treatment. [40]  
 
St John’s Wort (SJW)-Cyclosporine Interaction:  Interaction between SJW and 
clyclosporine is one of the most serious, potentially fatal and hence the most studied. [37] 
Cyclosporine is one of the most widely used immunosuppressant drugs following 
transplantation, but it is essential that blood levels are maintained within a narrow 
concentration range.  A drop below the therapeutic index ratio may result in the rejection 
of transplanted tissue or organ where as an increase can be associated with kidney and 
hepato toxicity.  Most of the cases reported indicate a drop in the blood cyclosporin levels 
of the patient after the patient has been stabilized with the immunosuppressant post organ 
transplantation leading to tissue rejection.  One report refers to 30 kidney transplant 
patients whose plasma cyclosporin levels were nearly halved after taking SJW, though 
the dose of SJW was not specified.  Another case reports a female kidney transplant 
patient was maintained successfully on cyclosporin for 25 years, but suddenly blood 
levels dropped following a 4 week medication course of SJW.  Cyclosporin blood levels 
increased only after the intake of SJW was stopped.  Another heart transplant patient was 
stabilized on cyclosporin for 11 months.  Three weeks before admission to a hospital for 
elective endomyocardial biopsy, self medicated himself with SJW-900mg/day in three 
doses.  The biopsy revealed acute cellular transplant rejection.  Cyclosporin levels for 
that patient on investigation and analysis were found to be below 100µg/L when the 
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desirable effective therapeutic range was between 200-350µg/L.  SJW was discontinued 
and cyclosporin levels increased to subtherapeutic levels.   
In vitro studies indicate that methanolic and ethanolic extracts of SJW act as 
inhibitors of CYP3A4 activity showing that components of SJW can interact with this 
enzyme.  Exposure of healthy volunteers to SJW (3 x 300mg/day) for 2 weeks, resulted 
in increased expression of duodenal P-gp and CYP3A4 and hepatic CYP3A4.  This 
combined upregulation is expected to severely limit the bioavailability of drugs that rely 
on these proteins for their absorption and metabolism respectively.  Cyclosporin is 
metabolized through hydroxylation and N-demethylation by CYP3A4 to a large number 
of pharmacologically inactive products.  This clearly suggests that SJW doses that have 
been reported to lower plasma cyclosporine concentrations to subtherapeutic levels are 
sufficient to stimulate CYP3A4 activity in the liver and the intestine and increase 
expression of P-gp. [37]  
 
1.5:  PERFORMANCE MARKERS 
1.5.1:  Need for Markers  
While many conventional drugs or their precursors are derived from plants, there 
is a fundamental difference between administering a pure chemical and administering a 
chemical in a plant matrix.  It is this issue of the possible advantage of chemical 
complexity which is rejected as having no basis in fact and avoided by most researchers 
as introducing too many variables for comfortable research.  Multiple variables in a 
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matrix give rise to the concept of synergy which is a very common and important in 
medicinal use of botanicals.  Just like biologicals, botanicals are crude extracts or semi-
purified extracts manufactured to contain a definite amount of a particular constituent or 
a group of constituents, which are called marker compound(s).  Since potency requires 
biological assessment of an extract, the presence of marker compounds does not 
guarantee the potency of an extract.  Even if the marker compound demonstrates 
bioactivity the biological activity depends on the composition of the rest of the extract.  
Hence, other components even those showing no direct physiological effect can influence 
the absorption, distribution, metabolism and excretion of the active compounds.  Such a 
background matrix can also lead to a difference in solubility, oil-water partitioning, 
permeability and bioavailability of any single compound in the given extract.  Thus, it 
becomes necessary to know the physicochemical and biopharmaceutic properties of each 
of the compounds present.  
Botanicals contain a group of constituents which act together to exhibit a 
synergistic pharmacologic effect.  The basic advantage of synergism is the presence of an 
active constituent in the plant matrix which enhances its solubility and bioavailability 
properties.  Consequently, if that particular constituent was administered alone, it would 
have much lesser bioavailability leading to sub therapeutic levels, as compared to when 
the constituent is administered as an extract.   
Herbal extracts consisting of a range of active compounds are ascribed with 
pharmacological activity with often unresolved synergistic effects between individual 
compounds.  These active constituents are complex labile compounds that traditional 
analytical techniques had difficulty in extracting and quantifying.  As sophisticated 
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analytical techniques were introduced, more active constituents were discovered and 
designated as marker compounds which actually signified the presence of active 
constituents.  Though the chemical profiling of extracts has advanced only to a certain 
extent, bioavailability and pharmacokinetic profiling of individual constituents still poses 
a major hurdle in the characterization of the extract.   
Also due to the presence of an array of compounds in each extract, it is still 
difficult to physically isolate each component on a preparative scale, leading to lack of 
pure reference standards.  Progress has been slow concerning the characterization and 
selection of markers for an extract due to lack of conclusive evidence for the activity of 
specific compounds, multiple active constituents in an herbal product and probable 
synergistic effects and to add to it, the reluctance of health authorities to accord 
recognition to medicinal herbs as valid therapeutic agents.  When an individual 
component is chosen as a marker for activity in a herb there must be meaningful 
consistent relationship between the amount present and a quantitative therapeutic benefit.  
 
1.5.2:  Classification of Markers 
Since herbal extracts consist of a wide array of active constituents, all of which 
are usually not characterized for pharmacologic effect, chemical profiling or 
bioavailability.  Even if each of the constituent was characterized, non active constituents 
in the extract cannot be neglected since therapeutic effect exhibited by the extract is 
synergistic.  Hence, it should be an accepted fact that a particular constituent, active or 
non active, is an integral part of standardization and marker development for a botanical.  
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Conducting bioavailability/routine bioequivalence studies for each likely component in 
the extract is not only an uphill task, with the non availability of pure reference standards, 
almost impossible.  Thus, selecting a performance marker that represents the chemical 
composition of the extract for a quality control assay or a bioavailability marker that 
represents the bioavailability or bioequivalence of an extract would definitely be helpful 
in regulating a botanical product.  Thus, performance markers for an extract can be 
classified in the following 5 categories:  
 
1. Performance Markers based on Active Principles:  These markers can be used 
when the active principle of the extract is known. Such a type of marker selection is 
analogous to the usage of botanicals during the olden days when extracts were recognized 
or characterized according to their therapeutic effect.  This was an obvious approach 
during that time period mainly due to lack of scientific data concerning an extract.  Thus, 
even today there are certain botanicals where data is available only for the therapeutic 
effect and individual constituent profiling is not available.  In such cases the marker 
assigned is based on a therapeutic scale where in the mechanism of therapeutic effect is 
accurately known and assigned a certain magnitude.  
 
2. Pharmacologically Active Markers:  These markers are based on the 
pharmacologically active constituents of an extract.  An extract may contain 
pharmacologically active and non active markers, but as explained earlier, due to 
synergism these non active markers cannot be neglected.  Thus, an assay for a 
pharmacological marker can be based on the extent of pharmacologic affect exhibited by 
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the particular constituent or a group of constituents (where individual profiling is not 
possible), wherein the assay can be a bioassay.  If data on individual constituent profiling 
is available a decision can be made on the selection of a particular constituent as a 
pharmacological marker for that extract. Assigning pharmacological markers can be 
relatively easy since there is sufficient data on many, if not all, of the herbal extracts.  
The major drawback with assigning pharmacological markers can be the non 
reproducibility of pharmacological assays and the inability to validate them.  
 
3. Negative Markers:  A particular herbal extract can be profiled based on the 
presence of certain toxins or allergens present.  An extract can be standardized and 
assigned safe or unsafe based on the amount of a particular unwanted constituent.  
Selection and characterization of such negative markers requires highly sensitive and 
specific analytical assays that can measure minute quantity of toxin present in the extract.  
Examples of negative markers can be Ginkgo toxin (4-o-methylpyridoxine) which is a 
neuro toxin present in ginkgo biloba, known to cause loss of consciousness, tonic/clonic 
seizures and sometimes death. [41]  Other examples are the valepotriates 
(valtrate/isovaltrate and dihydrovaltrate) in valerian which are known to be cytotoxic to 
the gastrointestinal mucosal cells after oral administration of the extract. [41] 
 
4. Analytical Markers:  Analytical markers are selected based on the constituents 
that are characteristic of the extract.  These constituents potentially provide a finger print 
towards the identity of the extract.  Analytical markers can be detected by the use of 
sensitive chromatography techniques which can be highly specific and validated for 
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reproducibility.  It should be noted that a particular selected analytical marker need not be 
necessarily pharmacologically active, and in some cases, measurement of such a marker 
can give a false sense of safety and efficacy.  Hypericin, which is present in St. John’s 
Wort can be a good example of an analytical marker for the extract, since it is 
characteristic of the extract, unlike quercetin which can be found commonly in more than 
one herbal extract.  Hypericin though being an analytical marker, is not 
pharmacologically active component of the extract.  
 
5. Bioavailability and Phytoequivalence Markers:  Bioavailability or 
phytoequivalence (bioequivalence of herbal products) markers can be regarded as one of 
the most meaningful class of markers because the efficacy and therapeutic effect of an 
extract finally depends on the rate and the extent of active constituents reaching the 
systemic circulation (an estimate of the amount of drug at the site of action).  It is not 
wrong to assume that a majority of the herbal products are designed for oral 
administration and given the complex nature of contents of an extract, assigning a 
bioavailability marker for an extract would render the measure of efficacy and therapeutic 
effect to a much simpler level.  When primary research is conducted on proprietary 
preparations or extracts, if a researcher/manufacturer is able to document 
bioavailability/phytoequivalence for each of the active constituents, in addition to the 
chemical profile, it gives rise to a strong data base as regards to the in vivo behavior of 
the compounds.  In terms of phytoequivalence, these results get transferable to a claim for 
a preparation and no new pharmacological or clinical studies are required.  Now once the 
constituents are characterized for bioavailability, marker selection is based on the most 
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conservative approach, by choosing the least bioavailable constituent as a measure for the 
bioavailability and phytoequivalence of that extract.  Selecting the least bioavailable 
constituent ensures that if the selected marker reaches the systemic circulation to a certain 
extent, the remaining constituents in the extract would be easily bioavailable. 
 
1.5.3:  Criteria for Marker Selection 
Before the criteria for marker selection are discussed in this section, it is 
necessary to give the reader a very skeletal and brief idea of the work undertaken for this 
project.  This dissertation consists of three types of experimental studies where in: 
a:  The qualitative permeability of the active constituents of selected herbal 
extracts is predicted using a semi empirical model based on the in silico descriptors 
(surface areas and physicochemical descriptors such as CLogP) and in vitro cell 
permeability of the extract constituents. 
b:  The experimental physicochemical properties of the active constituents of a 
representative herbal extract are determined. 
c:   Finally the pharmacokinetics and absolute bioavailability of each of the active 
constituents in the selected representative extract are determined using an animal model.  
The criteria for marker selection are applied right from the very beginning when 
the qualitative predictions regarding the permeability behavior of the active constituents 
are made.        
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Thus, while selecting a bioavailability/phytoequivalence performance marker for 
a particular herbal extract, the following criteria were maintained: 
I:  The selected marker should have the least permeability/bioavailability in its 
group of compounds in the particular herbal extract. 
II:  The marker should be easily available as a reference standard, at a reasonable 
cost and acceptable purity for routine analysis. 
III:  The proportion of the selected marker in the extract should be sufficient for 
its precise quantitative determination in biological fluids after oral administration.   
 
1.6:  SELECTION OF HERBAL EXTRACTS TO PREDICT PERFORMANCE    
MARKERS 
Based on a survey conducted in 2002 which reported the top fifteen selling herbal 
supplements in the United States (Table 1.4) [42] 8 herbal extracts comprising of 37 
active compounds were selected for the qualitative prediction of permeability based on 
the estimation of their in silico descriptors.  
Three herbal extracts comprising of 20 active constituents, were analyzed and  a 
performance marker was selected for each of the three extracts.  The 3 selected extracts 
were Kava, Ginkgo biloba and Milk thistle.   
After performance markers had been predicted for each of the three extracts, Milk 
thistle was selected as the representative extract for the verification of predicted 
properties and for the determination of pharmacokinetics and absolute bioavailability.  
Milk thistle was the choice of extract mainly for two reasons: 
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1. Milk thistle is composed of six isomers from which 4 are diastereomers of 
each other.  The presence of isomers and diastereomers has always presented a 
challenge in the chemical and bioavailability profiling of the extract.  Further 
among the three selected herbal extracts, Milk thistle is the one for which least 
clinical and pharmacokinetic studies have been conducted.  Pure reference 
standards are yet not commercially available for a few of the active isomers.  
Thus, it was thought that Milk thistle would present a sufficient and interesting 
challenging during the process of standardization and performance marker 
selection for the extract.  
2. Kava and Ginkgo biloba are among the most studied herbal extracts in 
terms of pharmacokinetics and bioavailability.  There is a abundant experimental 
data available concerning the physico-chemical and permeability properties of 
ginkgo and kava.   
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Table 1.4:  Top selling Herbal Supplements in the United States  
(Retail Sales-2002, 2005) [42, 43] 
Rank 2002 Herb 






1 Garlic 34.5 3 1 
2 Ginkgo 32.9 1 4 
3 Echinacea 32.44 2 2 
4 Soy 28.25 5 5 
5 Saw palmetto 23.05 6 3 
6 Ginseng 21.68 4 7 
7 St. John’s wort 14.96 7 9 
8 Black cohosh 12.33 10 8 
9 Cranberry 11.85 9 6 
10 Valerian 8.12 8 12 
11 Milk thistle 7.76 12 10 
12 Evening primrose 6.02 13 11 
13 Kava 4.42 11 -- 
14 Bilberry 3.38 15 14 
15 Grape seed 3.05 14 15 
 47
1.6.1:  Kava (Piper methysticum) 
1.6.1.1:  Introduction and Regulatory Status 
Kava, also referred to as Kava kava is the dried rhizome and roots of Piper 
methysticum a large shrub largely cultivated in many Pacific islands from Hawaii and 
Tahiti to New Guinea. [38] It has large heart shaped leaves and is propagated exclusively 
by root cuttings.  The extract of Kava consists of six known kava lactones (≥3.5% in 
exract) known as kava pyrones: Kawain (1.8%), Dihydrokawain (0.6%), Methysticin 
(1.2%), Dihydromethysticin (0.5%), Yangonin (1%) and Desmethoxy-yangonin 
(1%).[44, 45]  (Figure 1.1) The kava extract is prepared traditionally by water extraction 
of the root, and commercially by ethanol extraction (~30% kava lactones) or by acetone 
extraction (~70% kava lactones).  Other constituents of Kava include 2 chalcones, 
flavokawains A and B [46] which are known to be responsible for the cause of 
dermopathy in heavy kava users.  The process of supercritical fluid extraction of kava 
lactones from its roots has been patented by the Schwabe company which also claims to 
have negligible amounts of chalcone content.  
The kava pyrones have a centrally muscle relaxing, anti-convulsive and anti 
spasmodic effects.  The herb also contains hypnotic/sedative, analgesic and psychotropic 
properties contributing to its use for anxiety and insomnia.   
Kava was first mentioned in scientific records in 1886 and began gaining 
popularity for soothing the nerves and inducing relaxation and sleep.  In 1914 it was 
listed in the British Pharmacopoeia and entered into the U.S Dispensary in 1950 for the 
treatment of gonorrhea (‘Gonosan’) and nervous disorders (‘Neurocardin’).  During the 
 48
last two decades, kava preparations have made their way into the European market and in 
the USA, standardized as kava lactones to provide a daily dose in the range of 60-120 
mg.  In 1990, kava was approved in Germany as a non prescription drug for conditions 
such as anxiety, stress and restlessness, to be banned later on for its adverse effects. Kava 
is banned for sale in Switzerland, Germany and Canada.  There has been considerable 
protest from the scientific community as well as ardent kava users and followers 
suggesting that the ban on kava sale in Germany is an exaggerated safety measure and 
that more safety data should be collected through research for the study of kava toxicity. 
[47, 48] There are news that Germany has reversed the ban on kava, but there are still no 
kava products on sale in the German market as kava manufacturing licenses have been 
suspended. [48] The oral route is the prevalent route of administration for kava dosages.  
Kava doses can be obtained in various denominations from 100 mg-500 mg per dose in 
the form of comminuted rhizome filled in capsules as a galenic preparation.    Oral doses 































DESMETHOXYYANGONIN ( DY )
COMPONENTS OF KAVA KAVA :
Figure 1.1:  Structures of Kava Components 
 
1.6.1.3:  Pharmacology 
Kava pyrones have a centrally muscle relaxing, anticonvulsive and antispasmodic 
effects.  The herb is primarily used as an anti anxiety drug or as a mild sedative for 
insomnia due to its hypnotic, sedative and psychotropic properties.  The pyrones are 
lipophilic and better absorbed with food.  Also, the pyrones show greater absorption and 
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higher activity when administered as an extract as compared to when administered as 
single pyrones. This suggests synergism, indicating that the background matrix (kava 
resin) though not pharmacologically active, aids in the physiological processes to 
enhance the pharmacologic effect.  The exact mechanism of action of the kava pyrones is 
not yet exactly known and research data indicates that concentration of the lactones, type 
of preparation (dosage form) and the variety of kava species used influences the 
pharmacologic effect.  Some experiments suggest that the sedative effects may be due to 
an increase in the number of GABA (γ-amino butyric acid) binding site.  Other 
preliminary evidence suggest that the sedative effects might be a result of dopamine 
antagonism, particularly by the Yangonin constituent.  The kava pyrones, methysticin and 
Kawain also inhibit the uptake of noradrenalin which are suspected to contribute to the 
psychotropic actions of kava.  Kava does not affect the benzodiazepine receptors.  Also 
the effects of kava are not reversed by naloxone and hence analgesic effect does not 
occur by the opiate pathway.  At high doses, kava does not impair cognitive function and 
sedation effect of kava occurs without respiratory depression.  Consumption of kava 
results in an overall feeling of being sociable, tranquil and generally happy, similar to the 
feelings after sociable alcohol drinking in the West.  The kava pyrones 
desmethoxyyangonin and methysticin competitively inhibit monoamine oxidase B. [49-
51] 
 
Adverse Effects:  On oral administration kava can cause gastrointestinal upsets, 
headaches, dizziness, enlarged pupils, oculomotor equilibrium and accommodation 
disturbances, dry mouth and allergic skin reactions.  Dopamine antagonism effect is 
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thought to be responsible for the twisting movements of the head and trunk.  Being 
considered as sedative, normal doses of kava can impair the ability to drive or operate 
machinery.  Cases of DUI (“driving under the influence”) have been registered against 
individuals driving after drinking large quantities of kava at kava tea parties.  
    Hepatotoxicity had been observed in individuals after 3-4 weeks of continuous 
kava usage, accompanied by yellowing of skin due to jaundice, fatigue and dark urine.  
Further continuous use of kava for 4-8 weeks can cause elevated hepatomegaly (chemical 
driven liver damage) leading to the onset of encephalopathy.  In isolated cases, short term 
use of kava has caused acute hepatitis which required the patient to undergo a liver 
transplant in as little as 1-3 months of kava use.  These supplements have been banned 
from Germany, Switzerland and Canada.  [51]  It is interesting to note that adverse 
effects in most of the cases have been observed in extracts obtained from ethanol or 
acetone.  Aqueous extracts that are used traditionally, by the Samoans and Pacific 
islanders do not report these adverse effects.  But this does not imply that aqueous 
extracts are safe and hence more data needs to be collected.  
 
1.6.1.4:  Pharmacokinetics 
In vivo studies in rats and humans following intravenous and oral administration 
of kava extract have been reported, with the pharmacokinetic profiling being done for 
kawain as the marker compound.  Tarbah et al. studied the pharmacokinetics of kawain 
and its metabolite p-hydroxykawain in humans after oral administration of 6.9 and 7.7 
mg/kg of kawain. [52]  The main metabolic pathway of kawain is hydroxylation, the 
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metabolites being excreted mainly in their conjugate form (sulfates and glucuronides).  
Post oral administration in human, p-hydroxykawain reached peak plasma concentrations 
of 13ng/mL at ~0.75 hours.  Free kawain showed peak plasma concentration of 41ng/mL 
whereas p-hydroxykawain in the form of glucuronide reached peak plasma concentration 
of 53ng/mL.  The half lives for kawain and its metabolites was found to be between 0.7 
to 1.9 hours and the areas under the plasma concentration time curve reflected that high 
amounts of metabolites were present in the glucuronide and sulfate conjugate form 
(~45% each) where as the free form represented only 10%.  Renal excretion of the 
metabolite p-hydroxykawain was similar in magnitude to the creatinine clearance 
(~7.2L/h) whereas glucuronide and sulfate metabolites showed very high clearance 
values.  Excretion via urine continued beyond 24 hours as high amounts of all three 
metabolites (38.4mg/mL) were found in urine at the end of 24 hours.  Thus, 4.8% of the 
kawain dose of 800mg appeared in urine as p-hydroxykawain during 24 hours.   
Mathews et al. determined the pharmacokinetics of kawain in rats after 
intravenous and oral administration and 7 days of repetitive oral administration of kava 
extract. [53]  They also studied the pharmacokinetics of kawain coadministered with the 
kava extract.  Mean peak plasma concentrations of kawain after intravenous 
administration (7.19mg/kg) were found to be 7.2µg/mL and the half life was 0.62 hours.  
On oral administration of 96.7mg/kg of kawain, peak plasma concentration of 2.6µg/mL 
corresponding to Tmax of 0.88 hours was observed.  The half life was found to be 1.3 
hours.  Plasma concentrations for kawain after oral coadministration (single and repeated 
doses) with the extract were not significantly different from those obtained following a 
single oral administration.  It was also found that the oral bioavailability of kawain 
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increased when administered along with the extract as compared to when administered 
alone.  
1.6.2:  Ginkgo biloba   
1.6.2.1:  Introduction and Regulatory Status 
The ginkgo is the world’s oldest living tree species and it can be traced back more 
than 200 million years to the fossils of the Permian period.  Individual trees grow up to a 
height of 125 feet and have fan shaped leaves. The trees can live up to 125 years.  The 
active components of ginkgo are the flavonol glycosides of quercetin, kaempferol and 
isorhamnetin and the ginkgo terpenes called ginkgolide A, ginkgolide B, ginkgolide C, 
ginkgolide J and bilobalide (Figure 1.2).  Ginkgo biloba is sold as a dietary herbal 
supplement in the United States and is purported to improve blood flow to the brain and 
to improve peripheral circulation.  It is promoted to mainly sharpen mental focus in 
healthy adults and those suffering from dementia.  It is also used for diabetes related 
circulatory disorder and supposedly for vertigo.  Ginkgo shows positive anti-
inflammatory, cognitive promoting, antioxidant and vascular effects.  Ginkgo is not 
effective in the treatment of cocaine dependency, depression, multiple sclerosis, and 
uncreative colitis.  If is also used in the treatment of peripheral occlusive arterial disease, 
platelet aggregation inhibition, increasing the coronary blood flow and vasodilation and 
reducing hypertension.  Ginkgo inhibited platelet activating factor improves 
hemodynamic parameters such as blood flow by decreasing blood viscosity and 
erythrocyte aggregation.   
Ginkgo biloba extracts are standardized to contain 24% flavonols and 6% terpene 
lactones.  An acetone-water mixture is usually used to extract the dried and milled leaves.  
The dry extract powder is obtained after the solvent has been removed.  Regular doses 
range between 40-80 mg, 3 times a day.  Ginkgo is available in the form of oral dosage 
forms in the denomination range 30 mg to 500mg per capsule, 30 mg to 260 mg per tablet 
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ISORHAMNETIN ( Ih )
COMPONENTS OF GINKGO BILOBA:
Figure 1.2:  Structures of Ginkgo components 
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1.6.2.3:  Pharmacology 
The effects of ginkgo biloba are synergistic, hence attributed to the composition 
of the whole extract rather than any one single component.  The two groups of active 
components are the flavonol glycosides and the terpene lactones.  The mechanism of 
action of the ginkgo extract is only partially understood and there are several theories on 
how it might work in several disease states.  One theory is that the extract might work by 
protecting the tissues from oxidative damage since the flavonoids have antioxidant and 
free radical scavenging properties.  The flavonoids potentially seem to reduce cell 
membrane lipid peroxidation and decrease oxidative damage to erythrocytes.  The extract 
is also known to protect neurons and retinal tissues from oxidative stress and injury 
following ischemic episodes.  Protecting neurons and other tissues from oxidative 
damage might prevent progression of tissue degeneration in patients with dementia and 
other conditions.  Ginkgolides in the leaf competitively inhibit platelet inhibiting factor 
(PAF) by binding at the membrane receptors of the respective cells.  PAF inhibition 
decreases platelet aggregation, decreases phagocyte chemotaxis, and smooth muscle 
contraction.  Preliminary research has also shown that the ginkgo extract inhibits 
formation of platelet thromboxane A2, further reducing platelet aggregation. [41, 44, 54, 
55]  
 
Adverse Effects:  Ginkgo leaves and the ginkgo extract also contain a neurotoxin 
called the ginkgotoxin (o-methylpyridoxine, MPN) which can lead to seizures in 
susceptible people.  Ginkgotoxin indirectly inhibits GABA.  It antagonizes the activity of 
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pyridoxine, possibly by inhibiting enzymes such as pyridoxal kinase and glutamate 
decarboxylase in the brain.  GABA is synthesized by glutamate by glutamate 
decarboxylase.  Hence, by inhibiting glutamate decarboxylase, ginkgotoxin indirectly 
inhibits GABA.  Ginkgotoxin is present in much higher amounts in seeds than in the leaf. 
Thus, ingestion of fresh ginkgo seeds may cause stomach ache, nausea, vomiting, loss of 
consciousness and shock and in some events can be fatal.  In vitro experiments show that 
ginkgo extract affects several CYP450 enzymes, however in humans it does not seem to 
significantly affect any of these enzymes. 
 
1.6.2.4:  Pharmacokinetics         
In humans, absolute bioavailability of ginkgolide A is found to be 100%, for 
ginkgolide B is 80-93%, for bilobalide is 70% and for ginkgolide C is very low.  Peak 
plasma concentrations were attained within 2-3 hours for the flavonol glycosides 
(measured as their respective aglycones, due to the hydrolysis in the gut) after oral 
administration of 50mg, 100mg and 300 mg of extract.  Food intake did affect the time to 
peak concentrations for the terpene lactones and the glycosides but did not affect 
bioavailability.  Rat studies using radiolabeled extract have revealed a two compartment 
model for the distribution of the terpene lactones with extensive distribution in the 
glandular and neuronal tissues and in the eyes.  The volumes of distribution for 
ginkgolide A, ginkgolide B and bilobalide were 40-60L, 60-100L and 170L. [41] The 
elimination half life for ginkgolide A, ginkgolide B and bilobalide was 4 hours, 6 hours 
and 3 hours respectively.   Approximately 70% of ginkgolide A 50% of ginkgolide B and 
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30% of bilobalide were excreted unchanged in urine.  Metabolites accounted for less than 
30% of the administered dose and were not detectable in blood samples. [41, 44, 54, 55] 
1.6.3:  Milk thistle (Silybum marianum) 
Milk thistle is an indigenous plant of Europe but now found almost all around the 
world.  The seeds are particularly known for their medicinal benefits.  The active 
constituents of milk thistle are a group of six flavonolignan isomers: silycristin, 
Silydianin, silybin A, silybin B, isosilybin A and isosilybin B (Figure 1.3).  From these 
six isomers, silybin A and silybin B and isosilybin A and isosilybin B are diastereomers 
of each other.  The isomers collectively are known as silymarin.  Silybin A and silybin B 
make up almost 50% of the extract and are collectively called silybin.  Silycristin is 
present up to 25% in silymarin. Isosilybin B and silydianin are the minor components of  
silymarin.  The composition of the isomers in the seed is usually in the range of 1.5-3%.  
Orally, milk thistle is used for liver disorders including toxic liver damage by chemicals, 
Amanita phalloides mushroom poisoning, jaundice, chronic inflammatory liver disease, 
hepatic cirrhosis and chronic hepatitis.  The extract is deemed safe when used orally and 
appropriately.  Milk thistle extracts are standardized to contain 70-80% of silymarin 
content in market dosage forms.  Numerous studies have shown that regular intake of 
milk thistle in recommended dose has proven to be safe with no adverse effects. [18, 44, 
51, 56-60]   
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1.6.3.3:  Pharmacology 
Several activities seem to contribute to the therapeutic effect of silymarin isomers 
in liver disease.  Silymarin seems to cause an alteration of the outer hepatocyte cell 
membrane that prevents toxin penetration.  It also stimulates nucleolar polymerase A 
resulting in increased ribosomal protein synthesis, which can stimulate liver regeneration 
and the formation of new hepatocytes.  There is also some evidence that suggests that 
silymarin might have anti fibrotic, anti inflammatory and immunomodulating effects that 
could also be beneficial in liver diseases.  silymarin isomers inhibit beta glucuronidase, 
which might help protect against hepatic injury and possibly colon cancer.  Inhibition of 
beta-glucuronidase is thought to reduce the hydrolysis of glucuronides into toxic 
metabolites in the liver and intestines.  Preliminary evidence also suggests that silymarin 
might protect the kidney from nephrotoxic drugs like acetaminophen, vincristin and 
cisplatin.  In vitro experiments show that silymarin isomers might have antiproliferative 
effects on androgen responsive prostrate cancer cells, triggering some interest in that 
area.  As regards to herb-drug interaction with respect to metabolism, silymarin is not a 
significant inhibitor of CYP3A4.  Various reports have suggested that silymarin does not 
affect CYP1A2, CYP2D6, CYP2E1 or CYP3A4.   
Other than isolated allergic reactions and minor gastrointestinal disturbances, milk 

























































































COMPONENTS OF MILK THISTLE (Silymarin) :
Figure 1.3:  Components of Milk thistle (Silymarin) 
1.6.2.4:  Pharmacokinetics 
A detailed and comprehensive account describing the pharmacokinetics and 
bioavailability issues of silymarin is given in Chapter 5 of this dissertation.  
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CHAPTER 2:  IN-SILICO DESCRIPTORS AND IN VITRO 
PERMEABILITY 
2.1:  CHAPTER INTRODUCTION 
In this chapter we attempt to establish an interrelationship or a link between the in 
silico descriptors and the in vitro permeability obtained for the active components of 
select herbal extracts.  The effect of parameters such as the CLogP, polar surface area and 
the minimal cross sectional area on the in vitro permeability is studied with an aim to 
predict qualitatively, the least permeable component in selected herbal extract.  Inter 
relationships are studied by plotting various in silico descriptors with permeability using 
2D and 3D graphs.  Selection of the least permeable compound from a particular extract 
as a bioavailability/bioequivalence marker, would be the most conservative approach 
towards ensuring the bioavailability of the entire extract.  Apart from being the least 
permeable component, other criteria that need to be fulfilled for being a suitable 
bioavailability marker are also discussed.  From the various herbal extracts under 
investigation, markers are selected for kava, ginkgo biloba and milk thistle (silymarin).  
Post selection of markers, silymarin is chosen as a representative extract, for the 
verification of marker prediction by solubility, partition coefficient, and in vivo 
pharmacokinetic and bioavailability experiments. 
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2.2:  IN-SILICO DESCRIPTORS 
The meaning of the word ‘in-silico’ refers to something derived or obtained from 
a computer or by performing a computer simulation.  The phrase has its origin from the 
Latin phrases ‘in vitro’ and ‘in vivo’ which are commonly used in biological research.  In 
silico descriptors can be defined as theoretical parameters of a drug molecule that are 
determined by using complex computer programs.  In contrast to wide spread belief, the 
word ‘in silico’ does not mean anything is Latin but the word ‘in silicio’ does mean ‘in 
silicon’.   
2.2.1: Introduction 
Absorption of drugs through the gastrointestinal membrane is a complex process 
depending on drug molecular properties, formulation factors and physiological variables 
of the gastrointestinal tract.  Permeability, absorption and/or bioavailability are are 
complex processes that depend on molecular structure and physicochemical properties of 
the drug as well as physiological variables of the gastrointestinal tract. [61] Thus, 
accurate and quantitative prediction of permeability values derived from molecular 
structure parameters without correlation to some permeability data is a very difficult task. 
 In silico descriptors are classified into 3 types mainly as one dimensional, 2-D 
and 3-D descriptors depending on the representation of drug molecular structure. [62] 
Molecular weight is a typical example of a 1-D descriptor, calculations such as CLogP 
(predicted log of octanol-water partition coefficient) which is based on fragment counts is 
an example of 2-D descriptor and molecular surface areas (polar surface area, minimal 
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cross sectional area) and molecular volume are examples of 3-D descriptor. [62] 
Estimations or results obtained from these descriptors can be of two types namely 
qualitative or quantitative.  Qualitative estimates of a drug include high/intermediate/poor 
or a yes/no answer to a certain property (commonly absorption, permeability or 
bioavailability) where as quantitative estimates may include absolute numbers 
representing or estimating a certain property of the drug.  Lipinski’s rule-of-five is a well 
known example of a qualitative type of estimate which provides an approximate yes/no 
answer to whether a molecule can be considered as a potential drug candidate with 
respect to permeability and bioavailability considerations. [63, 64] Quantitative estimates 
can be obtained from various computer programs available, some of which can be 
accessed using the internet and some which are standalone.  Actelion®, Advanced 
Chemistry Development®, ChemSilico®, Pharma Algorithms® are some of the examples 
of such available programs. [65, 66]  
Solubility and permeability are very complex phenomena and hence there is some 
controversy concerning the accuracy with which these predictions are made.  Further 
since permeability is not a completely structure based phenomena; its prediction is not 
only inaccurate, but probably impossible just based on molecular structure making very 
challenging the development of simple global structure based models to predict intestinal 
permeability.  Models developed to predict permeability are generally applicable to 
transcellular passive transport. [62] Such models may involve conclusions based on 
correlations between in vitro permeability and descriptors like partition coefficient and 
molecular size. In smaller and simpler datasets, polar surface area also acts as a descriptor 
to predict the permeability of a lead compound.  All these models require that the 
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experimental permeability values used for creating the model should be highly accurate 
and generated from one source.   
Further as data sets become more complex with the inclusion of diverse molecular 
structures, model development requires more descriptors derived from structural 
calculations and correlation of these descriptors using complex statistical techniques such 
as multivariate data analysis and projection to latent structures. [62]  
 
2.2.2:  Definitions of Various In silico Descriptors 
2.2.2.1:Predicted Octanol-Water Partition Coefficient (CLogP) 
Drug lipophilicity is widely used as a predictor of membrane permeability since it 
is assumed that drug partitioning in the lipophilic cell membrane is a rate determining 
process for passive membrane permeation.  Lipophilicity is traditionally expressed as the 
n-octanol water partition coefficient: the concentration ratio of the compound between n-
octanol and water at equilibrium.  n-Octanol is usually though not always the solvent of 
choice for the substitution of the intestinal bilayer to study drug partitioning because it 
best mimics the intestinal phospholipid bilayer.  Transcellular diffusion requires 
desolvation of the compound and entry into the lipid bilayer of the cell membrane.  The 
compound travels through the cytoplasmic aqueous phase or along the lipid membranes 
of the cell and crosses the cell membrane again to exit.  Hence, transcellular diffusion 
must depend on the lipophilicity of the compound. [67]  
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2.2.2.2:  Polar Surface Area 
The polar surface area of a molecule can be defined as the surface area associated 
with the hydrogen bonding acceptor atoms nitrogen and oxygen, and the hydrogen atoms 
bound to these heteroatoms. [68] 
2.2.2.3:  Minimal Cross-Sectional Area 
Solution phase properties such as desolvation and membrane permeabilities can 
be predicted using the general solute-solvent interaction (GSSI) approach.  The GSSI 
approach is based on the principle that all solution phase processes can be modeled in 
terms of one or more gas-to-solution transfer processes. [69] The free energy of each gas 
to solution transfer process is calculated as the sum of the free energy of cavity formation 
and the free energy of solute-solvent interaction.  The solutes contributions to the free 
energies are modeled on the various quantities computed from the solute’s three-
dimensional (3D) structure, where as the solvent’s contributions are modeled by 
empirically determined regression coefficients. [69]  
The minimal cross sectional area can be defined as that cross sectional area of the 
solute molecule when it is partitioned into the lipid bilayer interior and is preferentially 




    
Figure 2.1.  Schematic Representation of Minimal Cross-Sectional Area. 
 
This alignment minimizes the work required to create a cavity big enough so that 
the solute molecule can be accommodated into the lipid bilayer. More specifically, the 
free energy of cavity formation is modeled on the basis of the total solvent accessible 
surface area of the solute. [69] Hence, the extent of permeation of the solute through the 
lipid bilayer mainly depends on its cross sectional area along the longest axis of the 
solute.  Therefore transcellular diffusion occurs when a cavity or opening of free volume 
with cross sectional area equal to or greater than the minimum cross sectional area of the 
solute is created. [70] 
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2.2.3:  Use of In Silico Descriptors to Predict Permeability 
2.2.3.1:  Lipinski's Rule of Five 
Lipinski’s Rule of Five states that poor absorption or permeation are more likely 
when: 
1. There are more than 5 H-bond donors (expressed as sum of OH’s and NH’s).  
2. There are more than 10 H-bond acceptors (expressed as the sums lof N’s and 
O’s). 
3. The MW is over 500. 
4. The log P is over 5. 
5. Compound classes that are substrates for biological transporters are 
exceptions to this rule.  
The rule of five is widely recognized as fundamental for the design of orally 
absorbed compounds.  Though the rule is purely based on computational evaluations, it 
identifies the most prominent factors influencing drug absorption. [71]  
 
2.2.3.2:  Role of Calculated LogP and Polar Surface Area in Predicting Permeability   
Membrane permeability is a two step process, where in first the unionized solute 
assumed to be in the solvated form needs to dehydrate itself from the solvent and then 
penetrate the lipid bilayer.  Thus, 1-Octanol/water partition coefficient (LogP) and 1-
Octanol/water distribution coefficient at a selected pH (LogD) are considered as key 
descriptors when modeling a biological process like permeability. [71]  A high partition 
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coefficient implies greater partitioning of the drug in to the lipid bilayer indicating higher 
permeability.  Thus, prediction of partition coefficients has had considerable success in 
developing quantitative structure-activity relationships during the drug discovery stage.  
Some of the programs that can be used to predict the octanol-water partition coefficient 
and distribution coefficient are: 
• ACD LogP: by Advanced Chemistry Development Inc. 
• ACD LogD: by Advanced Chemistry Development Inc. 
• CLogP: PCModels/Daylight CIS, CLOGP/Biobyte 
• MLOGP: Moriguchi LogP [72, 73]  
From these above mentioned methods, CLogP is the most widely used for the 
estimation of partition coefficient.   
During the second stage of the permeation phase when the drug penetrates lipid 
bilayer, after dehydrating itself from the solvent, the interactions between the bilayer and 
the polar parts of the molecule become important.  During this process, the region of the 
lipid bilayer that a drug molecule interacts with first, is densely apolar and hence polarity 
of a drug molecule acts as a rate limiting factor towards the permeation process.  Thus, 
higher the polar surface area of a drug molecule, lower the ability of the drug to penetrate 
the intestinal membrane.  Conversely, it can also be implied, that higher the polar surface 
area of the drug, the less lipophilic the drug becomes, which means the drug tends to 
solvate more in a polar solvent, which in our case is water thus decreasing permeability.  
Hence, as polar surface area increases, which means the non polar surface area of the 
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molecule decreases (Non Polar Surface Area= Total surface area-polar surface area).  
Hence, the value of CLogP decreases as non polar surface area increases. 
2.2.3.3:  Minimal Cross-Sectional Area (MCSA) 
  The minimal cross sectional area is not a commonly used descriptor for 
predicting permeability when compared to partition coefficient or polar surface area.  The 
MCSA is also termed as the Minimal Collisional Cross Sectional Area and is a directly 
related to the permeant size.  Based on the General Solute Solvent Interaction model, the 
MCSA is calculated considering the solute-solute, solute-solvent, and solvent-solvent 
interactions.  According to Pearlman et al. if the free energy of gas-to-solution transfer 
can be calculated accurately, the prediction of free energies of desolvation, partition 
coefficients, membrane permeabilities is possible. [69]  
Lane et al. studied the relationship between rat intestinal permeability and 
hydrophilic probe size and geometry. [74] They concluded that cross sectional diameter 
of a molecule is a more important descriptor than molecular volume for evaluating 
molecular size retarded permeability.   
According to Anderson et al. the minimal cross sectional area can be defined as 
that cross sectional area of the solute molecule when it is partitioned into the lipid bilayer 
interior and is preferentially oriented with its longest axis along the bilayer normal. [70] 
Hence, theoretically this alignment minimizes the work required to create a cavity 
big enough so that the solute molecule can be accommodated into the lipid bilayer. 
Hence, the extent of permeation of the solute through the lipid bilayer mainly depends on 
its cross sectional area along the longest axis of the solute.  Therefore transcellular 
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diffusion occurs when a cavity or opening of free volume with cross sectional area equal 
to or greater than the minimum cross sectional area of the solute is created. 
2.2.4:  Previous Related Studies 
Predicting biological properties like permeability for drug like molecules is 
common and numerous references can be found in literature pertaining to the estimation 
of polar surface areas, molecular volume and predicted partition coefficient.  Prediction 
of permeability characteristics as well as lipophilicity for herbal components is highly 
uncommon.  Avdeef and coworkers studied the transport properties of kava lactones 
through filter immobilized artificial membranes laying emphasis on the effects of stirring 
during transport experiments. [75] They also determined predicted octaol-water partition 
coefficient using the program ACD LogP by Advanced Chemistry Development 
(Advanced Chemistry Development, Toronto, Canada; www.acdlabs.com), the calculated 
aqueous solubility of the uncharged species and the log of partitioning of the kava 
lactones in the blood-brain barrier using the program ABSOLV (Sirius Analytical 
Instruments, Forest Row, E. Sussex, UK; www.sirius-analytical.com).  The log partition 
coefficients (LogP) for the Kava lactones ranged between 1.51 and 2.05, with Yangonin 
and Desmethoxy-yangonin being the most lipophilic and Methysticin being the least 
lipophilic. [75]   
2.2.5:  Why In Silico Descriptors? 
Herbal supplements are crude extracts or semi purified extracts manufactured to 
contain a definite amount of a particular constituent or a group of constituents, which are 
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called marker compound(s).  Since potency requires biological assessment of an extract, 
the presence of marker compounds does not guarantee the potency of an extract.  Even if 
the marker compound demonstrates bioactivity the biological activity depends on the 
composition of the rest of the extract.  Bioavailability data for these herbs or herbal 
supplements in humans is not readily available or difficult to obtain.  If data is available it 
is accompanied by variation and ambiguity. [41] There have been several bioavailability 
studies of silymarin (a group of active markers in milk thistle), but most of them have 
been in terms of silybin or considering silybin as a measure for silymarin.  It should be 
pointed out that silybin and isosilybin exist as diastereomers suggesting significant 
differences in their solubility and bioavailability. [76-79]  
The complexity in the composition of the herbal extracts, lack of genuine in vitro 
permeability data and ambiguous bioavailability studies, in silico descriptors provide a 
preliminary economic alternative to expensive permeability and bioavailability 
experiments.  Since in many cases, the pharmacologic effect of an herbal extract is 
synergistic, selection of a particular component as a marker based on in silico descriptors 
that give a certain idea about the permeability of the component becomes helpful in 
providing a lead for a performance and bioavailability marker.  These descriptors 
(qualitative or quantitative) give a certain directional focus in the selection of a single 
marker compound from a pool of numerous active ingredients present in particular herbal 
extract.  
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2.2.6:  Selected Herbal Extracts and their Active Components 
 
Selection of herbal supplements was primarily based on their highest consumption 
and ranking according to retail sales. [80, 81] Since studying all the known active 
compounds in an herbal extract would be a tedious task, Table 2.1, gives the list of herbal 
extracts and their corresponding active compounds selected for investigation.  The herbal 
extracts were selected as per their rankings based on retail sales in the United States in 
the years 2001 and 2002 (Table 1.4).  The second criterion for selection was structural 
diversity which included kavalactones from kava, terpene trilactones and flavonol 
aglycones from ginkgo, flavonolignan isomers from the fruit of milk thistle and the 
ginsenosides from ginseng.  All together they spanned a wide range of molecular weights 
and functional groups.  Thus, a total of 8 herbal extracts comprising of 37 active 
ingredients were selected for the estimation of their in silico parameters. 
 
2.2.7:  Estimation of In Silico Descriptors 
Estimation of in silico descriptors included the calculation of:  
i. Polar Surface Area (PSA) 
ii. Minimal Cross Sectional Area (MCSA) 
iii. Predicted Octanol-Water Partition Coefficient (CLogP) 
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Table 2.1: Selected Herbal Extracts and their Active Constituents for the Estimation of In 
Silico Descriptors 
Herbal Extract Active Compounds Ranking 
  1997 1998 2001 
Kava Kawain (K), Dihydrokawain (DK), 
Methysticin (M), Dihydromethysticin (DM), 
Yangonin (Y), Desmethoxy-yangonin (DY). 
13 17 11 
Milk thistle Silybin A (SbA), Silybin B (SbB), Isosilybin A 
(ISbA), Isosilybin B (ISbB), Silycristin (Sc), 
Silydianin (Sd), Taxifolin (Tx) 
12 13 12 
Ginkgo biloba Ginkgolide A (GA), Ginkgolide B (GB), 
Ginkgolide C (GC), Ginkgolide J (GJ), 
Isorhamnetin (Ih), Kaempferol (Kf), Quercetin 
(Q) 
1 1 1 
Ginseng Ginsenoside Rb1(GRb1), Ginsenoside Rb2 
(GRb2), Ginsenoside Rc (GRc), Ginsenoside 
Rd (GRd), Ginsenoside Re (GRe), Ginsenoside 
Rf (GRf), Ginsenoside Rg1 (GRg1), 
Ginsenoside Rg2 (GRg2). 
2 3 4 
Black Cohosh 26-deoxyactein (dAcn), 26-deoxyacteol (dAcl) 
Actein (Acn) 
17 N/A 10 
Echinaceae Caftaric acid (CfA), Chicoric acid (CcA) 4 5 2 
Garlic Alliin (Aln), Deoxy-alliin (dAln) 3 4 3 
Valerian Hydroxy-valerenic acid (HVA), Valerenic acid 
(VA) 
10 2 10 
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2.2.7.1:  Molecular Structures 
Conventional molecular structures when viewed on a computer screen are in the 
2-D format, the file names typically having .mol or the .cdx form of a file extension.  In 
order to estimate molecular descriptors such as polar surface area, molecular volume and 
minimal cross-sectional area, it is necessary that the compounds are represented as 
geometrically optimized 3-D structures.  Hence, we used CONCORD® for the conversion 
of 2-D or crude 3-D input structures to accurate and geometrically optimized 3-D 
structures. [82]  
 
2.2.7.2:  Generation and Selection of Conformers 
Since a molecule now exists in 3-D, it gives rise to numerous conformers with 
varying energies.  CONFORT,® a powerful conformational analysis tool, based on a 
novel algorithm for conformational searching, performs exhaustive and rapid analysis of 
3-D drug sized molecules.[83] We used CONFORT® to identify various global energy 
and maximally diverse conformers.  Only conformers having a global conformational 
energy less than 250 kilo calories per mole were selected for the estimation of the polar 
surface and the minimal cross sectional areas. The conformer with the maximum non 
polar surface area was selected for the calculation of PSA and the conformer with 
minimal cross-sectional area was identified for the calculation of the MCSA. 
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2.2.7.3:  Calculation of Polar Surface Area and Minimal Cross-sectional Area. 
In order to calculate the PSA and the MCSA of a solute molecule, it is necessary 
to calculate the accessible surface area (van der Waal’s surface area) of the molecule. 
Solvent accessible surface area of a solute can be described as that surface created by the 
centre of a probe or solvent sphere, when the probe is rolled over the entire van der Walls 
surface of a solute molecule (Fig. 2.2) [84] The accessible surface area was determined 
using SAVOL3, a widely distributed program for calculating the mentioned molecular 
descriptors.[85]  The algorithm computes the molecular (or solvent accessible) surface 
area by summing the non occluded surface area of each atom in the molecule.  This can 
be done by imagining a slicing plane (passing through the two poles of the sphere) being 
rotated incrementally about its axis, thereby cutting the sphere into many double lunar 
segments (imagine, for example, two slicing planes intersecting at the centre of the 
sphere at an angle of one degree from each other, the resulting pair wise spherical 
segments are what is referred to as double lunar segments).[84, 86]  The non-occluded 
surface area of each double lunar segment is calculated by analytically summing up 
portions which are not contained in the van der Walls sphere of a neighboring atom.  The 
precision of the surface area depends on the angle of increment used for rotating the 
slicing plane. 
 SAVOL3 was incorporated along with the GSSI [69, 86] (General Solute 
Solvent Interaction) model for the calculation of the minimum cross sectional area of the 
solute.  The GSSI model is based on a semi-empirical approach to enable the prediction 








Figure 2.2.  van der Waal’s Accessible Surface 
2.2.7.5:  Determination of CLogP 
In the following work SYBYL6.8® which incorporates the program CLogP was 
used to predict the octanol-water partition coefficient of the molecules. [87] The program 
divides the molecule into basic fragments and calculates the log Po/w by the summation of 
hydrophobic contributions of these fragments. [88] CLogP has been tested on an 
elaborate database which includes nearly 8000 compounds and yields good results (r2 = 
0.970). [89] 
2.2.8:  Results 
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The following tables 2.2-2. describe the calculated molecular descriptors (CLogP, 
PSA and MCSA) for the selected 39 active herbal constituents.   
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Table 2.2:  Data for Kava constituents: 
Compound Mol. Wt. C Log P PSA (Ǻ2) MCSA (Ǻ2) 
Desmethoxy-yangonin 228.24 2.79 89.232 92.250 
Dihydrokawain 232.28 2.15 83.790 107.726 
Dihydromethysticin 276.28 1.71 136.049 113.722 
Kawain 230.26 2.04 92.568 106.461 
Methysticin 274.27 1.61 145.773 105.66 
Yangonin 258.27 2.71 108.388 97.242 
 
 
Table 2.3: Data for Milk thistle constituents: 
Compound Mol. Wt C LogP PSA (Ǻ2) MCSA(Ǻ2) 
Isosilybin A 482.44 1.94 350.239 123.707 
Isosilybin B 482.44 1.94 350.593 133.146 
Silybin A 482.44 1.95 349.809 146.32 
Silybin B 482.44 1.94 348.589 125.89 
Silycristin 482.44 1.38 410.998 131.682 
Silydianin 482.44 -0.39 368.061 157.108 
Taxifolin 304.25 1.02 347.423 101.285 
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Table 2.4: Data for Ginkgo biloba constituents: 
Compound Mol.Wt. CLogP PSA(Ǻ2) MCSA (Ǻ2) 
Bilobalide 326.30 -2.64 271.405 139.435 
Ginkgolide A 408.40 -1.55 283.058 128.28 
Ginkgolide B 424.40 -1.45 313.477 132.547 
Ginkgolide C 440.40 -2.48 309.311 134.402 
Ginkgolide J 424.40 -2.58 326.152 134.414 
Isorhamnetin 316.26 1.75 282.536 109.498 
Kaempferol 286.24 1.90 307.353 96.256 
Quercetin 302.24 1.30 353.742 111.565 
 
Table 2.5: Data for Ginsenosides (Ginseng) 
Compound Mol. Wt. CLogP PSA (Ǻ2) MCSA (Ǻ2) 
Ginsenoside Rb1 1109.29 4.544 647.745 224.914 
Ginsenoside Rb2 1079.27 5.232 603.788 232.126 
Ginsenoside Rc 1079.27 4.299 622.799 282.806 
Ginsenoside Rd 947.15 5.726 556.208 273.938 
Ginsenoside Re 947.15 3.869 623.308 295.768 
Ginsenoside Rf 801.01 4.726 417.294 209.152 
Ginsenoside Rg1 801.01 4.932 438.223 245.672 
Ginsenoside Rg2 785.01 4.758 350.105 209.695 
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Table 2.6: Data for Black cohosh, Echinaceae, Garlic and Valerian: 
Herb Compound Mol. Wt. CLogP PSA (Ǻ2) MCSA(Ǻ2) 
26-deoxyactein 660.83 6.124 186.216 152.839 
26-deoxyacteol 600.78 6.781 184.475 164.142 
Black cohosh 
Actein 676.83 5.419 269.289 182.592 
Caftaric acid 312.23 -1.540 420.790 104.414 Echinaceae 
Chicoric acid 474.37 0.139 516.139 167.085 
Alliin 177.22 -2.708 215.180 83.821 Garlic 
Deoxy-alliin 161.22 -1.198 202.245 83.847 
Hydroxy-valerenic acid 250.33 2.650 172.723 116.400 Valerian 
Valerenic acid 234.33 4.737 117.788 124.200 
 
2.3:  IN VITRO PERMEABILITY  
2.3.1:  Introduction 
Assessment of the absorption of a given compound from the gastrointestinal tract 
simply means establishing the permeation of this compound across the wall of the 
gastrointestinal tract.  The gastrointestinal absorption process can be influenced by 
factors such as the dissolution properties of the drug, which may be modified due to 
physiological parameters such as gastric juice and bile resulting in precipitation of the 
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drug at the absorption site, adsorption of the drug to components in the gastrointestinal 
tract, chemical and bacterial degradation of the drug and metabolism of the drug in the 
lumen, and the brush border or in the intestinal wall and others.  There are no in vitro 
methods that can assess all these influences simultaneously during the permeation 
process unless these studies are done in intact humans or animals.  Conducting 
permeability transport experiments in intact humans or animals limit the number of 
compounds that can be screened and also present ethical and significant technical 
difficulties.  There are a wide variety of in vitro methods that are used to study only the 
translocation of drug molecules across the intestinal membrane after oral administration, 
but none of these methods take into account other factors that influence the actual 
bioavailability of the drug. 
 
2.3.2:  Factors Affecting Drug Permeability 
During permeation after oral administration, the drug in order to be able to cross 
the gastrointestinal membrane has to overcome two big hurdles: (i) Release of the drug 
from the formulation matrix and dissolution in the gastrointestinal fluids. This mainly 
depends on the physicochemical properties of the drug; (ii) Transport itself across the 
gastrointestinal membrane and into the blood stream, with minimal or no degradation.  
This mainly depends on the anatomic and physiologic conditions present in the 
gastrointestinal tract.  The rate at which the drug reaches the systemic circulation is 
determined by the slowest step in the sequence which is known as the rate limiting step. 
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2.3.2.1:  Physicochemical Properties of the Drug    
 
When a drug is administered orally, it must be transferred from the dosage from 
to the systemic circulation to be bioavailable.  Thus, bioavailability is a measure of the 
amount (extent) of drug entering the blood stream and the rate at which it enters.  
Bioavailability of a drug absorbed from the gastrointestinal tract is influenced by the 
anatomic and physiological properties of the gastrointestinal system and the 
physicochemical properties of the drug or the drug product.  Physicochemical properties 
include solubility, rate of dissolution, ionization, particle size, surface area, crystal form 
and stability of the drug or the drug formulation.   
 
2.3.2.1.1:  Solubility and Dissolution Rate 
For a drug to undergo passive diffusion, it is required to be released from the 
formulation matrix and enter into solution form.  Thus, for an orally administered drug in 
the form of a capsule, tablet or a suspension, the rate of absorption is governed by the rate 
of dissolution of the drug into the biological fluids.  
2.3.2.1.2:  Particle Size and Surface area 
 A drug dissolves more quickly when the surface area is increased.  Therefore a 
faster dissolution rate can be achieved by reducing the particle size of the drug.   
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2.3.2.1.3:  Crystalline Form 
Drug molecules can exist in more than one crystalline form, thus giving rise to 
polymorphism.  Polymorphs of a drug may differ from each other in physical properties 
such as density, solubility and dissolution rate, and melting point.  The crystalline from of 
a drug is less soluble than the amorphous form as high energy is required to pull the drug 
crystal apart and get it into solution.  Many drugs may associate with solvents to produce 
crystalline forms called solvates.  Solvate forms of a drug with organic solvents may 
dissolve faster than the non-solvated form. [90] 
2.3.2.1.4: Stability 
Acid and enzymatic hydrolysis of a drug may occur in the gastrointestinal tract 
causing extensive degradation of the drug leading to poor bioavailability [91, 92].  
Additionally interactions between the drug or dosage form and a dietary component may 
lead to alterations in the rate and extent of absorption of the drug.  
 
2.3.2.2:  Physiologic Variables of the Gastrointestinal System 
The physiological factors include mesenteric blood flow, gastrointestinal motility 
patterns, volume, viscosity, and flow rate of gastrointestinal contents, presence or 
absence of food, pH and membrane permeability.  
2.3.2.2.1:  pH 
The gastrointestinal barrier favors the permeability of uncharged, lipid soluble 
solutes.  Thus, the proportional ratio of the ionized to unionized species of the drug 
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highly depends on the pH of the solution.  Hence, pH at the site of absorption is an 
important factor during drug absorption.   
2.3.2.2.2:  Gastrointestinal Motility  
Gastrointestinal motility involves the movement of material mainly food through 
the gastrointestinal tract.  The stomach is composed of two main layers of smooth 
muscle.  The outer longitudinal muscle layer is in continuity with the duodenal muscle 
layer while the inner circular layer extends up to the pylorus.  The arrangement of 
muscles allows the stomach to produce coordinated movements of the gastric contents.  
The vagus and the splanchnic nerve connect the stomach to the central nervous system.  
Stimulation of these nerves produces contractions in the stomach.  The stomach also 
possesses two main plexuses of the nervous system: the mesenteric plexus and the 
submucosal plexus.  The major hormones that affect the stomach are secritin, gastrin, 
cholecystokinin, and glucose independent insulinotropic peptide (GIP) and 
enteroglucagon.  This hormonal and nervous network together regulates and optimizes 
the behavior of the gastrointestinal tract.  The stomach exhibits two pattern of motility:  
(i). Fasted Pattern of Motility: Gastric emptying occurs even during fasting and 
the pattern of electrical activity observed is markedly different to that observed in the fed 
state.  This activity is called the interdigestive myoelectrical cycle or the migrating 
myoelectric complex.  Migrating motor complexes are waves of activity which sweep 
through the gastrointestinal tract in a regular cycle during fasting state.  This cycle 
originates in the stomach every 75-90 minutes during inter digestive phase and is 
responsible for the rumbling observed when hungry. These complexes trigger peristaltic 
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waves which facilitate transportation of indigestible substances such as bone, fiber and 
foreign bodies from the stomach through the small intestine past the iliocecal sphincter 
into the colon.  It also transfers bacteria from the small intestine to the large intestine and 
inhibit the migration of colonic bacteria into the terminal ileum.  
Each cycle is divided into four consecutive phases of activity.  Phase I 
corresponds to 40-50% of the cycle duration, Phase II to 20-30%, Phase III to 10-15%  
and Phase IV to 0-5%.  During Phase I a series of weak intensity contractions are 
observed. Phase II comprises of irregular contractions gradually increasing in amplitude 
culminating in the onset of discharge of gastric contents.  During Phase III the 
contractions become regular and have the greatest amplitude.  Discharge of gastric 
contents is completed during this phase.  Finally Phase IV comprises of a reduction in the 
frequency and amplitude of contractions.  The whole cycle repeats itself every 2 hours 
until a meal is ingested, which then triggers a fed pattern of motility.   
Factors that can trigger a fasted pattern of motility are hungry state, alkaline 
buffer solutions, anxiety, lying on the right side, hyperthyroidism, metoclapromide and 
dopaminergic blockers.  Factors that prevent this cycle are diets rich in fatty acids, mental 
depression, lying on the left side, gastroenteritis, pyloric stenosis, gastric ulcer, Crohn’s 
disease and hypothyroidism. [93]  
 
(ii). Fed Pattern of Motility:  Stimulation of the parasympathetic nerves increases 
contractility and relaxes the pylorus, resulting in a decrease in the rate of emptying of 
solids and liquids.  Liquid and solid emptying is controlled by the proximal and distal 
portions of the stomach respectively.  The proximal stomach produces slow distal 
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contractions which are responsible for the basal pressure in the stomach which is 
responsible for the gastric emptying of liquids.  The distal portion or antrum of the 
stomach has a thicker muscular wall which is concerned with the emptying of solids.  The 
peristaltic waves initiated do not expel food from the stomach but cause the larger 
particles to accumulate away from the walls in a zone where the flow is reversed.  Thus, 
the larger particles are retropulsed into the antrum where they are caught up by the next 
peristaltic wave.  The liquid component of the meal empties exponentially while the solid 
component empties linearly after a variable lag time.  This lag time depends on the size 
of the food particles in the stomach and larger the particles, longer it takes to break these 
particles to a suitable size.  Eventually all material is emptied by the stomach into the 
small intestine where absorption occurs.  The small intestine like the stomach exhibits 
two distinct patterns of motility where the fed pattern is characterized by three sequential 
contractions separated by 5 to 40 seconds of inactivity.  This fed pattern consists of 
segmental and peristaltic contractions in which the segmental contractions are frequent.  
The interdigestive myoelectirc complex continues from the stomach to the small intestine 
repeating every 140-150 minutes and as one complex reaches the ileum another starts at 
the duodenum.   
Absorption from the small intestine is known to be rapid, depending on how fast 
the emptying process from the stomach takes place.  Absorption of drugs is significant 
from the small intestine and thus the emptying process from the stomach into the small 
intestine becomes the rate limiting step for efficient absorption of drugs.  Highly 
statistically significant correlations have been observed between the gastric emptying half 
life and the time to maximum plasma concentration of acetaminophen. [94] 
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2.3.2.2.3:  Gastrointestinal Blood Flow 
Passive transport of drugs takes place over a concentration gradient from a region 
of high drug concentration to a region of low drug concentration until equilibrium is 
established.  When a drug is transported through the gastric membrane to the systemic 
circulation, it is removed continuously by the blood flow maintaining sink conditions and 
continuous transport.  Thus, a decrease in the mesenteric blood flow decreases the rate 
removal of drug from the gastrointestinal tract thus affecting the rate and extent of drug 
absorption. [95, 96] However normal physiological variability in mesenteric blood flow 
does not significantly affect absorption rate of drugs.  
2.3.3:  Transport Mechanisms 
The biological membrane may be described as a dynamic lipoid sieve or a semi 
permeable lipoid membrane containing several aqueous pores or channels.  It hosts 
carrier molecules that shuttle ions, proteins etc back and forth across the membranes.  
Transport of drugs across the gastrointestinal membrane can be categorized into three 
main sections.  These are diffusion, active transport and transcytosis. 
2.3.3.1:  Diffusion 
This is a process in which molecules spontaneously move from a region of higher 
concentration to a region of lower concentration, until equilibrium is established.  The 
concentration gradient is the main driving force for this phenomenon.  Diffusion is a 
movement due, solely, to the kinetic energy and the electrical charge of the molecules, 
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and the electrical field in which they exist. [97, 98]  No external energy is required for 
this process.   
2.3.3.1.2:  Passive Diffusion 
In this process the flux is proportional to the concentration of the solute and the 
rate is independent of direction.  
2.3.3.1.3:  Facilitated Diffusion 
This is a carrier mediated transport phenomenon where the flux is saturable with 
increasing concentration.  The mechanism is structurally selective and drugs with similar 
structure may act as competitive substrates for the transport system.  The rate of flux in 
facilitated diffusion may be asymmetric.  Glucose and other medium sized molecules are 
transported in this manner.   
2.3.3.2:  Active Transport 
  
This is a carrier mediated transmembrane process characterized by transport of 
drug against a concentration gradient (or an electrochemical gradient), i.e from a  region 
of low concentration to a region of high concentration [99, 100].  The mechanism 
involves a directly or indirectly coupled energy consuming system and the flux rate is 
asymmetric.  The energy for active transport is usually derived from the hydrolysis of 
high energy phosphate bonds contained in adenosine triphosphate,   creatinine phosphate 
or arginine phosphate.  The system is substrate specific and drugs with similar structures 
may compete for binding sites on the carrier molecule.  Further more because only a 
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certain amount of carrier is available, at high drug concentrations, all binding sites on the 
carrier molecule become saturated.   
Cotransport is a variety of active transport in which the absorption into the cell 
against the concentration gradient is linked to the secretion of a cellular ion such as 
sodium down its concentration gradient.  This process is important for the absorption of 
amino acids in the small intestine.    
2.3.3.3:  Transcytosis (Endocytosis or Vesicular Transport) 
Endocytosis is a process whereby cells absorb material (molecules such as 
proteins) from the outside by engulfing it with their cell membrane. It is used by all cells 
of the body because most substances important to them are large polar molecules, and 
thus cannot pass through the hydrophobic plasma membrane. This process takes place 
against a concentration gradient and therefore is usually energy dependent.  The opposite 
of endocytosis is exocytosis.   
 
2.3.3.3.1:  Absorptive Endocytosis 
During this process the solute attaches itself either to the surface proteins or to the 
glycolipids.  The mechanism often has high capacity, but can be saturable and show high 
competition due to non-specific receptor binding.  
 
2.3.3.3.2:  Receptor-mediated Endocytosis 
The substrate has high affinity for the specific receptor and hence the process is 
very substrate specific, saturable and asymmetric.   
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2.3.3.3.3:  Fluid-phase Endocytosis 
This process is also known as pinocytosis where in small soluble molecules are 
internalized with the vesicle volume.  The process is non specific and non saturable and 
occurs due to the fluidity of the cell membrane.  Phagocytosis differs from pinocytosis in 
that very large particles are taken up from the lumen and released into the circulation by 
migrating leukocytes or macrophages.  The particles can also enter the intestinal villi 
across the gap created by the sloughing off of the enterocytes at the tip of the villi.  
Pinocytosis appears to be more substrate specific that phagocytosis.   
2.3.4:  Transport Pathways 
Passage of molecules across the epithelial cell membrane occurs either 
paracellularly (between two adjacent cells) or transcellularly (through the cell).  The 
permeating solute is open to both these pathways, however the relative contribution of the 
observed transport pathway depends highly on the properties of the solute and the type of 
membrane involved.  
2.3.4.1:  Paracellular Transport  
Paracellular transport occurs strictly by passive diffusion.  Generally, polar, 
membrane impermeant molecules diffuse through the paracellular route which is 
dominated by the tight junctions.  Exceptions to this are molecules that are transported 
actively through one or both membrane domains of the cell.   The tight junction is a mesh 
work of continuous chains of membrane proteins.  This intercellular space occupies 
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0.01% of the total surface area of the epithelium.  The closely fitting tight junctions on 
the apical side gate them.  In humans, the duodenum has the largest mean pore radii of 
intercellular spaces, which is approximately 0.8 nm.  The mean pore radii o the 
intercellular spaces in the ileum and the colon are approximately 0.3nm. [101]  As a 
result drugs excluded from the transcellular route are often well absorbed from the upper 
part of the small intestine. [102] The mean pore radius presents only a crude estimate 
since the pores of the paracellular pathway range between large number of small pores 
and small number of large pores.  This explains how, for many drug molecules, even 
though the mean pore radius is too small to permeate through tight junctions, they can 
still be transported from these channels.  Additionally nutrients and hormones regulate 
the permeability of the paracellular pathway for several drug molecules. [103, 104] 
2.3.4.2:  Transcellular Transport  
Transcellular transport can occur through passive, facilitated or active processes.  
Moderate and highly lipophilic molecules diffuse passively across cellular barriers by the 
transcellular route.  Tanscellular diffusion can occur through a number of mechanisms. 
[105] According to one mechanism the solute can pass through the aqueous diffusion 
layer and partition from the aqueous extracellular environment (including the negatively 
charged glycocalyx) into the cell plasma membrane.  In the membrane the solute can 
remain mostly within the hydrocarbon domain of the, lipid bilayer and diffuse laterally 
around the tight junctions.  The transport of the solute is then completed by desorption 
from the receiver side membrane or by repartitioning into the aqueous receiver 
compartment.  Alternatively it has been proposed that the solute can partition out of the 
donor side membrane into the cell cytoplasm.  The solute then diffuses through the cell 
cytosol and repartitions into the basolateral cell membrane.  The solute thus can 
sequentially partition its way through the cell depending on its relative affinity for 
different intracellular membranes.  Further, there maybe specific carrier proteins within 
the cytosol that transfer the solute across the cell or among various subcellular 
compartments.       
 
2.3.5:  Mathematical Models for Drug Absorption 
The amount, M of material flowing through a unit cross-section, S, of a barrier in 
unit time, t, is known as the flux, J (Equation 2.1). [106] 
 
Sdt
dMJ =                                                     Equation 2.1 
 




dCDJ −=                                                     Equation 2.2 
 
In which, D is the diffusion coefficient of the permeant in cm2/sec, C is the 
concentration in g/cm3 and x is the distance of movement perpendicular to the surface of 
the barrier in cm.  The negative sign of the equation implies that the diffusion occurs 
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from a region of high concentration to a region of low concentration.  In other words, 
diffusion occurs in the direction of decreasing concentration of the permeant and hence 
the flux will always be a positive quantity.  The diffusion constant of the diffusivity, D, 
can be affected by temperature, pressure, solvent properties and the chemical nature of 
the permeant.  Hence, D should be referred to as a diffusion coefficient rather than a 
constant.   
The schematic representation of diffusion across a semi-permeable membrane is 
illustrated in Figure 2.3.  When C1 represents the concentration in the membrane on the 
donor side and C2 refers to the concentration in the membrane on the receiver side. ‘h’ 
represents the thickness or the width of the membrane.   
The concentration gradient within the membrane is assumed to be constant for a 
quasi-stationary state to exist.  It is also assumed that the aqueous boundary layers on 
both sides of the membrane do not significantly affect the transport process.   
 
Therefore, combining the equations 2.1 and 2.2, the flux (diffusion rate) can be 
described as:  
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Figure 2.3: Schematic representation of diffusion across a semi-permeable membrane 
 
Although the concentrations C1 and C2, within the membrane are not ordinarily 
known they can be related to the concentration of the permeant in the donor 
compartment, Cd, or the concentration in the receiver compartment, Cr, by using the 
intrinsic partition coefficient between the membrane, the donor and the receiver 




dM )( −=                             Equation 2.5 
 92
Since the apparent permeability coefficient, Papp, is defined as, 
h
DkPapp =                                                  Equation 2.6 




app −= )                               Equation 2.7 




app=                                          Equation 2.8 
Another method to determine drug absorption rate (the flux) has been suggested 
by Amidon et al. [35] 
CwPwJw .=                                                     Equation 2.9 
Where Jw (x,y,z,t) is drug flux (mass/area/time) through the intestinal wall at any 
position and time, Pw (x,y,z,t) is the apparent permeability of the intestinal wall, and Cw 
(x,y,z,t) is the drug concentration a the intestinal membrane.  The rate of loss of drug 







      Equation 2.10 
where the double integral is over the entire intestinal surface. [35] 






∫∫∫=                                    Equation 2.11 
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For generality the permeability is considered to be both time dependent and 
position dependent.  Based on the above analysis, it is seen that the two factors that are 
primarily involved in drug absorption are drug permeability and concentration at the 
absorption site.  Maximum absorption would occur when the drug has the highest 
permeability and highest concentration (given by its saturation solubility) at the site of 
absorption.  As a result oral absorption of a drug in vivo could be predicted in vitro based 
on the solubility and permeability measurements of the drug.  The local mass absorbed 
per unit time, per unit area is therefore the basis of first principle of bioequivalence. The 
analysis implies that if two drug products containing the same drug have the same 
permeability-concentration time profile, at the intestinal membrane surface, then they will 
have the same rate and extent of absorption.  This further implies that if two drug 
products have the same in vivo dissolution profile under luminal conditions, then they 
will have the same rate and extent of absorption. [35] Thus, this approach can also be 
used to establish bioequivalence of drug products.   
2.3.5.2:  pH Partition Theory 
The pH partition theory proposed by Brodie and associate’s states that drugs are 
absorbed from the gastrointestinal tract mainly in their molecular and undissociated form. 
[107-109] It is reasoned that the partition coefficient between the membrane and the 
gastrointestinal fluids is large for the unionized species and favors the transport of the 
molecular form from the lumen through the predominantly lipophilic gastrointestinal 
barrier and into the systemic circulation.  In developing the pH-partition hypothesis, 
Brodie studied intestinal absorption by opening up rats and perfusing their stomachs or 
intestines with drug solutions and simultaneously injecting drug solutions in to their 
blood.  Thus, by doing so an instantaneous equilibrium was established between the two 
fluids, described by the following equation:  
Cb
CgD =                                                                                Equation 2.12 
where,  
Cg: Total drug concentration in the gut. 
Cb: Total drug concentration in blood. 
Therefore mathematically D can be calculated using the following equations: 














                                                            Equation 2.13 













=                                                             Equation 2.14 
where pH1 and pH2 are the pH of blood and the gastrointestinal fluid, 
respectively.  
Brodie found an excellent correlation between the experimentally determined D 
and the mathematically determined D.  However results from a large number of in vitro 
and in vivo experiments indicate that Brodies’ theory (pH partition hypothesis) is only 
partly applicable to biological systems. [110] In many cases, the ionized as well as the 
unionized drug partition into, and is transported across the lipophilic membrane. 
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2.3.5.3:  Alternative Approach to the pH -partition principle 
An alternative physical model approach to the pH-partition theory was presented 
by Ho and Huguchi.  This model describes the intestinal membrane as a barrier 
containing a lipoidal membrane interspersed with aqueous regions called aqueous pores.  
At the surface of this membrane is a stagnant aqueous diffusional barrier which could be 
rate limiting in certain conditions.  When empirically verified, the model indicates that 
unionized species partitions into the lipoidal membrane and diffuses across whereas small 
ionized species and unionized species diffuse through the pores. [111, 112] Thus, this 
alternative approach differs from the original pH-partition theory which states that only 
the unionized species permeates through the intestinal barrier during the absorption 
process.  Theoretically, a sigmoidal relationship should exist between the mathematical 
and experimental values of rate of absorption and drug lipophilicity.   At low 
lipophilicity, the rate of absorption approaches a plateau with minimal rates of absorption 
due to diffusion through the aqueous pore pathway.  At high lipophilicity the absorption 
rate assumes a plateau with maximal rate, and absorption in this region is limited by the 
rate of diffusion through the stagnant aqueous layer.   
 
2.3.6:  In vitro Methods to Study Intestinal Permeability 
Assessment of absorption of a given drug from the gastrointestinal tract implies 
the determination of permeability of that drug, but there are more factors involved in the 
net process.  Apart from permeation resulting in translocation there are factors that have a 
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negative influence on the absorption of the drug such as influence of the physiological 
components such as gastric juice and bile on the dissolution properties of the compound, 
precipitation at absorption site, chemical or bacterial degradation of the compound and 
metabolism of the drug in the lumen, at the brush border or in the intestinal wall.  No in 
vitro method can assess all these aspects simultaneously with the exception of studies in 
intact animals or humans.  Whole animal or human studies pose ethical difficulties and 
are unsuitable for screening large number of trial drug candidates.  Certain in vitro 
methods such as brush border membrane vesicles and isolated intestinal segments are 
used to perform detailed studies on intestinal drug absorption.   
2.3.6.1:  Brush Border Membrane Vesicles 
In this approach, cell homogenates or intestinal scrapings are treated with the 
calcium chloride precipitation method by centrifugation.  The obtained pellet contains the 
luminal wall bound proteins and phospholipids which are responsible for the brush border 
enzymatic and carrier activity.  Resuspension of the pellet into a buffer results in the 
formation of vesicles.  These vesicles are mixed with permeant in buffer and filtered after 
a fixed time to determine the amount of permeant taken up by the vesicles.  Since the 
precipitation-centrifugation procedure results in the isolation of only the brush border 
components only the apical transcellular transport can be measured by this system. [113]  
An interesting modification to this procedure was done by Pidgeon et al. who isolated 
brush border components and immobilized these components on a chromatographic 
system leading to the famous and well known Immobilized Artificial Membranes (IAM).  
The drugs under investigation are eluted with an aqueous eluent, thus enabling the 
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estimate of permeation capacity factors.  Though this method is bound by limitations, it is 
more popular due to its fast and less complicated procedure. [113]   
   
2.3.6.2:  Isolated Intestinal Cells 
The method of isolated intestinal cells can be divided fundamentally into to 
categories: an in situ procedure, in which the intestine is perfused with enzyme solutions 
that release the cells; and an ex vivo approach, in which the cells are treated by chelating 
agents or by enzymatic means. [113] The freshly isolated cells are immediately 
suspended in Krebs-Hanseleit buffer with 10mM glucose added and kept on ice for 
fifteen minutes, during which they are bubbled with carbogen (95% O2, 5% CO2).  The 
exposure to glucose increases the viability of the cells even after the media has been 
replaced by glucose free media.  During a typical experiment, the cells are separated from 
the primary buffer by centrifugation and resuspended in buffer under carbogen, in the 
presence of the permeant and shaken well. After a designated time, the cells are separated 
by gradient centrifugation or rapid filtration and extracted.  The major drawback of this 
method is that it requires the permeant to be radio labeled.   
2.3.6.3:  Caco-2 Cell Model 
The Caco-2 cell line was established by Dr. Jorgen Fogh (Memorial Slough-
Kettering Cancer Center, NY) in 1974. [114, 115] However the original proposal of the 
Caco-2 model for intestinal absorption was proposed by Borchardt and coworkers in 
1989. 
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The Caco-2 cells undergo spontaneous enterocytic differentiation in culture that 
starts when cell reach monolayer integrity (7 days) and is completed in 20 days.  The 
cells form numerous domes spontaneously after reaching confluence.  This is consistent 
with their ability to undertake transepithelial transionic transport.  Except for the mucous 
layer the Caco-2 cells caontain the major permeability barriers (aqueous boundary layer, 
cell membranes and intercellular junctions between the cells) to drug absorption.  The 
ability of Caco-2 cells to achieve a high degree of enterocytic differentiation than other 
cell lines and their spontaneous dome formation makes this cell line the most relevant in 
vitro system investigating transport processes associated with intestinal cells.  Many 
researchers have demonstrated that Caco-2 cell monolayers can be successfully grown on 
microporous filters.  The cells are grown in a similar way as the Madin-Darby canine 
kidney cells where the apical and the basal fluids are separated, which helps to carry out 
transport studies of drug molecules from one fluid to the other.  The presence of collagen 
matrix on the basement (polycarbonate) membrane promotes cell growth and attachment.  
Therefore when cell epithelia are in direct contact with the basement membrane, cell 
matrix interactions are important for the regulation of cell polarity.  Hilgers et al. studied 
the effect of collagen presence on the confluency of the Caco-2 cell monolayers and 
found that collagen matrix is unnecessary for the establishment of monolayers.  Further 
they also found that collagen promotes the migration of cells through the filter during the 
early stages of the culture resulting in the depolarization of the Caco-cell model. [116]  
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2.3.6.3.1:  Growth and Morphology 
The Caco-2 cells develop a typically enterocytic morphology as seen in villous 
cells and also posses the polarity of a number of brush border enzymes.  As per the 
experimental growth conditions, these properties are fully expressed within 15-20 days in 
culture. By the fourth day after seeding on uncoated polycarbonate filters (pore size 3µ), 
patchy clusters of actively dividing cells are seen with tight junctions between adjacent 
cells.  The cells appear squamous in shape, containing many endoplasmic reticulum and 
mitochondria and no glycogen. At this stage very few immature microvilli can be seen on 
the apical side.  By day 7 the cells reach confluence, their shape changing from squamous 
to cuboidal and establish desmosomes.  At day 10 mature microvilli develop and large 
vacuoles containing unknown material are present.  By the fourteenth day the cells 
become columnus in shape and the nucleus can be seen eccentrically located in the 
basolateral border of the cell.  Glycogen is the major component of the cytoplasm 
between the nucleus and the apical brush border.  Intercellular lumens expressing 
microvilli are seen running parallel to the polycarbonate filter.  After 16 days it is seen 
that the Caco-2 cell monolayers are about 25-30µ in height and posses a morphology 
similar to that observed in the simple columnar epithelia of the small intestine.  After day 
21 small amounts of cytoplasm are seen extending into the filter and these keep on 
increasing through 28 days, but no microvilli are seen in the receiver chamber of the cell.  
Fifteen day old Caco-2 cell cultures have an average height of 25µ, an average width of 
6µ and the tight junction between two adjacent cells has an average length of 0.1µ.   
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2.3.6.3.2:  Cell Polarity       
The degree of functional polarity achieved by the cells is determined by the 
specific activity and the ultrastructural distribution of the enzyme alkaline phosphatase in 
the brush border membrane.  In normal intestinal epithelial cells this enzyme is highly 
polarized and located exclusively on the apical brush border membrane.  
Caco-2 cells express sucrase-isomaltase, lactase, aminopeptidase, dipeptidyl 
aminopeptidase, γ-glutamyl transpeptidase, all brush border enzymes that are 
differentiation-specific markers for small intestinal enterocytes.  Cytosolic phase II 
enzymes such as glutathione S-transferase, Sulfotransferase, and glucuronidase as well as 
microsomal cytochrome P450 are expressed in Caco-2 cells. [116, 117] 
2.3.6.3.3:  Integrity of the Monolayer      
Monolayer integrity, meaning the ability of the cell membrane to act as a barrier 
to let/let not certain molecules through can be determined by a certain characteristic 
molecules known as permeability markers.  The inability of horseradish (Mol. Wt 40,000 
g/mole) to cross the Caco-2 cell tight junctions demonstrates that this in vitro 
permeability system is very much similar to the characteristics of the small intestine in 
vivo.  Minimal leakage (<0.25%/hour) is observed for Lucifer Yellow CH (Mol. Wt. 453 
g/mole), Polyehtylene glycol (Mol. Wt. 4000 g/mole), Inulin (Mol. Wt. 5000 g/mole), 
Dextran (Mo. Wt. 70,000 g/mole).  One of the most common permeability marker is 
Mannitol (Mol. Wt. 180 g/mole) which is exclusively transported by the paracellular 
pathway and its uptake by the cell membrane is very low.   
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Transepithelial electrical resistance (TEER), which is the measurement of 
electrical resistance across the cellular monolayer, is also a very sensitive and reliable 
method to check the monolayer for its integrity and permeability.  This measurement 
reflects the resistance across the cell tight junctions and not the cell membrane.  An 
average value between 150-400Ω-cm2 has been reported from different laboratories, 
indicating that under different culture conditions Caco-2 cell monolayers can demonstrate 
electrical properties of the small intestinal or colonic enterocytes.  In one study the TEER 
measurements for 103 monolayers was compared and was found to be between 220-380 
Ω-cm2.   TEER values of 700-900 Ω-cm2 have been reported for Caco-2cell monolayers 
by Augustijns et al.  It seems that high TEER values were related to the passage number 
of the cells as cells with passage number between 50-100 were found to have a TEER 
measurements between 260-900 Ω-cm2 .  Cells with a low passage number, in the range 
of 19-35, were found to have TEER values between 170-250 Ω-cm2.  Although these 
high TEER values dependent on passage number were significantly higher than what 
would be expected for the human small intestine. [113, 116, 117] 
2.3.6.3.4:  Transport and Permeability Properties 
  Several studies have been carried out to determine the suitability of the Caco-2 
cell line to carry specific carriers that are characteristic of the small intestine.  A number 
of specific transport systems that are capable of carrying nutrients and macromolecules 
such as folates, sugars, dipeptides, and cephalosporins have been seen to be functional in 
the Caco-2 cell system.  It has been reported that the properties of apical H+/dipeptide 
cotransport in the Caco-2 cell system closely resembles to that of the small intestine.  The 
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systems involved in the carrier mediated transport of bile acids and large neutral amino 
acids show many of the basic properties (specificity, saturability, competitiveness, 
unidirectionality) shown by the small intestine in vivo. [113, 116, 117]      
One of the major advantages of the Caco-2 cell model is its application to high 
throughput screening (HTS) strategies in large numbers due to its simple and highly 
reproducible culturing techniques.  Rubas et al. compared the permeabilities of a series of 
compounds with poor intrinsic permeabilitiy (eg. gamma interferon) in both Caco-2 cells 
and human large intestinal tissue and found that the cells well reflect permeability 
characteristics of the large intestine.  This implies that flux measurements across Caco-2 
monolayers may be predictive for permeabilities of the human colon and rectum. [113, 
117, 118]   
2.3.6.4:  In vivo and In Situ Techniques 
 Most of the in vivo and in situ models for drug absorption are based in animals.  
Physiological conditions are maintained in both these models and the intestine maintains 
a constant blood supply from its own systemic circulation.   
The in situ rat gut technique is a small closed loop system in which the drug 
solution is perfused through a segment of the intestine and the disappearance of the drug 
is measured as a function of time.  The method is simple, economical, fast and perfusion 
studies can be performed using easily available apparatus.  Data obtained from a single 
animal can be subjected to complete kinetic analysis and physiological variability from 
animal to animal is minimum.  Therefore this method is used for studying drug 
absorption in vivo.     
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Schanker et al. and Kakemi and others have studied the dynamics of absorption 
using single pass perfusion.  In single pass experiments drug solution is perfused through 
the gut and the entering and leaving concentrations are determined.  It is assumed that the 
absorption process follows first order kinetics and the decrease in drug concentration is 
followed.  The disadvantage of this technique is that the volume of the perfusion fluid is 
larger than the volume of the gut and hence at any instant of time, only a small fraction to 
of the perfusion fluid is exposed to the absorption site.  The through and through 
perfusion technique developed by Ho et al. lays emphasis on the volume of the boundary 
layer (which can be rate limiting for highly permeable drugs) as compared to the in situ 
rat gut technique. Perfusion studies in humans are carried out using multiple lumen tubes 
for intubation.  In these studies mostly open or semi open perfusion systems were used, 
and these methods were hampered by the fact that conditions at the absorption site could 
not be controlled due to the extensive penetration of the proximal/distal luminal contents.  
The technique also required higher perfusion flow rates than normal jejunal flow of 0.6-
4.2 ml/min.  A new perfusion instrument developed by Lennernas consists of multi 
channel tubes with two inflatable balloons.  A 10 cm long segment is created between 
these balloons enabling perfusion of a defined and closed part of the jejunum.  The 
technique was first tested for antipyrine and a good correlation was observed between the 
absorption from the intestinal perfusate and the absorption obtained by deconvulation of 
plasma concentrations. [113, 116, 117, 119]    
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2.3.6.5:  Simulated Biological Dissolution and Absorption System (SimBioDAS®) 
SimBioDAS® was developed by Kinetana Inc. and is an epithelial cell based in 
vitro permeability assay which can be used to predict absorption. [120] SimBioDAS® is 
an acronym for Simulated Biological Dissolution and Absorption System, the patent for 
which was issued in 2000.  Although SimBioDAS® has not been published in the peer 
reviewed literature, the inventors have made presentations at various scientific 
conferences. [121, 122] The SimBioDAS® assay has two key components: a non-human 
cell-line and a computer model that “scales” the in vitro cell permeability to absorption 
along the intestine in vivo. To determine the absorption and permeability of a compound, 
a solution of a botanical extract is applied to the donor side and the absorbable 
components appear on the receiver side. Absorption is estimated by scaling the in vitro 
permeability with the use of a seven-compartment model. Permeability is estimated on 
the basis of the rate at which the compound is transported across the cell membrane. 
Kinetana has compared the performance of SimBioDAS® with that of Caco-2 cell 
monolayers in estimating the absorption of 35 commercially available substances, 
including ginkgo (Ginkgo biloba L., Ginkgoaceae) extracts. [122]  
The schematic set up for SimBioDAS® is very similar to the Caco-2 cell set up 
which involves the Transwell® chamber with a polycarbonate filter membrane.  The drug 
under investigation is applied in the upper, apical chamber and the amount of drug 
transported to the basal chamber, through the cell monolayer is accounted for.  The cell 
monolayer which is non human in origin is cultured over the polycarbonate membrane 
and its integrity is tested by trans-epithelial electrical resistance (TEER).  The 
monolayers of SimBioDAS® achieve differentiation within three days.  During transport 
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studies, integrity of the cells is monitored by TEER and by using Lucifer Yellow as the 
permeability marker.  
Three day SimBioDAS® has been directly compared to 21 day Caco-2 cells on 
35 validation compounds shown in Table 2.7.   
Table 2.7: List of Model Drugs for Comparison of SimBioDAS® and Caco-2 
permeability 
Drug Human Fa Mol. Wt. Drug Human Fa Mol. Wt. 
Testosterone 1 288 Furosemide 0.61 331 
Piroxicam 1 331 Chlorothiazide 0.56 296 
Glucose 1 180 Ranitidine 0.56 314 
Verapamil 1 455 Atenolol 0.55 266 
Naproxen 0.99 230 Metformin 0.51 129 
Cefalexin 0.99 347 Methotrexate 0.51 454 
Phenazone 0.97 188 Sulpiride 0.35 341 
Theophylline 0.96 180 Erythromycin 0.35 734 
Glibenclamide 0.95 494 Nadolol 0.34 309 
Metoprolol 0.95 267 Benzylpenicillin 0.3 334 
Ketoprofen 0.92 254 Acyclovir 0.215 225 
Propranolol 0.9 257 Foscarnet Na 0.171 192 
Saccharin 0.85 183 Mannitol 0.159 182 
Gabapentin 0.74 171 Gancyclovir 0.03 255 
Terbutaline 0.73 225 Cefuroxime 0.01 424 
Amoxicillin 0.72 365 Raffinose 0.003 504 
Hydrochlorothiazide 0.67 298 Doxorubicin 0 544 
Cimetidine 0.64 252    
 




Figure 2.5:  Human in vivo Fa versus Peff of 35 model drugs in SimBioDAS® and Caco-2 
monolayers with error bars (SD) for Fa and permeability 
 
Figure 2.4 is a plot of human in vivo Fa versus the permeability by SimBioDAS® 
and Caco-2 cell monolayers for the 35 model drugs used during the comparison process.  
Figure 2.5 shows the same plot with error bars (SD) for the 35 model drugs.  It can be 
seen that SimBioDAS® and Caco-2 cell permeabilities for highly permeable drugs 
absorbed via transcellular diffusion require only a cell membrane surface area correction 
(roughly 10 fold) to correlate to published human in vivo data.  Drugs with moderate to 
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low Fa show less scatter with SimBioDAS® than with Caco-2.  Also the magnitude of 
variation in permeability values observed for SimBioDAS®, Caco-2 cells and human Fa 
is similar and the application of a certain area correction helps in the correlation of the 
three properties with each other.  None of the orally administered drugs tested with 
SimBioDAS® were found to be outliers.  SimBioDAS® requires an approximate 10 fold 
area correction for high, moderate and poorly permeable drugs, to correlate to the 
published human in vivo data, where as Caco-2 cell permeability for moderate to poorly 
permeable drugs require an approximate 100 fold area correction, probably due to Caco-
2’s too tight junctions.  Thus, the Caco-2 data may lead to an under estimation of the 
paracellular diffusion values of these drugs and thus an under estimation of the total 
passive diffusion.  SimBioDAS® and Caco-2 cell permeability values for well absorbed 
drugs are the same.  
2.3.7:  Estimation of CaCo-2 cell Permeability of Silymarin Isomers (Silybin A&B) 
CaCo-2 cell monolayers have been widely accepted as an in vitro human 
permeability surrogate and as a high through put permeability screening tool for new 
drug candidates.  This section describes the CaCo-2 cell transport studies for silymarin 
isomers Silybin A and Silybin B.  CaCo-2 cell permeability experiments were carried out 
only for the diastereomers due to solubility limitations and also due to non availability of 
pure reference standards for each of the isomers in silymarin. 
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2.3.7.1:  Materials and Reagents  
The CaCo-2 cell line used in the transport experiments was obtained from Cedra 
Corporation, Austin, Texas.  Transwell® cell culture chambers (24.5mm diameter, 3.0 µm 
pore size, 4.71 cm2 growth area), six well cluster plates, and cell culture flasks (T-25, T-
75 and T-162) were obtained from Corning Costar Corporation (Cambridge, MA).  
Dulbecco’s Modified Eagle Medium (DMEM, 10x, powder) with 4.5g/liter D-glucose 
and 584 mg/liter L-glutamine was obtained from Sigma Aldrich (St. Louis, MO).  
Phosphate Buffer Saline with/without calcium and magnesium (10x solution) were 
obtained from Sigma Aldrich (St. Louis, MO).  Non essential amino acids solution 
(NEAA, 100x), sodium pyruvate soloution (100mM), and HEPES 
(hydroxyethylpiperazine ethane sulfonic acid) were obtained from Gibco-BRL Life 
Technologies Inc (MD).  Fetal Bovine Serum (FBS, certified) was obtained from Atlanta 
Biologicals (Norcross, GA).  Trypsin-EDTA and D-Glucose were obtained from Sigma 
Aldrich.  All other reagents used were of analytical grade unless otherwise specified.   
2.3.7.2:  Preparation of Growth Medium   
CaCo-2 cells were grown in a medium containing 90% DMEM, 10% FBS, 1% 
NEAA, and 1% sodium pyruvate.  10x DMEM powder was dissolved in 90% of the final 
required volume of sterile distilled water, at room temperature (15-20°C).  The growth 
medium was sterilized by passing through a 0.22µm membrane.  All procedures were 
carried out under sterile conditions under a laminar flow hood and precautions were taken 
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to prevent any contamination.  The media was stored in sterile bottles at 4°C and warmed 
to 37°C in a water bath prior to use.   
2.3.7.3:  Growing Caco-2 Cells     
Caco-2 cells grow in monolayers and domes arise when the cells become 
confluent.  Caco-2 cells were grown and expanded using the prepared growth medium in 
a carbon dioxide incubator maintained at 37°C in an atmosphere of 5% CO2 and 95% 
relative humidity.  The cells were grown in a 162cm2 T-flask and the medium was 
changed every other day for the first seven days and then once a day.  95% of the cells 
are known to be confluent by the end of seven days.  The cells were then passaged.   
For passaging the cells the media was removed gently by suction and then the 
cells were rinsed with phosphate buffered saline (PBS without Ca++ and Mg++) solution to 
remove any remaining medium. The PBS was removed by suction and the cells were 
treated with 10ml of EDTA in Ca++-Mg++ free PBS until the cells started to move apart 
from each other (~5-10 minutes).  They were then incubated with 4 ml trypsin for 1-2 
minutes.  At this time the cells started to detach from each other and from the substratum.  
Addition of 10ml of DMEM to the flask inhibited the action of trypsin.  The cells were 
then transferred to a centrifuge tube and spun at 80g (<1000 rpm) for 10 minutes.  The 
supernatant solution was suctioned off and the cell pellet was resuspended in fresh 
medium.  The cells were brought into ta single cell suspension by drawing them up and 
down in a pipette.   
A 10µL aliquot of the single cell suspension was then transferred to each side of 
the hemocytometer using a pipettor fitted with a sterile pipette tip.  The cells in one 
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square (or a total of at least 100 cells in one or more squares) were counted on each side 
of the hemocytometer and the average number of cells in each square was estimated.  
Each side of the hemocytometer with the cover slip in place represents a total volume of 
10-4 cm3.  The number of cells per mL was estimated using this relationship.  The cells 
were then seeded into a Transwell® cup (for transport experiments) or into another 
162cm2 T-flask for the continuation for the cell line.  The required density for seeding a 
4.71 cm2 Transwell® chamber was 63000 cells per cm2 and the required density for 
inoculation a T-162 flask was 2 x 105 cells per mL.   
In the Transwell® chamber, 1.5 ml of the cell suspension was added to the apical 
chamber and 2.5 ml of medium was added to the basal chamber to promote optimal 
growth of cells.  The Transwell® chambers were then labeled and incubated at 37°C, 95% 
relative humidity and 5% CO2.                
25 ml of the diluted cell suspension was added to a T-162 flask, labeled and 
incubated under the same conditions as mentioned above.  The filtered vented flask 
allowed the equilibration of air within the flask with the atmosphere of the incubator.   
The Transwell® system used in the transport studies consists of microporous cell 
culture inserts designed to fit the cell culture clusters.  A schematic representation of the 
Transwell® system is shown in Figure 2.5.  
 
          
Apical chamber 
Basolateral chamber 









Figure 2.6. Schematic of a Transwell® System  
 
The insert hangs from top of the well providing independent access to both the 
apical and the basolateral membrane of the cell.  Every insert has openings for pipette tips 
so the media and samples can be added and removed during experiments.  The thin 
microporous polycarbonate membrane present in the inserts provides permeable growth 
support for the cells.  Transwell® inserts used for permeability experiments were sterile 
with a pore size of 3.0µ and a diameter of 24mm resulting in a growth area of 4.71 cm2.   
2.3.7.4:  Assessment of Monolayer Integrity 
The integrity of the Caco-2 cell monolayers was determined by measuring the 
trans-epithelial electrical resistance (TEER).  The passage number of cells was another 
critical factor that was controlled during transport experiments, since repeated passaging 
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can lead to singling of the cells into a sub population that can have characteristics 
different from the parent population.    
The TEER of the Caco-2 cell monolayers was measured prior to starting the 
transport experiments for each Transwell® chamber.  A Transwell® cup without a 
monolayer, and filled with DMEM was used as a blank to eliminate any background 
signal.  A pulsating current of 3µA was through two electrodes filled with 3M potassium 
chloride and 3% agar using a DVC 1000 voltage/current clamp.  The zero adjustment was 
done so as to eliminate the background noise caused by the electrical system and the 
polycarbonate membrane.  Then a Transwell® cup with the monolayer was placed and a 
pulsating current of 50µA was passed, and the corresponding voltage recorded.  The 
corresponding epithelial resistance was calculated by multiplying the voltage change with 
the surface area (4.71cm2) and then applying Ohms Law.    
2.3.7.5:  Preparation of Transport Buffer 
The transport buffer was composed of Dulbecco’s Phosphate Buffered Saline (D-
PBS), HEPES (hydroxyethylpiperazine ethane sulfonic acid) and glucose.  10ml of 10x 
D-PBS in 1 liter sterile water was mixed with 15 mmol (3.575 g/liter) of HEPES and the 
pH was adjusted to 7.2 with 1N NaOH, giving a buffer with pH control from 6.8 to 8.2.  
Finally 1g/liter D-Glucose was dissolved into the buffer.  Due to the high concentration 
of glucose in the solution, and its susceptibility to microbial contamination the buffer 
solution was prepared fresh prior to each experiment and stored in the refrigerator up to 
seven days. 
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2.3.7.6:  Transport Experiments 
Fifteen day old monolayer of Caco-2 cells grown in Transwell® chambers was 
used during the transport experiments.  The transport of silymarin isomers, Silybin A and 
Silybin B was determined from the apical to the basal side at pH 7.2.  Silybin solution for 
the transport experiments were prepared by dissolving the appropriate amount of Silybin 
A+B in transport buffer.  Due to the limited solubility of Silybin isomers, only one 
concentration, of each isomer could be tested for transport experiments.  The 
concentration of Silybin A was 32µg/mL and concentration of Silybin B was 
34.31µg/mL.  Prior to the experiment the growth medium was suctioned off from both 
the chambers and the monolayers were washed thrice with pH 7.2 transport buffer.  The 
monolayers were then incubated with 1.5ml of transport buffer (pH 7.2) in the apical 
chamber and 2.5ml of transport buffer in the basal chamber for 15 minutes.  Transport 
experiments were conducted on triplicate at 37°C in an atmosphere of 5%CO2 and 95% 
relative humidity.  Sampling intervals for the experiment were set according to the 
chemical structure, lipophilicity and available pKa data of the isomers.  The sampling 
intervals were also approximated accordingly so that not more than 10% of the drug went 
across the monolayers between each sampling interval.  Thus, the transport experiment 
was carried out under sink conditions and the amount of drug diffusing back from the 
basal to the apical side was minimized.  The sampling time intervals were 5, 10, 20, 30, 
45, 70, 90, 120, 150 minutes.  The amount and reason for drug loss due to metabolism, 
precipitation or accumulation of solute, or adsorption to apparatus was accounted for by 
mass balance calculations.  Adsorption of drug to the Transwell® cups was also checked 
prior to the transport experiments, by incubating the Transwell® cups (without 
monolayers) with the drug solution  for 3 hours and calculating the amount of drug 
adsorbed, if any.  Amount of drug accumulated into the cells was determined by treating 
the monolayers with a cell solubilizing agent (Triton-X®) and analyzing for drug content.   
 
2.3.7.7:  Quantitative Determination of Silybin A and Silybin B 
The amount of Silybin A and Silybin B transported from the apical side to the 
basal side was determined by high performance liquid chromatography using ultraviolet 
detection.  The complete procedure has been described in detail in the Analytical 
Methodology section of this dissertation. 
 
2.3.7.8:  Calculation of Apparent Permeability Coefficients   
The percent mass transferred to the receiver side during each time interval was 










            Equation 2.14 
where, [R]t is the amount in the receiver compartment at time t, [D]0 is the amount 
in the donor compartment at time zero, i.e. the initial amount in the donor compartment.  
[Rcum]t-Δt is the cumulative amount transferred until the beginning of that time interval 
and, Δt is the length of the time interval.    
During the transport experiments the concentration in the donor compartment 






















Figure 2.7.  Schematic diagram illustrating the continuous decrease in donor 
concentration as function of time. 
Since permeability across the cell monolayer remains constant, equation 2.15 
suggests that decreasing concentration would result in a decrease in the flux over a period 
of time.   
CPJ .=                                                 Equation 2.15 
Suppose at the beginning of a time interval the amount of drug in the donor 
compartment is [D]0 - [Rcum]t-Δt then at the end of the time interval, the amount of drug 
in the donor compartment would be [D]0 - [Rcum]t-Δt – [R]t It was therefore assumed that 
the amount of drug in the donor compartment throughout the time interval remained 
uniform at [D]0 - [Rcum]t-Δt – [R]t/2 
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The percent mass transferred at each time interval was then normalized to account 



















   Equation 2.16 
The average normalized percent mass transferred during each time interval was 
calculated, excluding the first and the last data point to increase the precision of 
estimation.  The percent mass transported per unit time (Δ%/Δt) was estimated by simply 
dividing the normalized percent mass transferred by the duration of the time interval.  






%.                                                               Equation 2.17 
 
Where Pe is the effective permeability coefficient measured in cm/sec, Vd is the 
volume of the donor compartment (1.5ml) during the apical to basolateral transport 
experiments, A is the surface area of the monolayer (4.71cm2) and Δ%/Δt, which has 
been previously defined.   





=                               Equation 2.18 
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 Where, [R]cum is the cumulative amount transported to the receiver compartment, 
D is the amount of drug remaining in the donor compartment, D0 is as previously defined.  
2.3.7.9:  Results 
Integrity of the Monolayers: The trans-epithelial electrical resistance (TEER) 
reflects the resistance across the tight junctions of the cell.  The TEER for the Caco-2 
monolayers was consistently between 320-380 ohms-cm2 indicating that the monolayers 
used in the transport experiments did not have any leaks or have any imperfectly formed 
occluding junctions or holes.  Monolayers having values of TEER above 300ohms-cm2 
are usually considered fit for transport studies, though the value may vary considerably 
with the increase in passage numbers.     
Permeability of Silybin A and Silybin B:  The effective permeability coefficients 
of Silybin A and Silybin B were measured in the apical to basal direction at pH 7.2.  The 
transport of the silymarin isomers was found to be linear over the time intervals studied.  
The results of the permeability experiments for Silybin A and Silybin B are shown in 
Table 2.8.   
Table 2.8:  Effective Permeability of Silybin A and Silybin B 
Peff x 10-6 (cm/sec)Compound Conc. (µg/mL) 
n1 n2 
Mean Peff x 10-6 
cm/sec (± SD) Log Peff 
Silybin A 32.00 1.67 1.52 1.60 ±0.106 -5.795 
Silybin B 34.31 2.53 2.70 2.62 ±0.119 -5.581 
Peff= Effective Permeability, Conc. = Concentration, SD= Standard Deviation 
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2.3.8:  Estimation of In vitro Permeability using SimBioDAS® 
 In vitro cell permeability values for the active ingredients of the selected herbal 
extracts were obtained in collaboration with Kinetana Inc. [120]  
2.3.8.1:  Results  
Permeability results obtained using SimBioDAS® are shown in Table 2.9-2.13. 
Table 2.9: SimBioDAS® Permeability Results for Kava Compounds. 
Compound Mol. Wt. Peff x10-6 (cm/sec) SD x10-6 (cm/sec) 
Desmethoxy-yangonin 228.24 21.66 1.03 
Dihydrokawain 232.28 19.33 0.81 
Dihydromethysticin 276.28 19.33 0.81 
Kawain 230.26 20 1.09 
Methysticin 274.27 20.33 0.81 
Yangonin 258.27 65.66 16.84 
Peff= Effective Permeability, SD= Standard Deviation 
 121
Table 2.10:  SimBioDAS® Permeability Results for Milk Thistle Compounds. 
Compound Mol.Wt Peff x10-6(cm/sec) SD. x10-6 (cm/sec) 
Isosilybin A 482.44 N/A N/A 
Isosilybin B 482.44 N/A N/A 
Silybin A 482.44 1.88 1.02 
Silybin B 482.44 1.86 0.99 
Silycristin 482.44 1.31 0.80 
Silydianin 482.44 N/A N/A 
Taxifolin 304.25 2.20 0.63 
Table 2.11:  SimBioDAS® Permeability Results for Ginkgo biloba Compounds. 
Compound Mol. Wt. Peff x10-6 (cm/sec) SD x 10-6 (cm/sec) 
Bilobalide 326.30 3.89 0.13 
Ginkgolide A 408.40 6.20 0.26 
Ginkgolide B 424.40 3.921 0.17 
Ginkgolide C 440.40 4.25 0.24 
Ginkgolide J 424.40 3.19 0.51 
Isorhamnetin 316.26 N/A N/A 
Kaempferol 286.24 0.83 0.07 
Quercetin 302.24 0.76 0.10 
Peff= Effective Permeability, SD= Standard Deviation 
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Table 2.12:  SimBioDAS® Permeability Results for Ginseng Compounds. 
Compound Mol. Wt. Peff x10-6 (cm/sec) SD x10-6 (cm/sec) 
Ginsenoside Rb1 1109.29 0.16 0.12 
Ginsenoside Rb2 1079.27 N/A N/A 
Ginsenoside Rc 1079.27 0.28 0.25 
Ginsenoside Rd 947.15 0.20 0.06 
Ginsenoside Re 947.15 0.99 0.37 
Ginsenoside Rf 801.01 N/A N/A 
Ginsenoside Rg1 801.01 2.03 0.92 
Ginsenoside Rg2 785.01 N/A N/A 
Peff= Effective Permeability, SD= Standard Deviation 
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Table 2.13:  SimBioDAS® Permeability Results for Black cohosh, Echinaceae, Garlic & 
Valerian Compounds. 





26-deoxyactein 660.83 11.067 2.551 
26-deoxyacteol 600.78 5.267 1.457 
Black 
Cohosh 
Actein 676.83 2.883 0.366 
Caftaric acid 312.23 9.750 0.683 Echinaceae 
Chicoric acid 474.37 11.500 0.837 
Alliin 177.22 1.333 0.308 Garlic 
Deoxy-alliin 161.22 2.400 0.456 
Hydroxy-valerenic 
acid 
250.33 5.800 1.006 Valerian 
Valerenic acid 234.33 39.667 10.328 
Peff= Effective Permeability, SD= Standard Deviation 
2.4:  CORRELATION BETWEEN IN SILICO DESCRIPTORS AND SIMBIODAS® 
IN VITRO PERMEABILITY 
This section attempts to establish a link between in silico descriptors and the in 
vitro permeability, the discussion of which leads to the selection of a meaningful 
bioavailability and performance marker.  Tables 2.14-2.18 lists the in silico descriptors 
and the in vitro permeability for 39 actives from the various herbal extracts studied.   
 124















228.24 2.79 89.232 92.250 21.66 1.03 
Dihydrokawain 232.28 2.15 83.790 107.726 19.33 0.81 
Dihydromethysticin 276.28 1.71 136.049 113.722 19.33 0.81 
Kawain 230.26 2.04 92.568 106.461 20.0 1.09 
Methysticin 274.27 1.61 145.773 105.66 20.33 0.81 
Yangonin 258.27 2.71 108.388 97.242 65.66 16.84 
Table 2.15: In Silico & Permeability Data for silymarin Compounds. 







Isosilybin A 482.44 1.94 350.239 123.707 N/A N/A 
Isosilybin B 482.44 1.94 350.593 133.146 N/A N/A 
Silybin A 482.44 1.95 349.809 146.32 1.88 1.02 
Silybin B 482.44 1.94 348.589 125.89 1.86 0.98 
Silycristin 482.44 1.38 410.998 131.682 1.31 0.80 
Silydianin 482.44 -0.39 368.061 157.108 N/A N/A 
Taxifolin 304.25 1.02 347.423 101.285 2.20 0.63 
MCSA=Minimal Cross sectional Area, PSA=Polar Surface Area, Peff= Effective Permeability, SD= 
Standard Deviation 
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Table 2.16: In Silico & Permeability Data for Ginkgo biloba Compounds. 
Compound Mol. 
Wt. 








Bilobalide 326.30 -2.64 271.405 139.435 3.89 0.13 
Ginkgolide A 408.40 -1.55 283.058 128.28 6.20 0.26 
Ginkgolide B 424.40 -1.45 313.477 132.547 3.92 0.16 
Ginkgolide C 440.40 -2.48 309.311 134.402 4.25 0.24 
Ginkgolide J 424.40 -2.58 326.152 134.414 3.19 0.51 
Isorhamnetin 316.26 1.75 282.536 109.498 N/A N/A 
Kaempferol 286.24 1.90 307.353 96.256 0.83 0.07 
Quercetin 302.24 1.30 353.742 111.565 0.76 0.10 











Ginsenoside Rb1 1109.29 4.544 647.745 224.914 0.16 0.12 
Ginsenoside Rb2 1079.27 5.232 603.788 232.126 N/A N/A 
Ginsenoside Rc 1079.27 4.299 622.799 282.806 0.28 0.25 
Ginsenoside Rd 947.15 5.726 556.208 273.938 0.19 0.06 
Ginsenoside Re 947.15 3.869 623.308 295.768 0.98 0.37 
Ginsenoside Rf 801.01 4.726 417.294 209.152 N/A N/A 
Ginsenoside Rg1 801.01 4.932 438.223 245.672 2.03 0.92 
Ginsenoside Rg2 785.01 4.758 350.105 209.695 N/A N/A 
MCSA=Minimal Cross sectional Area, PSA=Polar Surface Area, Peff= Effective Permeability, SD= 
Standard Deviation 
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Table 2.18: In Silico & Permeability Data for Black Cohosh, Echinaceae, Garlic and 
Valerian  
Herb Compound Mol. 
Wt. 








26-deoxyactein 660.83 6.124 186.216 152.839 11.067 2.551 
26-deoxyacteol 600.78 6.781 184.475 164.142 5.267 1.457 
Black 
cohosh 
Actein 676.83 5.419 269.289 182.592 2.883 0.366 
Caftaric acid 312.23 -1.540 420.790 104.414 9.750 0.683 Echina-
ceae Chicoric acid 474.37 0.139 516.139 167.085 11.500 0.837 
Alliin 177.22 -2.708 215.180 83.821 1.333 0.308 
Garlic 
Deoxy-alliin 161.22 -1.198 202.245 83.847 2.400 0.456 
Hydroxy-valerenic 
acid 
250.33 2.650 172.723 116.400 5.800 1.006 
Valerian 
Valerenic acid 234.33 4.737 117.788 124.200 39.667 10.328 
MCSA=Minimal Cross sectional Area, PSA=Polar Surface Area, Peff= Effective Permeability, SD= Standard 
Deviation 
 
The CLogP for the actives ranged from -2.70 for alliin to +6.7 for the highly 
lipophilic acteols from black cohosh. The Ginsenosides are found to be the largest 
molecules in terms of size and though being highly lipophilic, have low permeability 
mainly due to their size. (Figure 2.8, 2.9)  The kava lactones from kava are found to be 
the most lipophilic followed by the flavonolignans from milk thistle, and the flavonol 
aglycones from ginkgo biloba.  Though flavones are present as glycosides in ginkgo 
biloba, they are known to be hydrolyzed to aglycones (quercetin, kaempferol and 
isorhamnetin) after oral administration of ginkgo biloba.  Hence, the aglycones are taken 
into consideration when studying permeability.  The terpene trilactones from ginkgo are 
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Figure 2.10.  Plot of Permeability (Peff) vs Minimal Cross Sectional Area (MCSA) 
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In this section an attempt has been made to study the interrelationships between 
the in silico descriptors and in vitro permeability to see whether these correlations help us 
select the least permeable component in select herbal extracts (kava, Ginkgo biloba and 
Milk thistle).  Selecting the component which has the least intestinal permeability is the 
most conservative approach to ensure the bioavailability of a multicomponent herbal 
supplement. 
Hence, while selecting a bioavailability marker for a herbal extract three criteria 
need to be fulfilled: 
1.  The selected marker should have one of the least permeability among its active 
components in the extract 
2.  The proportion of the selected marker in the extract should be sufficient for its 
precise quantitative determination in biological fluids after oral administration.(e.g. 
silycristin in milk thistle, kawain in kava). 
3.  The selected marker should be easily available as a reference standard, at a 
reasonable cost and acceptable purity for routine analysis. 
A plot of the predicted octanol-water partition coefficient versus the polar surface 
area is shown in Figure 2.8.  The plot depicts an overall rough trend that the polar surface 
area of all the components (except the outliers) increases as the components move from 
the lipophilic scale to the hydrophilic scale.  This holds true for the kava components, all 
the ginkgo terpenes (GT) and 3 isomers of silymarin (Tx, Sd, Sc).  The ginsenosides and 
the acteols from Black cohosh can be considered as outliers due to their unrealistic high 
values of CLogP.  These unrealistic high CLogP values can be attributed to their large 
molecular weight (between 600-1100g/mole) and structure.  It has been reported that the 
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efficiency of partition coefficient predicting programs such as CLogP goes down as the 
molecular weight or the size of the compound increases. [123] Thus, the ginsenosides and 
and the acteols can be considered as clear outliers.  High polar surface area indicates the 
greater hydrophilic nature of the compound and thus a lower polar surface area implies 
greater lipophilicity and hence higher permeability which is again true in the case of kava 
compounds, which are lipophilic, have a low polar surface area and are the smallest and 
simplest of the molecules in terms of molecular weight and structure (Ch.1; Figure 1.1: 
Structure of kava components). 
Figure 2.9 is a plot of the effective permeability determined using SimBioDAS® 
(Peff) versus the polar surface area for the active herbal components.  The plot depicts a 
clear trend that as the PSA increases, the Peff of the components decreases.  If metoprolol 
(Peff = 10 x 10-6 cm/sec) is considered as a cut off limit to distinguish between high 
permeability and low permeability compounds, we see that most of the herbal 
components fall into the low permeability class with the exception of the kava 
components.  The plot depicts a linear decrease in permeability with the increasing PSA 
(R2 =0.72) indicating that the decrease in permeability is probably due to the solvation of 
the compound and the increasing molecular size.  It can be inferred from this plot that 
from a group of components in each extract, the one which has a low permeability and a 
high PSA would indicate lower intestinal permeability and can be selected as a probably 
marker.  For the kava compounds, yangonin (Y) is the only component which has a very 
high permeability (Peff =65.66x 10-6 cm/s) where as the other 5 components have 
permeabilities in a close range with each other (19.3-21.6 x 10-6 cm/sec).  Between these 
low permeability components, methysticin and dihydromethysticin (M&DM) have the 
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highest PSA (~140 Ǻ2) followed by kawain (92.56 Ǻ2).  Yangonin cannot be considered 
as a marker, mainly due to its high permeability.  Kawain (K)is one of the major 
components of the kava extract, in proportion  and in terms of pharmacologic effect and 
thus kawain is considered as a marker, for kava.   
For the ginkgolides in ginkgo biloba, ginkgolide J (GJ) has the highest polar 
surface area accompanied with the lowest permeability, and can be considered as a 
marker.  The proportion of GJ in the extract is very minimum as compared to the other 
ginkgo terpenes like GA, GB or GC and the next least permeable component among the 
terpenes is GB.  GB is also easily available commercially as a reference standard and 
hence GB can be considered as a marker for the ginkgo terpenes.  Similarly quercetin can 
be considered as a marker for the flavonol glycosides in ginkgo biloba.   
Among the silymarin isomers, silydianin (Sd) has the highest polar surface area 
and is expected to be the least permeable compound in the extract, due to its very low 
lipophilicity (-0.39).  Sd is one of the minor components of silymarin and also suspected 
to be pharmacologically inactive as compared to the silybins [56], where as the next least 
permeable compound silycristin (Sc) has a very high proportion in the extract and is 
easily quantifiable.  Thus, Sc can be selected as a marker for the silymarin isomers.  
Hence, based on the plot of effective permeability versus PSA we have we have 
kawain as a marker for kava, ginkgolide B as a marker for the ginkgo terpenes and 
quercetin as a marker for the flavonol glycosides and silycristin as a marker for milk 
thistle. 
Figure 2.10 shows the plot of effective permeability (Peff) versus minimal cross 
sectional area (MCSA).  The plot depicts an approximate trend of decreasing 
 132
permeability with the increase in the MCSA which is expected, as the MCSA is the area 
of the molecule when it is partitioned in the lipid bilayer during the permeation process.  
Hence, larger the cross sectional area , the more difficult it is for the molecule to 
permeate in to the lipid bilayer, in this case the gastro intestinal membrane.  Among the 
kava components, we have DM and DK with similar permeability values and increasing 
MCSA’s.  They are followed by kawain which has the next highest MCSA and a similar 
permeability of 20x10-6 cm/sec.  As earlier, among the three, kawain is selected as a 
marker for kava based on its pharmacology and its major proportion in the extract.  Also 
kawain is readily available as a reference standard.   
Among the silymarin isomers, between Sc and SbA, Sc would be selected as a 
marker.  Sd is not a choice due to its minor proportion in the extract.   Even though SbA 
has a higher MCSA (146 Ǻ2) than Sc (131 Ǻ2) SbA is more lipophilic (1.95) as compared 
to Sc (1.38) and has a lesser permeability value as compared to SbA.  Hence, the low 
lipophilicity and the low permeability value of Sc makes it a more lesser permeable 
candidate than  SbA and hence based on this plot, Sc is selected as a marker for 
silymarin.   
Among the ginkgo terpenes a choice needs to be done between bilobalide (B) and 
ginkgolide B (GB) as performance marker.  The previous plot, based on Peff versus PSA 
predicted GB as a marker, due to its high polar surface area and proportion  in the extract 
among the terpenes.  Considering the permeability values, there is no significant 
difference between the permeability values of GB and B. Also GB has a moderately 
hydrophilic nature (CLogP=-1.45) as compared to B (CLogP=-2.64) which is highly 
hydrophilic.  This increases the chance of GB being as the least permeable compound, as 
compared to B which would not be permeable at all due to high salvation.  Thus, GB is 
selected as a marker for the terpenes and quercetin which has a high MCSA (111 Ǻ2) and 




Figure 2.11.  Graph of MCSA vs. CLogP vs. Permeability of all Active Components 
 
Figure 2.11 shows a 3D plot of the MCSA vs CLogP vs Peff of the active 
components of the herbal extracts.  This further clarifies the choice of markers predicted 
for the select extracts, based on the inter-parameter relationships between CLogP, MCSA 
 133
 134
and Peff of the compounds.  Figure 2.11 shows the effect of MCSA and CLogP on the 
permeability of the compounds indicating the basic trend that most of the compounds 
have a low permeability (<5 x 10-6cm/sec) and range in a window with CLogP from  -1.5 
to +2.2 and MCSA from 100 Ǻ2 to 160 Ǻ2.  Thus, considering these limits for 
permeability, CLog P and MCSA, a rectangular box can be drawn so as to include this 
cluster of marker compounds. 
Considering that the least permeable marker in a group of compounds in a 
particular herbal extract, gives rise to a theoretical marker and a practical marker for each 
of the three herbs.  Due to obvious reasons the performance standard selected should be 
characteristic of the extract, the components of kava are considered to be an exceptional 
case due to their high permeability values. Yangonin has a high permeability and smaller 
MCSA among the kava components and hence does not fulfill the conditions for our 
conservative approach of least permeability. Dihydromethysticin and dihydorkawain 
have similar permeability values, but differ in the MCSA and CLogP values. Higher 
MCSA value indicates lower permeability and dihydromehtysticin is comparatively less 
lipophilic than dihydrokawain.  Hence, dihydromethysticin can be assigned as the 
theoretical marker for kava. Ideally dihydromethysticin would be the practical marker 
too, but a performance standard should be easily available at a reasonable cost for daily 
analysis.  Further the proportion of dihydromethysticin among the kava lactones is in the 
range of 5.2%-7.4 % where as that of kawain is around 33-35%. The individual 
proportion of kawain being much higher for higher sensitivity and easy analysis, the low 
permeability value along with an intermediate CLogP and MCSA value indicate that 
kawain would be an appropriate practical marker for Kava. 
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Considering kava as an exception, all other compounds that lie out of proposed 
‘box’ cannot be considered as suitable markers due to their isolation from the observed 
cluster.  These compounds either have a high permeability from its fellow compounds or 
even if the permeability is within range (<5 x 10-6 cm/sec) either the CLogP or the 
MCSA provide a hint that these candidates can pose as a false lead towards being a 
performance standard. Hence, observing the effect of two variables (CLogP & MCSA) on 
the third variable (in vitro permeability), using a 3D scatter plot proves to be extremely 
useful.  Bilobalide from ginkgo biloba can be considered as a good example of a false 
lead, where it has a low effective permeability (3.891 x 10-6 cm/sec) and MCSA (139.435 
Ǻ2) not very different from other compounds but its CLogP value (-2.64) warns us about 
its high hydrophillic nature and isolating it from the proposed cluster box.   
Ginkgolide B, a terpene lactone from ginkgo biloba can be selected as the 
theoretical and practical marker due to its low permeability, moderate CLogP and MCSA 
values as compared to its fellow terpene lactones in the extract.  Similarly among the 
flavonol aglycones quercetin, kaempferol and isorhamnetin, quercetin is a suitable 
candidate as a standard.  
The study of milk thistle includes seven active flavonolignans from which 6 are 
isomers. The MCSA plays a major role as a deciding factor in this case as the CLog P 
values for the silybin and isosilybin diastereomers are similar.  Silydianin can be 
considered as a theoretical marker for milk thistle based on its CLogP and MCSA.  
Though the permeability value of silydianin is not available in this study, the higher value 
of MCSA definitely suggests that silydianin would have the least permeability among the 
milk thistle compounds.  The isosilybins cannot be considered as markers as the 
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separation of these isomers into separate compounds has not been possible to date.  Also 
the percentage of isosilybins in the extract is very less as compared to the other 
components such as silybin and silycristin.   Silycristin can be considered as the practical 
marker for milk thistle, being moderately lipophillic and having a comparatively low 
permeability.  Further isolation of silycristin from other silymarin isomers has been 
possible and also the percentage of silycristin in silymarin (milk thistle extract) is very 
high enabling higher sensitivity. 
The following three figures (Figures: 2.12, 2.13, 2.14), show the components of 
the individual extracts separately so as to give a clearer idea of how the predicted markers 
are positioned with respect to their permeability, lipophilicity and MCSA.  Observation 
of the data by plotting them on  3D axes is necessary to interpret the effects collective 
influence of each descriptors (MCSA and CLogP) on permeability and vice versa. 
 
 












Thus, from the inter-parameter relationships observed between the PSA, MCSA, 
CLogP and the effective permeability of the compounds, and maintaining the three 
criteria for the selection of an appropriate bioavailability/bioequivalence marker, the 
following active components are selected as markers for the respective herbal extracts: 
I. Kawain as a marker for the kava extract 
II. Ginkgolide B as a marker for the ginkgo terpenes and quercetin as a 
marker for the flavonol glycosides in Ginkgo biloba 
III. Silycristin is selected as a marker for the silymarin isomers in Milk thistle. 
 
In this section, an attempt has been made to classify the active compounds from 
various herbal extracts so as to facilitate the selection of bioavailability markers for the 
three herbs: Kava, Ginkgo biloba and Milk thistle (silymarin).     
2.4.1:  CHOICE OF EXTRACT FOR MARKER SELECTION 
From the previous section it is inferred that kawain is the best selected marker for 
Kava kava, ginkgolide B is a suitable marker for the terpene lactones and quercetin for 
the flavonol aglycosides in Ginkgo biloba, and silycristin is the best suitable marker for 
silymarin (Milk thistle).  Each herbal extract from three being studied is unique in its own 
sense in terms of therapeutic effect.  Each herbal extract shows exhibits a 
pharmacological effect in a synergistic way, due to the presence of six or more active 
components.  From these three extracts, silymarin presents itself as one of the most 
interesting due to the presence of its isomers and diastereomers.  silymarin consists of six 
active flavonolignan isomers, from which four of them exist as diastereomers.  Thus, 
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silymarin presents a considerable analytical challenge in the separation of all the isomers.  
Thus, we consider silymarin as our model extract to proceed with the in vitro dissolution, 
solubility and partition coefficient experiments.  Due to the presence of isomers and 
diastereomers in silymarin, it becomes very interesting to know how the pharmacokinetic 
parameters and bioavailability for each isomers differ from each other.  Hence, we select 
silymarin as our model extract to proceed with the in vitro solubility and dissolution 
experiments as well as the in vivo pharmacokinetic experiments.   
2.5:  SUMMARY 
The results in the previous section indicate that the minimal cross-sectional area is 
a function of molecular weight and also a good predictor of the extent of permeability of 
the compounds being tested.  Though the investigation includes 39 selected compounds 
from 8 herbal extracts, each marker has to be a characteristic of its herb which is a basic 
requirement for the selection of a performance standard.  Hence, the kava compounds 
which have high permeability values as compared to the other compounds, we select 
kawain as the marker which is one of the least permeable among its group.  Similarly the 
selection of Ginkgolide B and Quercetin as the markers for Ginkgo biloba satisfies the 
proposed requirements.  The MCSA proves to be very useful while explaining the 
selection of Silycristin as the marker for milk thistle extract, considering the fact that 6 of 
the 7 active compounds of milk thistle are isomers.  Hence, the decision of selecting a 
performance standard has been done by keeping in mind primarily its permeability 
extent, partition coefficient, its percentage in the extract and the pure commercial 
availability.  The conservative approach of selecting the least permeable compound as a 
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bioavailability marker seems logical considering the lack of quality control that is 
associated with the sale of these products. The effect of two variables, MCSA and CLogP 
on the permeability of the compounds explains the efficiency of a 3D scatter plot and 
warns the investigator about potential false leads. 
Hence, selection of the least permeable compound for bioavailability testing (in 
vitro and in vivo) would enable us to develop performance standards for the selected 
herbal supplements ensuring their efficacy and bioavailability. 
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CHAPTER 3: ANALYTICAL METHODOLOGY 
3.1: INTRODUCTION  
This chapter discusses the development of a reverse phase binary gradient HPLC-
UV method for the quantitative determination of the six silymarin isomers in various 
different chemical matrices and rat plasma.  A new method was required for the 
quantitation of isomers, because all of the previous methods did not separate the silybin 
and isosilybin isomers into its respective diastereomers.  Some of the previous methods 
were only focused on the separation and quantitation of silybin alone as a single isomer 
and did not measure the levels of any other silymarin isomers.  Hence, a new method that 
would measure all the silymarin isomers in chemical and biological matrices, and have a 
simple, efficient and less time consuming, extraction procedure (mainly for the extraction 
of isomers from a biological matrix) was required.  This chapter discusses a method that 
was developed and that could be used across various chemical and biological matrices 
with minor modifications.  The complete validation of the method for the quantitative 
determination of silymarin isomers in rat plasma is presented in this chapter.  Sample 
preparation methods in chemical matrices like the CaCo-2 cell transport media, capsule 
formulations and in vitro dissolution media, equilibrium solubility and octanol-water 
partition coefficient media are discussed.  The chapter explains the standardization of the 
silymarin extract to yield the exact proportion of each isomer present.  Sample 
chromatograms of the separated isomers in various chemical and biological matrices are 
shown.  
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3.2:  PREVIOUS RELATED STUDIES 
3.2.1: ANALYSIS OF SILYMARIN IN CHEMICAL MATRICES 
High performance liquid chromatography (HPLC) coupled primarily with ultra-
violet detectors, has been the method of choice ever since the discovery of silymarin 
isomers with initial references appearing in the 1970’s [57, 60, 124-128] Chemical 
matrices mentioned in the following references were either the standardized extract or 
pharmaceutical formulations such as tablets or capsules that contained the dried plant 
powder along with other pharmaceutical excepients.  Most common methods of 
extraction are of two types: (i) Dissolution of the extract or the sample powder into 
methanol followed by filtration to get a clear solution ready for analysis [76, 129]; (ii) 
Extraction of the sample powder using an appropriate solvent such ethyl acetate or ether 
followed by a solvent extraction procedure using a soxhelet or vortex mixer.[130, 131]  
Titel et al. carried out the analytical separation of silybin, silydianin, silycristin and 
taxifolin but their work did not give any account of the diastereomers of silybin and 
isosilybin. [127, 128] The work by Quercia et al. in 1983 indicated for the first time that, 
apart from silydianin and silycristin, silymarin consisted of diastereomers of silybin and 
isosilybin. [132]  Even after the proven presence of diastereomers in silymarin and a 
surge in its analytical research in the 1990’s, most of the methods still focused on the 
separation of isomers rather than the diastereomers. [76, 77, 130, 133, 134] This can be 
attributed mainly to the fact that silybin was considered as the major and important 
pharmacological constituent of silymarin extract which is in contradiction to the work 
proposed by Quercia et al. which states that there was no significant difference found in 
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the pharmacological activity of silybin and isosilybin against phalloidine poisoning. [132]  
Work by Ding et al. was one of the first ones to report the complete quantitative 
separation of silymarin isomers and diastereomers. [129] They reported differences in the 
proportion of isomers and diastereomers in extracts obtained from Germany and China, 
attributing the differences to differing geographical locations.  Bilia et al. reported on the 
stability of silymarin tincture (60%v/v ethanol) and found the isomers to be stable at 
25°C for up to 3 months. [133]  The most recent method following the work of Ding et 
al. was that by Lee et al. which involved the complete separation of all the isomers and 
diastereomers using a HPLC coupled with mass spectrometry, but did not report any 
validation data for the method. [131]  
 
3.2.2: ANALYSIS OF SILYMARIN IN BIOLOGICAL MATRICES 
Isomers of silymarin have low solubility resulting in minimal plasma levels and 
low bioavailability.  Since silybin has been considered to be the major portion of the 
extract quantitatively and pharmacologically, much of the in vivo work in human and 
animal models has been concentrated on the improvement of bioavailability by the 
formation of silybin-phosphatidylcholine complex or other modified formulations. [79, 
135-138] silymarin isomers are mainly excreted as metabolites into the bile and are 
subject to enterohepatic circulation. [56] Thus, methods have been developed that 
monitor silybin along with its conjugates in the bile. [79] Chronologically Martinelli et al. 
first developed the separation of free and conjugated silybin (as a single isomer) in 
human plasma and urine [135] followed by the diastereomeric separation of silybin 
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(silybin A and silybin B) and its conjugates by Wehenmeyer et al. [79, 139] 
Wehenmeyer’s method was found to be the most sensitive with a limit of detection of 2.5 
ng/mL for the unconjugated isomer.  Recently Lee et al. proposed that their method for 
the complete separation of silymarin isomers in a chemical matrix can be extended to 
biological matrices in human and animal models. [131]  There has been only one 
documented report involving the analysis of silybin in rat plasma, tagged with radioactive 
125I. [140] Thus, the complete separation and quantification of all silymarin isomers and 
diastereomers has just been achieved recently with very few documented references.[131, 
141]   
 
3.2.3:  PREPARATIVE SEPARATION OF ISOMERS AND DIASTEREOMERS 
Availability of silymarin isomers as pure and isolated reference standards is rare, 
with very limited suppliers and associated with prohibitive prices. The first ever complete 
preparative isolation of silymarin isomers (silycristin and silydianin) and diastereomers 
(silybin A and B, isosilybin A and B) was achieved by Wani et al. [142] This is the only 
documented research on the isolation of silymarin diastereomers on a preparative scale 
such that detailed pharmacologic and pharmacokinetic studies can be done on individual 
isomers.  
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3.3:  HPLC METHOD FOR SILYMARIN ISOMERS IN RAT PLASMA 
3.3.1:  QUANTITATIVE DETERMINATION OF SILYMARIN ISOMERS IN RAT PLASMA 
Initial method development leading to the quantitative separation of all the 
silymarin isomers resulted in an analysis runtime of approximately 45 minutes.  Thus, 
extraction of silymarin isomers from rat plasma required a quick and short method with 
no loss in analyte due to extraction.  Due to its plasma denaturing properties, high 
solubility of silymarin isomers and internal standard 1-naphthol, and being a part of the 
mobile phase, methanol was the solvent of choice for the extraction of silymarin isomers 
from rat plasma.   
3.3.1.1:  Chromatography 
During method development it was observed that pH of the sample was the most 
important factor influencing peak shape and resolution of the isomers.  A pH of 7.0 ±0.05 
had to be maintained in order to achieve optimum peak shape and response for all 
isomers as well as higher resolution between the diastereomers.  The second most 
influencing factor was the flow rate at 1ml/min from 28 to 36 minutes, when the 
proportion of methanol increased to 55%.  Any attempt to elute the peaks at an earlier 
time point resulted in the peak merging of the silybin and isosilybin diastereomers.    
Sample chromatograms of the six isomers along with their retention times, 
separated in rat plasma are shown in Fig. 3.1 & 3.2.  The resolution between the 
diastereomers silybin A and B was 1.59, between diastereomers isosilybin A and B was 
1.30 and between silybin B and 1-naphthol was 2.24.
 
Figure 3.1. Sample Chromatogram of Silymarin (1µg/mL) in Rat Plasma Comprising of 
Sc: 0.24µg/mL (24.66 mins); Sd: 0.03µg/mL <LOD (28.26 mins); SbA: 
0.18µg.mL (33.15 mins); SbB: 0.34µg/mL (34.18 mins); ISbA: 0.08µg/mL 
(37.1 mins); ISbB: 0.03µg/mL <LOD (37.8 m ins). 
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Figure 3.2. Sample Chromatogram of Silymarin (12.5µg/mL) in Rat Plasma comprising 
of Sc: 3.06µg/mL (24.66 mins); Sd: 0.45µg/mL (28.26 mins); SbA: 
2.36µg/mL (33.15 mins); SbB: 4.32µg/mL (34.18 mins); ISbA: 1.02µg/mL 
(37.1 mins); ISbB: 0.32µg/mL (37.8 mins). 
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3.3.1.2:  Sample Preparation 
400 µL of rat blood was placed in a heparinized 1.5mL centrifuge tube and 
centrifuged immediately at 8000 rpm for 7 minutes to obtain a clear supernatant plasma 
layer.  This was then transferred to a clean 1.5 mL centrifuge tube and frozen at -20°C 
until analysis.  At analysis time, the frozen plasma was thawed at room temperature 
before analysis.  200µL of thawed plasma was transferred to a clean 1.5mL centrifuge 
tube and 50µL of 0.2M o-phosphoric acid was added to it.  This was followed by the 
addition of 1mL of 0.5µg/mL internal standard (1-naphthol) prepared in methanol.  The 
mixture was vortexed for 10 seconds and then centrifuged at 5000 rpm for 5 minutes.  
The resultant clear supernatant solution was filtered through a 0.45µ nylon membrane 
and 50µL of this was injected directly into the HPLC for analysis. 
3.3.1.3:  Chromatographic Conditions 
Analysis of silymarin was performed using a Phenomenex Luna C-18(2) column 
(5μ, 150 x 4mm).  The binary gradient method used water (Solvent A) and methanol 
(Solvent B) in the following composition and corresponding time program as shown in 
Table 3.1.  
Table 3.1: Gradient Solvent B Concentration (%) and Time Program 
Time (minutes) Composition of B (%) Time (mins) Total Flow (ml/min) 
0 20 0 2 
0-28 50 0-10 2 
28-36 55 10-38 1 
36-41 20 38-41 2 
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1-naphthol (0.5µg/mL) was used as an internal standard.  The UV detector was set at 
288nm and the volume of injection was 50µL.  The total run time, including column 
equilibration was 41 minutes and carried out at ambient temperature. 
3.3.2:  METHOD VALIDATION 
The HPLC method was validated for complete separation and quantification of all 
the six silymarin isomers using 1-naphthol as internal standard.  The ratio of the peak 
area of the analyte to peak area of the internal standard was used to calculate the analyte 
response. 
3.3.2.1:  Linearity 
The linearity for silymarin extract was tested in a concentration range from 
2.5µg/mL to 250µg/mL comprising of 7 standard solutions. silymarin stock solutions 
were prepared in methanol.  These concentrations of the silymarin extract yielded the 
corresponding isomer concentrations as per their proportion determined from the 
standardization of the extract shown in Table 3.11.  Linearity samples were injected in 
triplicate and the peak area ratios of the isomers to the internal standard was calculated.  
A linear regression analysis was carried out on the peak area ratio versus concentration 
profiles to determine the slope, intercept and the correlation coefficient.  Unknown 
concentrations of isomers in the plasma samples were calculated using the resultant 
regression equation for each isomer. 
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The plasma linearity solutions were prepared in a way such that, when 150µL of 
drug free rat plasma was spiked with 50µL of silymarin, yielded 200µL of plasma 
solution containing the respective concentrations of the isomers as described in Table 3.2. 

















1 2.5 0.61 0.09 0.47 0.86 0.20 0.06 
2 5 1.22 0.18 0.94 1.72 0.41 0.128 
3 12.5 3.06 0.45 2.36 4.32 1.02 0.32 
4 25 6.13 0.90 4.72 8.64 2.05 0.64 
5 62.5 15.32 2.26 11.81 21.61 5.13 1.60 
6 125 30.65 4.56 23.63 43.23 10.27 3.20 
7 250 61.30 9.04 47.27 86.46 20.55 6.40 
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3.3.2.2:  Interday and Intraday Precision 
Three concentrations of each silymarin isomer were tested for interday (3 days, 
n=3) and intraday (n=6) precision.  Peak ratio of the respective isomer to internal 
standard was used in the subsequent calculations.  The concentrations of isomers tested 
are shown in Table 3.3. 






Silybin A Concentration 
(µg/mL) 
1.22 0.09 0.189 
3.06 0.452 0.945 
6.13 0.905 2.36 
Silybin B Concentration 
(µg/mL) 
Isosilybin A Concentration 
(µg/mL) 
Isosilybin B Concentration 
(µg/mL) 
0.345 0.082 0.064 
1.73 0.411 0.320 
4.32 1.027 0.640 
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3.3.2.3:  Accuracy and Recovery 
Method accuracy and extraction recovery for the six isomers was determined for 
one concentration (12.5µg/mL) at three levels, by spiking with silymarin. The spiked 
concentrations (L1, L2, & L3) of silymarin and its corresponding six isomers are shown 
in Table 3.4 















Std.(12.5) 3.06 0.45 2.36 4.32 1.02 0.32 
L1 (15) 0.61 0.09 0.47 0.86 0.21 0.06 
L2 (20) 1.84 0.27 1.41 2.59 0.62 0.19 
L3 (45) 7.97 1.17 6.14 11.24 2.67 0.83 
* L1= Recovery Level; L2= Recovery Level; L3= Recovery Level 3 
**Sc=silycristin, Sd=silydianin, SbA=silybin A, SbB=silybin B, ISbA=isosilybin A, ISbB=isosilybin B 
 
3.3.2.4: Limit of Detection and Quantitation 
Limit of detection (LOD) for the isomers was defined as the lowest analyte 
concentration having a signal to noise ratio of 3 that could be distinguished when 
compared to its blank.  Limit of quantitation was the lowest silybin A&B concentration 
that could be measured with a signal to noise ratio of 10 and had a relative standard 
deviation of less than 20%.
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3.3.2.5:  Stability  
Plasma samples spiked with silymarin were subjected to 3 freeze-thaw cycles and 
then assayed for their isomeric content.  Rat plasma spiked with silymarin, post sample 
preparation, was tested for stability at room temperature for 36 hours.  Stock solutions of 
silymarin and internal standard (1-naphthol) in methanol were also tested for stability at 
room temperature for 24 hours.    
3.3.3:  RESULTS 
3.3.3.1:  Linearity 
The mean slopes and intercepts for the silymarin isomers, obtained from the 
various calibration curves are listed in Table 3.5. 
Table 3.5: Mean Slopes and Intercepts of Silymarin Isomers. 












































3.3.3.2:  Interday and Intraday Precision 
The summary data for the intra-day and inter-day precision is shown in Table 3.6 
and 3.7.  
Table 3.6: Intra-day Precision 
Silycristin (n=6) Silydianin (n=6) 
Conc. 
(μg/ml) 
1.22 3.06 6.13 
Conc. 
(μg/ml) 
0.090 0.452 0.904 
*Mean 
Ratio 
0.112 0.339 0.725 
*Mean 
Ratio 
0.005 0.033 0.049 
SD 0.0045 0.023 0.0300 SD 0.0001 0.002 0.006 
CV (%) 4.07 6.80 4.14 CV (%) 3.47 8.12 13.07 
Silybin A (n=6) Silybin B (n=6) 
Conc. 
(μg/ml) 
0.189 0.945 2.36 
Conc. 
(μg/ml) 
0.345 1.73 4.32 
*Mean 
Ratio 
0.024 0.223 0.540 
*Mean 
Ratio 
0.062 0.418 0.989 
SD 0.004 0.002 0.0145 SD 0.009 0.005 0.006 
CV (%) 4.98 0.97 2.68 CV (%) 15.7 1.22 0.61 
Isosilybin A (n=6) Isosilybin B (n=6) 
Conc. 
(μg/ml) 
0.082 0.411 1.027 
Conc. 
(μg/ml) 
0.064 0.320 0.640 
*Mean 
Ratio 
0.013 0.093 0.235 
*Mean 
Ratio 
0.008 0.055 0.125 
SD 0.0010 0 0.0121 SD 0.001 0.0013 0.001 
CV (%) 8.01 0.317 5.17 CV (%) 11.64 2.43 0.88 
*Mean Ratio=Mean peak area ratio of analyte to internal standard 
Conc.= Concentration; SD=Standard Deviation; CV=Coefficient of Variation 
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Table 3.7: Inter-day Precision 













1.22 0.119 0.0045 4.07 0.09 0.0053 0.0001 3.47 
3.06 0.339 0.321 6.80 0.452 0.033 0.0027 8.12 
Day 1 
6.13 0.725 0.0300 4.14 0.905 0.049 0.006 13.07 
1.22 0.1088 0.0073 6.70 0.09 0.010 0.001 13.97 
3.06 0.283 0.0054 1.91 0.452 0.026 0.0001 0.58 
Day 2 
6.13 0.609 0.027 4.53 0.905 0.065 0.010 15.40 
1.22 0.134 0.013 10.35 0.09 0.0026 0.0001 6.54 
3.06 0.227 0.004 1.77 0.452 0.015 0.0012 7.78 
Day 3 
6.13 0.688 0.009 1.44 0.905 0.035 0.002 5.98 













0.189 0.024 0.004 4.98 0.345 0.063 0.009 15.7 
0.945 0.223 0.0021 0.97 1.73 0.418 0.0051 1.82 
Day 1 
2.36 0.540 0.0145 2.68 4.32 0.989 0.0060 0.61 
0.189 0.024 0.001 4.98 0.345 0.056 0.005 8.89 
0.945 0.095 0.002 2.65 1.73 0.393 0.018 4.72 
Day 2 
2.36 0.249 0.003 1.36 4.32 0.898 0.008 0.895 
0.189 0.043 0.003 8.68 0.345 0.068 0.008 12.65 
0.945 0.221 0.012 5.57 1.73 0.411 0.001 0.268 
Day 3 
2.36 0.519 0.005 0.96 4.32 0.952 0.001 1.19 
Mean Ratio=Mean peak area ratio of analyte to internal standard 
Conc.= Concentration; SD=Standard Deviation; CV=Coefficient of Variation 
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Table 3.7: Intra-day Precision (Contd.) 















0.082 0.013 0.001 8.01 0.064 0.008 0.001 11.64 
0.411 0.093 0.0002 0.317 0.320 0.055 0.0013 2.43 
Day 1 
1.027 0.235 0.0121 5.17 0.640 0.125 0.0011 0.88 
0.082 0.011 0.0005 4.58 0.064 -- -- -- 
0.411 0.093 0.0002 0.397 0.320 0.055 0.001 2.32 Day 2 
1.027 0.235 0.012 5.17 0.640 0.126 0.011 9.06 
0.082 0.009 0.001 11.67 0.064 0.008 0.0005 6.90 
0.411 0.089 0.001 1.67 0.320 0.047 0.001 3.01 Day 3 
1.027 0.227 0.004 1.96 0.640 0.107 0.018 17.04 
Mean Ratio=Mean peak area ratio of analyte to internal standard 
Conc.= Concentration; SD=Standard Deviation; CV=Coefficient of Variation 
 
3.3.3.3:  Accuracy and Recovery 
The method was found to be accurate according to the guidelines set by the FDA.  
The extraction efficiency of the isomers from rat plasma was also found to be within 
acceptable limits.  Data for accuracy and extraction recovery is shown in Table 3.8. 
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Table 3.8:  Accuracy and Recovery Data for Silymarin Isomers 






Accuracy(%) %CV Extraction 
Recovery(%) 
0.61 0.609 ±0.008 -0.59 1.35 99.40 
1.84 2.07 ±0.14 12.89 6.78 112.88 
Sc 3.06 
7.97 8.43 ±0.155 5.89 1.84 105.89 
0.09 0.095 ±0.010 5.38 10.62 105.38 Sd 0.45 
1.17 1.26 ±0.09 8.00 7.84 107.99 
0.47 0.47 ±0.023 0.10 4.91 100.10 
1.41 1.47 ±0.204 4.06 13.82 104.06 
SbA 2.36 
6.14 6.28 ±0.338 2.31 5.28 102.31 
0.86 0.79 ±0.093 -8.21 11.79 91.79 
2.59 2.78 ±0.230 7.21 8.27 107.21 
SbB 4.32 
11.24 10.87 ±0.162 -3.31 1.49 96.69 
0.21 0.242 ±0.01 17.58 5.49 117.58 
0.62 0.61 ±0.063 -0.15 10.24 99.85 
ISbA 1.02 
2.67 2.65 ±0.24 -0.93 9.13 99.07 
0.06 0.088 ±0.004 7.00 5.18 107.00 
0.19 0.196 ±0.020 2.09 9.99 102.09 
ISbB 0.32 
0.83 0.857 ±0.018 2.88 2.17 102.88 
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3.3.3.4:  Limit of Detection and Quantitation 
The limits of detection (LOD) and limit of quantitation (LOQ) for the silymarin 
isomers are specified in Table 3.9.  The LOQ %CV was ≤11% for all the isomers.  
Table 3.9: LOD and LOQ for the silymarin isomers 
 Sc Sd SbA SbB ISbA ISbB 
LOD 
(µg/mL) 0.03 N/A 0.02 0.02 0.03 0.03 
LOQ 
(µg/mL) 0.06 0.08 0.05 0.05 0.05 0.06 
 
The LOD for Silydianin was tested at 0.03, 0.04, 0.05µg/mL and the peak 
obtained at all the three concentrations was debatable and without any visual precision.  
On the contrary, at 0.08µg/mL the peak for Silydianin could be detected and quantified.  
Thus, only a LOQ for Silydianin was assigned at 0.08µg/mL. 
3.3.3.5:  Stability 
Silymarin isomers in plasma when subjected to 3 freeze-thaw cycles, upon 
analysis did not show any significant degradation (<5%).  Plasma samples spiked with 
silymarin, post sample preparation were stable for 24 hours. At the end of 36 hours, this 
aliquot showed light precipitation settling at the bottom of the sample vial, but analysis 
results did not show any degradation of silymarin isomers, suggesting precipitation of 
plasma proteins. 
Stock solutions of silymarin in methanol and internal standard (1-naphthol) in 
methanol were also stable for 24 hours at room temperature.
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3.4:  STANDARDIZATION OF THE EXTRACT 
Standardization of extract involved assaying two products obtained from Sigma 
Aldrich prior to their use in our experimental work.  The first product was a mixture 
silymarin diastereomers, Silybin A&B only and the second product was the pure 
silymarin extract that contained all the six silymarin isomers.  Silybin USP containing 
Silybin A&B was the only USP reference standard available prior to Caco-2 cell 
transport studies, while Silybin USP and Silydianin USP were available prior to in vitro 
dissolution and assay studies.  Silymarin USP was available only prior to the start of in 
vivo studies in rats.   
Assay of silybin (A&B) and silymarin obtained from Sigma Aldrich was 
determined by HPLC and calculated by the method of area normalization  
The certificate of analysis for Silybin USP indicated an assay of Silybin equal to 
94.00%, without any individual diastereomeric content.  Assay of Silybin USP by area 
normalization indicated a total assay of Silybin (A&B) equal to 94.00% comprising of 
44.91% Silybin A and 49.08% Silybin B.  
Assay of Silybin obtained from Sigma Aldrich was confirmed by area 
normalization and was calculated as 99.46% comprising of 48.00% Silybin A and 
51.46% Silybin B.  Silybin USP was used as a reference to confirm the retention times of 
the diastereomers during method development. 
Assay of silymarin obtained from Sigma Aldrich was determined by HPLC and 
calculated using the method of area normalization.  Table 3.10 shows the individual assay 
of each isomer in silymarin. 
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Assay and Chromatographic Conditions: An accurately weighed quantity of 
silymarin extract was dissolved in methanol so as to obtain a concentration of 100µg/mL.  
This solution was filtered using a 0.45µm nylon membrane and 10µL of the clear 
solution was injected onto the HPLC was analysis.  The assay used the following 
chromatographic conditions: 
Table 3.10:  Chromatographic Conditions for Determination of Isomer Proportions in 
Silymarin Extract 
Method Reverse Phase, Binary Gradient 
Column Type & Dimensions Phenomenex, Luna C-18 (2) 
Mobile Phase Water (A); Methanol (B) 
%B: 20-65 in 40 minutes 
Total Flow Rate 1 mL/minute 
Detection Ultraviolet; 288nm 
Injection Volume 10 µL 
Run Time Analysis: 40 minutes 
Equilibration: 10 minutes 
Temperature Ambient 
 
The results of the assay of individual isomers in the silymarin extract are shown in 
Table 3.11. 










Silymarin isomer Average Assay % (n=6) SD 
Silycristin (Sc) 24.52 0.312 
Silydianin (Sd) 3.61 0.278 
Silybin A (SbA) 18.90 0.263 
Silybin B (SbB) 34.58 0.264 
Isosilybin A (ISbA) 8.22 0.037 
Isosilybin B (ISbB) 2.56 0.026 
TOTAL 92.42 0.312 
SD= Standard Deviation 
3.5:  ASSAY OF SILYMARIN ISOMERS IN VARIOUS CHEMICAL MATRICES  
(CaCo-2 Cell Transport Buffer, Tablets, Capsules & in vitro Dissolution Media, 
Equilibrium Solubility and Partition Coefficient Media) 
 
The HPLC method used for the quantitation of silymarin isomers in rat plasma 
was used to analyze the isomers in different chemical matrices, with minor modifications 
in the gradient program, flow rate and the volume of injection.  The type of HPLC 
column, mobile phase (methanol + water), the wavelength of detection (UV, 288nm) and 
temperature were kept constant.  The sample preparation method and the 
chromatographic specifications for each chemical matrix are explained in the following 
sections.  Due to the limited solubility of the silymarin extract, Caco-2 cell transport 
experiments involved were carried out using only the Silybin A&B mixture obtained 
from Sigma Aldrich. 
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 3.5.1: Assay of Silybin A and B in Caco-2 Cell Transport Media 
3.5.1.1:  Sample Preparation 
After the transport experiments, aliquots of transport buffer from the basal 
chamber were mixed with an appropriate quantity of internal standard (1-naphthol in 
methanol) and filtered using a 0.45µ nylon membrane before injecting on to a HPLC for 
analysis. 
3.5.1.2:  Chromatographic Conditions 
Table 3.12:  Chromatographic Conditions for the Quantitation of Silybin A&B in a 
CaCo-2 Cell Transport Media 
Method Reverse Phase, Binary Gradient 
Column Phenomenex, Luna C-18 (2) 
Mobile Phase Water (A); Methanol (B) 
%B: 20-65 in 40 minutes 
Total Flow Rate 1 mL/minute 
Detection Ultraviolet; 288nm 
Injection Volume 10 µL 
Run Time Analysis: 40 minutes 
Equilibration: 10 minutes 
Temperature Ambient 
Figures 3.3-3.5 are representative chromatograms for the matrix blank, the  
internal standard alone, and the separation of silybin A, silybin B and internal standard. 
Figure 3.3:  Sample Chromatogram- Blank CaCo-2 Cell Transport Media 
Figure 3.4:  Sample Chromatogram- Internal Standard (1-Naphthol 10µg/mL; 35.7 mins) 




Figure 3.5.  Sample Chromatogram-Separation of Silybin A and Silybin B in CaCo-2 
Cell Transport Media. (Silybin A: 33.44 minutes; Silybin B: 34.34 minutes; 
Internal Standard: 35.85 minutes 
 
3.5.2:  Assay of Silymarin Isomers in Product Formulations, In Vitro Dissolution 
media and Equilibrium Solubility and Partition Coefficient Media   
Assay and in vitro dissolution testing of silymarin isomers in commercial 
formulations was done only for Silybin A, Silybin B and Silydianin only.  Equilibrium 
solubility and the experimental octanol-water partition coefficient values were 
determined for all the isomers in the silymarin extract. 
3.5.2.1:  Sample Preparation 
(i)  Assay of Silybin A, Silybin B and Silydianin in Product Formulations:  
Powdered sample approximately equal to 0.1g of silymarin was accurately weighed and 
transferred to a 100 ml volumetric flask.  After the addition of 50 ml of methanol, the 
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solution was sonicated for around 20 minutes and then the volume made up to 100ml 
with methanol.  This solution was then filtered through a 0.45µ nylon membrane, and 2 
ml of clear aliquot was transferred to a 10 ml volumetric flask.  1 ml of internal standard 
(1-naphthol; 75µg/ml prepared in methanol) was added to this solution and the volume 
made up to 10ml with methanol.  10µL of this solution was injected directly into the 
HPLC. 
(ii)  Quantitation of Silybin A, Silybin B and Silydianin in In Vitro 
Dissolution Media:  A sufficient volume of sampled aliquot was filtered through 0.45µ 
nylon membrane and to 1 ml of clear filtrate was added 0.5ml of internal standard (1-
naphthol, 420µg/mL) and 0.5ml of 0.5% ortho phosphoric acid.  This solution was then 
injected into the HPLC for analysis.   
 
(iii)  Partition Coefficient and Equilibrium Solubility Media:  A sufficient 
volume of octanol aliquot was filtered through 0.45µ nylon membrane and to 0.1 ml of 
this clear aliquot was added 0.1 ml of internal standard prepared in methanol.  20µL of 
this solution was injected into the HPLC for analysis.  Different dilutions of the aliquots 
were required, due to the high concentrations of silymarin isomers being distributed into 
the octanol phase.  Sample preparation was similar for the water phase of the partition 
coefficient media and phosphate buffer pH 7.2 used in the determination of the 
equilibrium solubility of silymarin isomers. 
The solutions of the internal standard were prepared in such a way that the final 
concentration of the internal standard in the sample solution was 75µg/mL. 
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3.2.1.2.2:  Chromatographic Conditions 
Chromatographic conditions for the quantitation of isomers during assay, in vitro 
dissolution, equilibrium solubility and partition coefficient experiments are shown in 
Table 3.13 and a sample chromatogram showing the separation of all the isomers along 
with the internal standard is shown in Figure 3.6. 
Table 3.13:  Chromatographic Conditions for the Quantitation of Silymarin Isomers in 
Assay, In Vitro Dissolution, Equilibrium Solubility and Partition Coefficient 
Experiments. 
Method Reverse Phase, Binary Gradient 
Column Type & Dimensions Phenomenex, Luna C-18 (2) 
Mobile Phase Water (A); Methanol (B) 
%B: 20-60 in 36 minutes 
60-65 in 45 minutes 
Total Flow Rate 1 mL/minute 
Detection Ultraviolet; 288nm 
Injection Volume 10 µL/20µL 
Run Time Analysis: 45 minutes 
Equilibration: 10 minutes 
Temperature Ambient 
 
Figure 3.6. Sample Chromatogram for the Separation of Silymarin Isomers in Dissolution 
Media (Silycristin: 26.95 minutes; Silydianin: 28.60 minutes; Silybin A: 
34.22 minutes; Silybin B: 35.13 minutes; Internal Standard: 36.50 minutes; 
Isosilybin A: 37.21 minutes; Isosilybin B: 37.78minutes 
3.6:  SUMMARY: 
A specific, sensitive and reproducible reverse phase, binary gradient HPLC method was 
developed and validated for the quantitation of six silymarin isomers (silycristin, 
silydianin, silybin A, silybin B, isosilybin A and isosilybin B) in various chemical 
matrices and in rat plasma.  The method used for the quantitation of the isomers in rat 
plasma was validated and applied for the determination of silymarin isomers in other 
chemical matrices.  The method had an approximate analysis runtime of 45 minutes and 
the process of extraction of the isomers especially from rat plasma was very simple and 
accompanied with high extraction efficiency.  This method can be confidently applied for 
the routine assay and in vitro dissolution of silymarin isomers in various milk thistle 
market formulations and also for the quantitation of isomers in rat plasma.
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CHAPTER 4:  EQUILIBRIUM SOLUBILITY, IN VITRO DISSOLUTION AND 
PARTITION COEFFICIENT OF SILYMARIN ISOMERS 
This chapter describes the determination of equilibrium solubility, apparent 
partition coefficient and in vitro dissolution of silymarin isomers in extract and in market 
formulations, respectively.  The apparent octanol water partition coefficients are 
compared to the predicted values (CLogP) for verification of prediction.  Based on their 
equilibrium solubility and partition coefficient (calculated and experimental) values the 
silymarin isomers are classified according to the Biopharmaceutics Classification System. 
[143] The model drug metoprolol is used as a reference to classify the isomers into the 
high permeability and low permeability class.  
The assay content of silymarin isomers (silybin A, silybin B and silydianin) was 
determined for three selected market formulations to check variation between dosage 
forms having the same label claim.  In vitro dissolution experiments were performed to 
investigate the release of silybin A, silybin B and silydianin from a select formulation. 
4.1:  EQUILIBRIUM SOLUBILITY AND BIOPHARMACEUTICS CLASSIFICATION 
SYSTEM 
The Biopharmaceutics Classification System (BCS) [143] is a scientific 
framework for classifying drug substances based on their aqueous solubility and 
intestinal permeability. When combined with the dissolution of the drug product, the BCS 
takes into account three major factors that govern the rate and extent of drug absorption 
from IR solid oral dosage forms: dissolution, solubility, and intestinal permeability.   
According to the BCS, drug substances are classified as follows: 
Class 1: High Solubility – High Permeability 
Class 2: Low Solubility – High Permeability 
Class 3: High Solubility - Low Permeability 
Class 4: Low Solubility - Low Permeability 
In addition, immediate release solid oral dosage forms are categorized as having 
rapid or slow dissolution. Within this framework, when certain criteria are met, the BCS 
can be used as a drug development tool to help justify waivers for bioequivalence studies. 
Determination of Solubility Class: The solubility class boundary for the 
silymarin isomers was designated as shown in Table 4.1. [144]  A drug substance was 
considered highly soluble when the highest dose strength is soluble in 250 ml or less of 
aqueous media over the pH range of 1-7.5. The volume estimate of 250 ml was derived 
from typical bioequivalence study protocols that prescribe administration of a drug 
product to fasting human volunteers with a glass (about 8 ounces) of water.  The dose 
number (D0) was calculated using the following equation: 
sC
VM
D 000 =           Equation 4.1 
where, 
M0=highest dose strength in milligrams 
V0=250mL 
Cs=Solubility in mg/mL 
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Drugs with dose numbers of ≤1 were classified as high-solubility drugs. 
Conversely, drugs with dose numbers of >1 were classified as low solubility drugs. 
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Table 4.1:  Solubility Definitions 
Descriptive 
Solubility Term 
Part of solvent 






Very Soluble (vs) <1 ≥10000 1000 
Freely Soluble (fs) From 1 to 10 100-1000 100 
Soluble From 10 to 30 33-100 33 
Sparingly Soluble 
(sps) 
From 30 to 100 10-33 10 
Slightly soluble (ss) From 100 to 1000 1-10 1 
Very Slightly 
Soluble (vss) 
From 1000 to 10000 0.1-1 0.1 
Practically Insoluble 
(pi) 
≥10000 <0.1 0.01 
 
Determination of Permeability Class:  The permeability class of the isomers 
needs to be determined in order to classify them in to the low permeability and high 
permeability class.  According to the BCS guidance, permeability class can be 
determined in humans by using the mass balance method, absolute bioavailability or 
intestinal perfusion method.  Non human methods to determine intestinal permeability 
would be in situ or intestinal perfusion techniques in an animal model, or in vitro 
permeability methods involving monolayer of suitable epithelial cells.  When a single in 
vitro method fails to conclusively demonstrate the permeability class, a second method 
such as the partition coefficient derived experimentally (using the right solvent systems) 
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or determined by calculations from the structure of the drug molecule (CLogP) can be 
used. 
Silymarin isomers in the following work are classified in to high permeability and 
low permeability classes by comparing their experimental and calculated partition 
coefficient values to model drug metoprolol.  Isomers which were more lipophilic than 
metoprolol will be classified as high permeability compounds and like wise. 
4.2:  ESTIMATION OF EQUILIBRIUM SOLUBILITY 
The following section discusses the estimation of saturation solubility of six 
silymarin isomers silycristin, silydianin, silybin A & B and isosilybin A & B.  There have 
been no published reports on the estimation of saturation solubility of each of the 
mentioned isomers of silymarin.  Koch et al. studied the solubility of silybin (A+B) as a 
single isomer, silydianin and silycristin in water as a function of increasing temperature 
and pH. [145] They found that aqueous solubility of silybin, silydianin and silycristin 
increased with the increasing temperature, respectively, and the heats of solution were 
found to be as follows: silybin (2.607 kcal/mol), silydianin (7.154 kcal/mol), silycristin 
(2.005 kcal/mol).  
4.2.1:  Experimental Design        
Saturation solubility for the silymarin isomers was estimated at 37°C in phosphate 
buffer (0.2M) at pH 7.2, representative of the human small intestine.   
Preparation of pH 7.2 buffer:  Accurately weighed, 6.9g of monobasic sodium 
phosphate and 1.51g of sodium hydroxide were completely dissolved in 1 liter of distilled 
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water.  The pH of the solution was adjusted to 7.2 by adding drop wise, either 1N sodium 
hydroxide or 1N hydrochloric acid as required. 
Determination of Equilibrium Solubility: The following procedure was used to 
estimate the equilibrium solubility of the silymarin isomers.  An excess of compound was 
placed in a vial containing the pH 7.2 phosphate buffer (0.2M).  The vial was then 
allowed to equilibrate in a shaking water bath maintained at 37°C for 16 hours.  At the 
end of 16 hours aliquots of the supernatant solution were withdrawn and filtered using a 
pre-warmed syringe filter (37-40°C) and analyzed for drug content.  The HPLC method 
used for the quantitation of silymarin isomers is described in detail in Chapter 3 of this 
dissertation.  The equilibration process was continued until successive aliquots 
withdrawn were similar in drug content indicating equilibrium which allowed the 
estimation of equilibrium solubility.   
Quantitation of Silymarin Isomers:  Quantitative determination of the silymarin 
isomers was accomplished using a reverse phase HPLC method with UV detection at 288 
nm.  Concentration range of the calibration curves used to determine the amount of each 
dissolved isomer were as follows: Silycristin: 1.2- 17 µg/mL; silydianin:  0.16-2.49 
µg/mL; silybin A:  0.96-13.8 µg/mL; silybin B:  1.76-25.2 µg/mL; isosilybin A:  0.41-6.0 
µg/mL; isosilybin B:  0.13-1.87 µg/mL.  Each standard curve concentration and sample 
was injected in triplicate into the HPLC and the relative standard deviation was found to 
be no more than 7% for all the injections.   
4.2.2:  Results and Discussion 
Table 4.1 shows the equilibrium solubility for each silymarin isomer at 37°C and 
at a pH of 7.2. 
Table 4.2:  Equilibrium Solubility for Silymarin Isomers at 37°C and pH 7.2. 











Silycristin (Sc) 34.52 0.0155 5x105 LS 
Silydianin (Sd) 5.05 0.0191 6.6x104 LS 
Silybin A (SbA) 26.46 0.0033 2x106 LS 
Silybin B (SbB) 48.41 0.0077 1.5x106 LS 
Isosilybin A (ISbA) 11.50 0.00094 3x106 LS 
Isosilybin B (ISbB) 3.58 0.00045 1.9x106 LS 
Metoprolol 
(Reference Drug) 
100 1000 0.0004 HS 
M0 =Maximum dose strength in 140mg of extract; V0= 250mL; HS=High Solubility; LS= Low 
Solubility   
*D0>1 = LS; D0≤1= HS 
 
Results shown in Table 4.2 indicate that silydianin is the most soluble isomer and 
isosilybin B is the least soluble isomer.  The solubility rank for the isomers decreases in 
the order Sd>Sc>SbB>SbA>ISbA>ISbB.  Koch et al. [145] studied the solubility of 
silymarin isomers silybin, silydianin and silycristin and found that the solubility 
decreases in the order silycristin>silydianin>silybin.  This trend is similar to the trend 
reported here, though the solubility experiments done here are only at 37°C.  Also it 
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should be noted that Koch et al. found the solubility of silybin isomer as a single 
compound without separating them into their respective diastereomers. 
Based on the calculation of dose number (D0) it can be seen that all the silymarin 
isomers fall into the Low Solubility (LS) class.  This is because D0 for all the isomers is 
much greater than 1 which means that the silymarin isomers are practically insoluble.  
The maximum dose strength (M0) was calculated by considering the amount of each 
isomer present in the extract as found from Table 3.11 in Chapter 3, where the 
standardization if the silymarin extract is explained.  
4.2:  DETERMINATION OF APPARENT OCTANOL-WATER PARTITION COEFFICIENT 
The octanol-water partition coefficient provides a thermodynamic measure of the 
tendency of a substance to prefer a non aqueous or oily phase rather than water (the 
hydrophilic/hydrophobic balance).  Thus, the partition coefficient is the ratio of the 
concentrations of unionized compounds between the oil phase and the aqueous phase.  To 
measure the partition coefficient of ionizable solutes, the pH of the aqueous phase is 
adjusted such that the predominant form of the compound is unionized.  The logarithm of 














SoluteLogLogP           Equation 4.1 
 
The 1-octanol-water system is an established system for simulating the 
partitioning between biological membranes and their natural environment, particularly 
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water saturated 1-octanolic phase which is highly structured. [146] Also, 1-octanol is an 
amphiprotic solvent having hydrogen bond donor and acceptor properties.  Water 
saturated 1-octanol is a reasonably good solvent for many organic compounds while other 
organic solvents have a more limited range due to solubility problems.  A further reason 
to 1-octanol-water partition coefficients is the fact that large compilations of 
experimental log P values are available, various theoretical approaches to estimate log P 
values are based on this solvent system and that theories referring to drug absorption as 
presently reviewed are all based on this system.   
Octanol-water partition coefficient for the silymarin isomers was determined 
using the classical shake flask (tube) method.  This was done by placing an excess of 
silymarin extract which contained the 6 isomer, in a vial containing equal amounts of 1-
octanol and water, which in turn was placed in a shaking water bath maintained at 37°C.  
The water-1-octanol mixture used for the experiments was equilibrated by shaking for 24 
hours at 37°C, before the addition of the extract for partition coefficient determination.  
The compound was allowed to partition between the 1-octanol and water phase for 16 
hours by shaking at 37°C.  At the end of 16 hours, samples were withdrawn from each 
layer, aqueous and organic and analyzed by HPLC for isomer content.  The log ratio 
(LogP) of the concentrations of isomer content in octanol and water was calculated as per 
Equation 4.1.   
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4.2.1:  Results and Correlation to Predicted Octanol-Water Partition Coefficient 
(CLogP) 
 
The experimental results obtained for the six silymarin isomers were compared to 
their predicted 1-octanol-water partition coefficient (CLogP) values calculated, using the 
program CLogP in Chapter 2 of this dissertation.  The values and the correlation results 
are shown here in Table 4.3. 






















Silydianin 482.44 -0.39 1.05 LP LS IV 
Silybin A 482.44 1.95 1.97 HP LS II 
Silybin B 482.44 1.94 1.87 HP LS II 
Isosilybin A 482.44 1.94 2.19 HP LS II 
Isosilybin B 482.44 1.94 1.95 HP LS II 
*R2 0.835     
Metoprolol* 
(Reference Drug) 1.35 1.72 Reference HS  
Metoprolol =Reference standard for Permeability;  
*= R2 for CLogP and Experimental LogP of silymarin isomers 
HP=High Permeability; LP= Low Permeability 
**I =High Permeability-High Solubility 
II=High Permeability-Low Solubility 
III=Low Permeability-High Solubility 
IV=Low Permeability-Low Solubility 
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Table 4.3 also shows the BCS classification of silymarin isomers based on the 
solubility class obtained from the dose number (D0) and the permeability class obtained 
by using the partition coefficient of metoprolol as a reference standard.  Isomers having a 
partition coefficient higher than metoprolol were classified as highly permeability and 
those having a partition coefficient lower than metoprolol were classified as low 
permeability.  Based on its calculated partition coefficient (CLogP) silycristin is 
classified as a highly permeable compound and based on experimental LogP it is 
classified as a low permeability compound.  Since experimental values are always 
considered more accurate than calculated values, we classify silycristin as a low 
permeability compound.  Thus, silydianin and silycristin are the only BCS class IV 
compounds meaning that they belong to the Low-Permeability and Low-Solubility Class.  
All the other 4 isomers silybin A, silybin B, isosilybin A and isosilybin B belong to the 
BCS Class II i.e. High Permeability-Low Solubility. 
Koch et al. [147] determined the true partition coefficients for silybin, silydianin 
and silycristin and got values similar to each other for the three isomers (LogP~ 1.08).  
They also found that the partition coefficient values increased with increasing pH.  
Though the values found by us are not identical to the values of LogP determined by 
Koch et al., the estimates make sense considering that all these are either isomers or 
diastereomers, and they also have a reasonable correlation (r2=0.835)  with the CLogP 
values calculated theoretically.  Also Koch et al. determined the partition coefficient of 
silybin diastereomers as a single compound where as we have determined the partition 
coefficient of both the diastereomers (silybin A and silybin B) separately.  
 180
4.3:  ASSAY AND IN VITRO DISSOLUTION STUDIES 
This section discusses the assay and in vitro dissolution tests carried out for the 
silymarin isomers.  Out of the six isomers, only silybin A, silybin B and silydianin were 
quantified due to the lack of pure reference extract of silymarin and lack of pure 
individual standards for silymarin isomers other than silybin A and silybin B.  Pure 
reference standards for diastereomers silybin A&B and silydianin were obtained from the 
USP.   
4.3.1:  Previous Related Studies 
A standardized extract of silymarin should contain not less than 80% of silymarin 
isomers (flavonolignans) in the extract.  Silymarin formulations (tablets and capsules) 
found on the market have a label claim of 140mg of standardized silymarin.  The United 
States Pharmacopoeia specifies that a standardized extract of Milk thistle (also known as 
Powdered Milk thistle extract in the USP) should contain not less than 90% and not more 
than 110% of the labeled amount of silymarin calculated as silybin, and consisting of not 
less than 20% and not more than 45% for the sum of silydianin and silycristin and not 
less than 40% and not more than 65% for the sum of silybin A and silybin B and not less 
than 10% and not more than 20% for the sum of Isosilybin A and Isosilybin B.   USP 
limits for content of silymarin in dosage forms (tablets and capsules) are not less than 90 
percent and not more than 110 percent of the labeled amount of silymarin as silybin 
calculated as the sum of the six isomers silycristin, silydianin, silybin A, silybin B, 
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isosilybin A and isosilybin B.  USP limits for in vitro dissolution of dosage forms are not 
less than 75 percent of the labeled amount of silymarin as silybin in 45 minutes.   
4.3.2:  Assay and Dissolution Methodology 
Three commercially available oral dosage forms of silymarin were analyzed for 
isomer content and in vitro release profile of silybin A, silybin B and silydianin.  The 
criteria for selection of market products were:  
(i) Milk thistle should be the only herbal extract present in the formulation 
and should not exist as a combination product with any other herbal 
extract or dietary supplement. 
(ii) Should be in the form of an oral dosage unit such as a capsule, tablet or 
a caplet intended to be swallowed with water.  
(iii) The formulation should not contain any solubility aid or ingredient 
such as surfactant nor should the dosage form or extract be altered with 
an aim to increase oral absorption after oral administration. 
(iv) Each dosage unit was required to have a label claim of 140 mg of 
silymarin, which is the standardized dose of silymarin. 
 
Based on these criteria, formulations manufactured by Company A, Company B 
and Company C were randomly selected from the market and the same lot of each 
product was used for the assay and dissolution studies as shown in Table 4.4.    
The analytical method specifications for the assay of diastereomers silybin A, 
silybin B and silydianin are described in section 3.2.1.2 of this dissertation.  Though the 
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analytical method could separate and quantify all the isomers, only silybin A, silybin B 
and silydianin could be assayed due to their availability as pure reference standards.   
Table 4.4:  Dosage Forms for Assay and Dissolution Studies  
Manufacturer Lot number Dosage Form 
Silymarin Label Claim 
(mg) 
Company A 32070901 Capsule 140 
Company B 429676 Capsule 140 
Company C 235467 Capsule 140 
 
Weight variation for each product was determined by individually weighing 20 
filled capsules and their respective empty shells, thus giving the weight of the powder 
contained in each capsule.  The filled weight, the standard deviation and the relative 
standard deviation (%) for each product is shown in Table 4.5 
Table 4.5:  Weight Variation for the Silymarin Dosage Forms 
Manufacturer 
Average Weight of powder±SD (g) 
(n=20) 
CV (%) 
Company A 0.510 ±0.012 2.37 
Company B 0.459 ±0.009 2.01 
Company C 0.396 ±0.006 1.72 
CV= Coefficient of variation;  SD= Standard deviation 
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As seen from Table 4.5, the % RSD for the capsule powder content for each of the 
three manufacturers was not more than 3% indicating that the capsules were uniformly 
filled and passed USP specification for weight variation. 
The assay for the content of silybin A, silybin B and silydianin in capsules was 
done by extracting the isomers in methanol and analyzing them using HPLC with 1-
naphthol as an internal standard.   
4.3.2.1:  Assay of Silybin A, Silybin Band Silydianin 
 
Preparation of Standard Silybin A and Silybin B:  Silybin USP contains 
silybin A (44.91%) and silybin B (49.09%).  An accurately weighed quantity of silybin 
USP was dissolved in methanol (HPLC grade) to obtain a stock solution from which 3 
concentrations of silybin A and silybin B could be prepared.  The three concentrations of 
silybin A were: 1.18µg/mL, 11.85µg/mL, 79.04µg/mL and that of silybin B were: 
1.29µg/mL, 12.9µg/mL, and 86.39µg/mL.  1-naphthol was used as the internal standard 
to calculate the principle peak to internal standard area ratio.  The area ratio 
(drug/internal standard) versus concentration was plotted for each isomer.  A linear 
relationship was obtained with an r2 of 0.999 and the content of each isomer was 
calculated by considering the highest concentration on the calibration curve as a standard 
(79.04µg/mL for silybin A and 86.39µg/mL for silybin B). 
 
Preparation of Standard Silydianin:  Silydianin USP contains 100 percent 
silydianin.  An accurately weighed quantity of silydianin USP was dissolved in methanol 
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(HPLC grade) to obtain a stock solution from which 4 concentrations of Silydianin (3.4, 
5.6, 17 and 51µg/mL) could be prepared.  1-naphthol was used as the internal standard to 
calculate the principle peak to internal standard area ratio.  The area ratio (drug/internal 
standard) versus concentration for the isomer was plotted to obtain a linear relationship 
with an r2 of 0.999.  The third highest concentration on the calibration curve (17µg/mL) 
was then considered as a standard for calculating the assay of silydianin in milk thistle 
formulations. 
4.3.2.2:  Dissolution Methodology for Silybin A, Silybin B and Silydianin  
  In vitro dissolution testing was performed as per the procedure described in USP 
XXVI, method 2 (paddle method).  Nine hundred milliliters of pH 7.5 phosphate buffer 
with 2% sodium lauryl sulfate was used as the dissolution medium.  The temperature of 
the medium was maintained at 37±0.1°C.  The stirring rate of the paddle was set at 100 
revolutions per minute.  One capsule was placed in the medium of each of the dissolution 
vessels.  In order to keep the capsule at the bottom of the vessel a sinker made of stainless 
steel metal wire was fixed uniformly to each of the capsules.  Samples at fixed time 
intervals were withdrawn with a syringe and filtered through a 0.45µ nylon membrane.  
Samples were collected at 10, 20, 30, 40, 50 and 60 minutes.  Equal volume of medium 
was replaced after each sample withdrawal and the volume changes were taken into 
consideration to calculate the actual amount dissolved.  Samples were immediately 
analyzed using reverse phase HPLC with UV detection at 288 nm after the addition of an 
appropriate concentration of internal standard, 1-naphthol.  The details of this method are 
explained in section 3.2.1.2 of chapter 3 of this dissertation.  
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Preparation of Dissolution Medium:  41.4g of monobasic sodium phosphate 
and 9.1g of sodium hydroxide were accurately weighed and completely dissolved in 6 
liters of distilled water.  The pH of the solution was adjusted to 7.5 by adding drop wise, 
either 1N sodium hydroxide or 1N hydrochloric acid as required.  120g of sodium lauryl 
sulfate was added to this solution and gently dissolved to obtain the required dissolution 
media. 
4.3.3:  Results and Summary 
4.3.3.1:  Assay of Silybin A, Silybin B and Silydianin 
The results for the assay of silybin A, silybin B and silydianin are shown in Table 
4.6.  The assay was carried out on three market formulations each from a different 
manufacturer.  All the three dosage forms tested were capsules.   
Table 4.6:  Assay Results for Silybin A, Silybin B & Silydianin in Market Formulations  
Capsule Company A Company B Company C 
Lot No. 32070901 429676 235467 
Weight Variation-CV (%) 2.37 2.01 1.72 
Assay±SD (mg/capsule) 
Silybin A 17.20 ±0.05 17.20 ±0.01 47.20 ±0.82 
Silybin B 29.9 ±0.11 30.19 ±0.21 69.36 ±1.02 
Silydianin 11.08 ±0.07 12.81 ±0.09 5.13 ±0.08 
CV= Coefficient of variation; SD=Standard deviation 
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Table 4.6 shows the assay of three market formulations for Milk thistle.  The 
capsules have a label claim of 140 mg of silymarin, meaning that each capsule should 
contain not less than 140mg of silymarin extract standardized to contain at least 80% of 
flavonolignan isomers.  The assay for the three market formulations indicated that 
Company A and Company B products contained similar amounts of silybin A 
(~17.3mg/capsule) and silybin B (~30mg/capsule), where as capsules from Company C 
contained a significantly high amount of both isomers (silybin A~47mg/capsule) and 
silybin B (~70mg/capsule).  Company A and Company B capsules also had similar 
amounts of silydianin (~12 mg/capsule), and significantly less silydianin in Company C 
capsules (~5.13 mg/capsule).  Silybin A and silybin B are considered as the main active 
ingredients and many researchers and manufacturers base their silymarin assays based on 
the content of silybin diastereomers.   
According to USP specifications for assay of milk thistle capsules, the sum of all 
isomer content should be between 90%-110% of the label claim.  Since we have reported 
the assay for silybin A, silybin B and silydianin content only, the total of these 3 isomers 
add up to 58.18% for Company A capsules, 43% for Company B capsules and 86.98% 
for Company C capsules.  Though it cannot be concluded whether these products pass 
USP specifications for assay content, it is obvious that there is significant variation in the 
isomer content between formulations having the same label claim.   
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4.3.3.2:  Dissolution of Silybin A, Silybin B and Silydianin 
In vitro dissolution test was done for capsules manufactured by Company A.  The 
release of silybin A, silybin B and silydianin was studied in 900ml of pH 7.5 phosphate 
buffer (0.2M) with 2% sodium lauryl phosphate.   
 
The data for the release of silybin A, silybin B and silydianin is shown in Tables 
4.7-4.9 along with the plot of percent release versus time in minutes (Figure 4.1-4.3).  
Table 4.7: In Vitro dissolution profile of Silybin A in Company A Capsules 
Company A Capsules (Silybin A: 17.20 mg/capsule) 
 Capsule Number (Percent Released) 
Time 
(minutes) 
1 2 3 4 5 6 Mean SD 
10 7.29 4.84 6.57 9.16 14.21 12.99 9.18 3.39 
20 8.72 16.33 19.57 20.60 24.19 25.41 19.13 5.53 
30 30.16 25.40 26.30 24.26 28.09 26.89 26.85 1.90 
40 31.39 25.11 29.12 31.26 27.76 30.42 29.17 2.21 
50 33.45 25.35 32.14 30.47 32.46 33.36 31.20 2.79 
60 34.37 32.42 32.08 30.94 32.02 30.74 32.09 1.18 






















Figure 4.1.  Plot of Percent release of Silybin A versus Time (Company A Capsules) 
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Table 4.8: In Vitro dissolution profile of Silybin B in Company A Capsules 
Company A Capsules (Silybin B: 29.90 mg/capsule) 
 Capsule Number (Percent Released) 
Time (min) 1 2 3 4 5 6 Mean SD 
10 16.73 12.45 13.75 16.61 25.41 22.66 17.94 5.07 
20 17.22 26.40 31.32 33.09 38.49 40.29 31.13 8.46 
30 44.88 38.03 40.08 37.27 43.10 42.03 40.90 2.97 
40 45.65 36.88 42.94 45.92 40.70 45.21 42.88 3.55 
50 47.90 36.51 46.10 43.97 47.49 48.52 45.08 4.50 
60 49.34 46.85 46.77 45.65 47.88 44.94 46.91 1.57 





















Figure 4.2.  Plot of Percent release of Silybin B versus Time (Company A Capsules) 
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Table 4.9: In Vitro dissolution profile of Silydianin in Market Formulations  
Company A Capsules (Silydianin: 11.08 mg/capsule) 
 Capsule Number (Percent Released) 
Time (mins) 1 2 3 4 5 6 Mean SD 
10 16.08 10.48 13.09 17.95 26.13 21.33 17.51 5.65 
20 18.01 24.21 30.55 32.46 41.59 47.29 32.35 10.80 
30 47.14 39.81 46.18 39.91 48.56 49.55 45.19 4.28 
40 47.14 38.10 46.21 48.49 40.91 49.30 45.03 4.49 
50 51.15 35.03 49.64 45.42 51.84 51.94 47.50 6.57 






















Figure 4.3.  Plot of Percent release of Silydianin versus Time (Company A Capsules) 
Results presented in Tables 4.7-4.9 show the in vitro dissolution of silybin A, 
silybin B and silydianin from Company A Milk thistle capsules.  According to the 
dissolution studies and based on the assay of Company A capsules we see that at the end 
of 60 minutes, for silybin A:5.51mg dissolved from 17.2 mg/capsule (32.09%); for 
silybin B: 14.02mg dissolved from 29.9 mg/capsule (46.91%); for silydianin: 5.56 mg 
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dissolved from 11.08 mg/capsule (50.26%).  Thus, the total dissolution from a label claim 
of 140 mg of isomers /capsule was 17.92 % which is extremely low after considering 
only 3 out of six isomers.  According to USP 30 specifications, not less than 75% of the 
labeled amount of silymarin measured as silybin (calculated as the sum of silydianin, 
silycristin, silybin A, silybin B, isosilybin A and isosilybin B) should dissolve in 45 
minutes.  Considering the low solubility nature of the isomers, it is evident that the tested 
capsules manufactured by Company A will surely fail the in vitro dissolution 
specifications set by the USP 30 for milk thistle capsules indicating potential issues into 
the quality control of these products and the requirement more stringent regulatory 
protocols to maintain the quality and efficacy of these products and other herbal 
supplements. 
The dissolution results also indicate that silybin A is the least soluble, followed by 
silybin B and silydianin is the most soluble among the three isomers tested for 
dissolution.  These results are in correlation with the equilibrium solubility results 
obtained for the isomers where in silybin A (0.0033 mg/mL) is less soluble than silybin B 
(0.0077 mg/mL) which is less soluble than silydianin (0.019 mg/mL). 
 
4.3.3.3:  Summary 
Silymarin capsules manufactured by Company A, Company B, and Company C 
were analyzed for content of isomers silybin A, silybin B and silydianin.  Company A 
capsules were further studied for the in vitro dissolution profile of silybin A, silybin B 
and silydianin.   Assay results indicated that capsules manufactured by Company C 
contained the highest amount of silybin A (47.2 mg/ capsule) and silybin B 
(67.3mg/capsule) and the lowest amount of silydianin (5.13mg/capsule).  Capsules 
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manufactured by Company B and Company A contained similar amounts of silybin A 
(~17mg/capsule), silybin B (~30mg/capsule) and silydianin (~12 mg/capsule).  Capsules 
manufactured by Company A were selected for studying the in vitro dissolution profile of 
silybin A, silybin B and silydianin.  Based on the content of the three isomers assayed, 
we expect milk thistle capsules tested from all the manufacturers to pass USP 
specifications.  The dissolution results indicate that for Company A capsules, at the end 
of 60 minutes, silybin A was the least dissolved (~32.09%) followed by silybin B 
(~46.91%) and then silydianin (~50.26%) which was the most soluble in the medium 
tested.  This is  agreement with the solubility experiments done for the silymarin isomers 
where in silydianin is the most soluble (0.019 mg/mL) and silybin A (0.0033 mg/mL) and 
silybin B (0.0077 mg/mL) have a lesser solubility, but not less than Isosilybin A and 
Isosilybin B.  The dissolution profile of the diastereomers silybin A and silybin B is also 
in agreement with the solubility profile where in silybin A is less soluble than silybin B.  
The dissolution results for the Company A capsules are not expected to pass the 
specifications set by the USP 30 leading to stricter regulatory protocols and better GMP. 
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CHAPTER 5:PHARMACOKINETICS OF SILYMARIN ISOMERS 
5.1:  INTRODUCTION 
Silymarin, the extract of milk thistle has been in traditional use for upper 
gastrointestinal disturbances, diseases of the liver and the biliary tract.  It has been 
reported to be effective in improving the clinical courses of acute and chronic, viral, drug 
and alcohol-induced hepatitis.   silymarin consists of six flavonolignan isomers known to 
be therapeutically effective, mainly against liver intoxication and poisoning.  Accurate 
pharmacokinetic and metabolism studies with silymarin isomers are extremely rare or 
non existent.  Pharmacokinetic studies are either inaccurate or not precise mainly due to 
the inability to quantify all the silymarin isomers in a biological matrix.  Researchers tend 
to quantify only Silybin- a single component as an active marker for silymarin [148], or 
quantify four components: Silycristin, Silydianin, Silybin and Isosilybin, where in Silybin 
and Isosilybin each are quantified as one component rather than as individual 
diastereomers [77, 136].  Thus, pharmacokinetic parameters of silymarin and the active 
principle of any silymarin containing product is usually referred to and standardized as 
Silybin.  In vivo experiments studying the pharmacokinetics of all the six silymarin 
isomers do not exist till date.   It has been reported that after intravenous administration 
of 100mg/kg of Silybin N-methylglucamine, significant amounts of unconjugated Silybin 
were found in feces during the following 24 hours and in the intestine 2 hours after 
administration. Further Mennicke et al. studied the biliary excretion of silymarin as 
Silybin after rectal administration in rats, and found 3-5% of the administered dose after 
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6 hours.  This data together with the presence of unmodified Silybin in the intestinal 
content and feces is strong evidence of the entero hepatic circulation of Silybin. 
5.1.1:  Absorption 
Absorption of silymarin isomers, in human and animal models, after oral 
administration of the plain extract, is very low mainly due to the low solubility of the 
isomers. Other factors that govern the extent of absorption of the isomers are content of 
accompanying substances in the formulation such as solubilizers, the concentration of 
isomers in the extract and the dose administered.  The bioavailability of silybin (A&B) 
can be greatly enhanced by its complexations with phosphatidylcholine (Lecithin) or β-
cyclodextrin, choice of the capsule material or by using modified drug delivery systems 
such as self-micro-emulsifying drug delivery systems and liposomes. [77, 78, 136, 149-
155] Complexation of Silybin with phosphatidylcholine is the most common method for 
the enhancing the bioavailability of silybin.  It should be noted that in all these studies, 
complexation is done with silybin (A&B) alone and not with the extract.  When studying 
different products, the amount of silymarin isomers dissolved during in vitro dissolution 
tests or the extent of absorption of silymarin or Silybin during in vivo studies should be 
compared with caution keeping in mind the method of analysis and the type of isomer 
analyzed.  Significant variation has been observed when comparing different market 
products claiming to have the same label claim. [76, 156]  Thus, when silybin is being 
reported as the isomer of interest in a certain study, it should be studied whether the 
amount of Silybin measured is the sum of all silymarin isomers reported as Silybin or the 
sum of diastereomers Silybin A and Silybin B.  If Silybin alone is being reported as the 
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isomer of interest, is should be observed whether the method of analysis measures Silybin 
content as a single entity or the combination of diastereomers silybin A and silybin B.  
Schulz et al. performed assay and in vitro dissolution test in seven market formulations of 
silymarin and based on these results selected three formulations for bioequivalence 
testing.  Their results showed a two fold higher bioavailability for silybin from one of the 
market products (LegalonTM by Madaus Pharma®) when compared to the other two 
products. Since the liver is the site of action of silymarin isomers, many researchers 
measure the conjugated and unconjugated forms of silymarin in bile and the systemic 
circulation, respectively.  Thus, systemic plasma concentrations of silymarin isomers 
should be measured, as they provide an estimate on the quantity of isomers being 
absorbed from the gastrointestinal tract. In vivo studies reporting the absorption of 
silymarin or Silybin after oral administration indicate a very high variability in the values 
of Cmax and Tmax.  As mentioned earlier, when comparing in vivo studies for silymarin, it 
should be made clear what isomer of interest was being measured.  As for the earlier 
reports it can be safely assumed that since the analytical separation of all the silymarin 
isomers was not evident, the isomer reported was silybin, which might have been a 
measure of all the isomers or particularly silybin.  Regardless of the isomer measured, all 
studies indicate a very low absorption extent of silymarin and a highly variable plasma 
peak concentration (Cmax) and time to plasma peak concentration (Tmax). 
One of the earliest reports on the experimental pharmacokinetics of silymarin is 
by Meyer-Burg [58, 125] who reported that after oral administration of 500-1000 mg/kg 
of silymarin in rats, 75% of the dose was found in the feces, where as after intraperitoneal 
administration of 100mg/kg, no silymarin was found in the serum, urine or feces. Janiak 
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et al. reported peak plasma concentrations of 500µg/mL of silymarin as silybin, 90 
minutes after oral administration of 200mg/kg of silymarin as silybin in mice. [58, 157]  
Unpublished work done by Chasseaud and cited by Mennicke [58, 126] described 
the blood-time concentration profile of radio labeled 3H-Silybin after oral administration 
in rats, where silybin showed peak concentrations at 30 minutes and an absorption rate of 
30% of the administered dose.  Morazzoni et al. compared the bioavailability of silymarin 
with silybin-phosphatidylcholine (Silipide®) complex. [136] The low bioavailability of 
silymarin was confirmed when after oral administration of a 200 mg/kg dose to rats, 
plasma levels of Silybin were under the analytical limit of detection.  In another study, 
Morazzoni studied the pharmacokinetic profile of separate isomers, silybin, silycristin, 
silydianin, and isosilybin in comparison to Silipide®. [77] Unconjugated Silipide® had a 
significantly higher bioavailability (AUC0-24h = 8.31µg.hr/mL) as compared to 
unconjugated silymarin isomers.  The sum of the AUC0-24h values for all the silymarin 
isomers was less than the AUC0-24h reported for Silipide® alone.  Unconjugated silycristin 
could not be detected after oral administration and unconjugated Isosilybin had the 
highest AUC0-24h (1.65) among the silymarin isomers.  For both Silipide® and silymarin, 
a major proportion of the isomers were found in the form of metabolites in bile as 
glucuronides and sulfates.   
Quineng and Yanyu [154] compared the bioavailability of silybin-N-
methylglucamine and silybin phospholipids complex in rats.  They found that the silybin 
phospholipids complex had significant enhanced bioavailability when compared to 
silybin-N-methylglucamine. 
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Table 5.1 gives an idea of the variability in absorption parameters (Cmax, Tmax) 
for the various silymarin isomers in the plain extract or in the form of a phospholipids 
complex for studies done in rats by various researchers. 
Table 5.1:  Comparison of Absorption Parameters Following Oral Administration of 
Unconjugated Silybin or Silymarin (Plain or Complex) as Silybin in Rats 











Silybin (200mg/kg) 200 NA Below LOD -- [136] 
§Silipide® (200mg/kg) 200 0.36 2-21∏ 9.78±3.29 [136] 
Silybin (200mg/kg) 200 0.13±0.09 0.06 ±0.04 0.02±0.01 
Silycristin  ND ND 0 
Silydianin  6 ±0 0.1 ±0.07 0.2±0.15 
Isosilybin  1.65±1.09 0.44±0.04 1.14±0.31 




9.1 0.08 0.104 0.235 [154] 
Silybin-phospholipid 
Complex 
9.1 0.17 0.126 1.220 [154] 
Silymarin in PEG 400 
(300mg/kg) * 
300 2.39±1.54 0.70 ±0.18 3.17±1.63 [153] 
Silymarin-SMEDDS 
as silybin (300mg/kg)* 
300 4.33±0.82 1.01 ±0.21 6.23±1.75 [153] 
§=Silipide® is a complex of silybin (A&B) with phosphatidylcholine. Doses of Silipide are 
measured as silybin (A&B) equivalents. 
*=Study in Rabbit; ∏=Range of Cmax observed 
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Thus, it can be seen from Table 5.1 that Tmax for silybin (A&B) after oral 
administration in an animal model varies significantly from 5 minutes 
(Cmax=0.104µg/mL) for silybin-N-methylglucamine to 4.33 hours (Cmax= 1.01µg/mL) 
for silybin in silymarin-SMEDDS formulation.  The Tmax and Cmax reported here are only 
for the unconjugated silybin isomer levels found in plasma. Variation can also be seen 
after administration of plain silymarin as silybin (Tmax range:  0.13 hours-2.39 hours). 
 Kim and coworkers [148] conducted a comparative bioavailability study in 
humans with three silymarin market formulations: Liverman Capsule (Dong A 
Pharmaceutical Company, Korea, silymarin tablet (Kunhil Pharmaceutical Company, 
Korea) and Legalon capsule (Madaus Pharma, Germany).  All subjects received an equal 
dose strength containing silymarin as 120 mg of silybin.  Significant variability in the 
area under the plasma concentration-time curve (AUCinf) was observed between the three 
formulations in spite of the same dose administered to subjects.  AUCinf for Liverman 
capsules was found to be highest (15.1±3.68µg.hr/mL) than Legalon (6.0±2.2µg.hr/mL) 
and silymarin tablet (4.63±1.96µg.hr/mL).  The Cmax for Liverman was 6.04±1.9 µg/mL 
where as that for Legalon and silymarin tablet was ~1.2µg/mL which was significantly 
lower.  The publication does not give any explanation for the observed variability in the 
extent of absorption, but this could possibly be due to the varying contents of silybin in 
the extract used in the formulation.  Further silymarin is known to be insoluble in 
aqueous media suggesting that the variability in the AUC might be due to dissolution 
limited absorption. Also, it has not been specified whether any of the formulations tested 
had any solubility enhancers present in the formulations which might lead to varying 
amounts of isomers being dissolved in the gastrointestinal contents. 
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Lorenz et al. studied the serum concentration levels of silybin in healthy human 
volunteers after the administration of a dose of 560mg of silymarin corresponding to 240 
mg of silybin.  The maximum plasma concentration was found to be 0.34±0.16µg/mL, 
time to peak was 1.32 hours, and AUC was 1.14µg.hr/mL. [158] Human 
pharmacokinetics of silymarin in healthy as well as cirrhotic patients was studied by 
Barzaghi et al. and Orlando et al. [58, 158] They reported that after a single dose of 360 
mg of silybin as silymarin, silybin was rapidly absorbed with a Tmax of 1.4 hours, a 
Cmax ranging from 0.024µg/mL - 0.2µg/mL, and mean AUC observed was 
0.252µg.hr/mL .  In cirrhotic patients these parameters did not show a significant change 
but the Tmax was observed to be 2.6 hours, indicating slower absorption as compared to 
healthy patients. 
Table 5.2 shows the comparative bioavailability parameters for free Silybin after 
oral administration in humans. 
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Table 5.2:  Comparison of Pharmacokinetic Parameters for Free Silybin After Oral 












Silipide® 360 0.298 1.6±0.3 0.881±207 [150] 
Silymarin Extract 360 0.102 1.4±0.3 257±66 [150] 
Silipide 
(Hard gel Capsule) 
80 0.193±0.182 2.9±1.3 0.387±0.340* [78] 
Silipide® 
(Soft Gel Capsule) 
80 0.710±0.799 1.25±0.62 1.068±1.040* [78] 
101.7 0.116 -- 0.254 [79] 
152.6 0.250 -- 0.423 [79] 
203.4 0.239 -- 0.670 [79] 
Silymarin Extract 
245.3 0.317 -- 0.751 [79] 
Legalon Capsule 120 1.33±0.54 1.83±0.94 6.0±0.22** [148] 
Liverman Capsule 120 6.04±1.9 0.875±0.36 15.1±3.68** [148] 
Silymarin Tablet 120 1.13±0.51 2.10±1.07 4.63±1.96** [148] 
*    = AUC0-24h 
 ** =AUC0-26h 
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5.1.2:  Distribution, Metabolism and Excretion 
In vitro studies on the plasma protein binding of silycristin, silydianin and silybin 
indicate that the isomers are extensively but reversibly bound to human albumin. [159] In 
a later study, the volumes of distribution for silycristin, silydianin and silybin were 
calculated from the partition coefficient between octanol and pH 7.4 buffer and binding 
to human albumin.  Based on the data, a one-compartmental model was fit for silybin, 
and silycristin and silydianin fit a two-compartment model. [160]  
As seen from the data in Tables 5.1 and 5.2, most of the early in vivo experiments 
concerning silymarin, were performed with silybin as a standard. [126, 136, 161, 162]  
Though results were measured as silybin, later experiments have shown that major 
silymarin isomers other than silybin, such as silycristin, silydianin and isosilybin show a 
similar behavior as silybin in terms of excretion and metabolism, the only difference 
being their individual proportion in the extract. [163] Sonnenbichler et al. studied the 
subcellular distribution and liver uptake of silybin and its metabolites following 
intravenous, intraperitoneal, and oral administration of radioactive 3H-Silybin in rats. 
[162] After 8 hours of intraperitoneal administration, the following percentages of 
radioactivity were found in various organs and tissues: 5.1% in liver; 2.1% in blood, 
0.3% in spleen and 0.1% in brain.  A similar trend in the percent distribution was found 
following other forms of administration.  Further qualitative analysis indicated that 80% 
of the silybin found in the liver homogenate and cytosol of the hepatic cell was in the 
unconjugated form while the remaining 20% was in the form of glucuronide and sulfate 
metabolites.   
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One of the earliest reports on the metabolism and elimination of silymarin was by 
Bulles et al. in 1975.  They published a study on the urinary and biliary excretion of 
silybin in rats after intravenous (20mg/kg) and oral (2-20mg/kg) administration of 
silybin-N-methylglucamine. [58, 126] The results indicated that independent of the route 
of administration, silybin was excreted in the urine unmodified and in the bile as 
metabolites, such as glucuronides and sulfates of silybin and dehydrosilybin.  The amount 
of silybin excreted in urine during 48 hours post administration, was minimum (~2-5% 
post oral) and ~8% after intravenous administration. Biliary excretion of silybin, as 
glucuronide and sulfate metabolites, after 48 hours was about 40-45% for the highest oral 
dose (20mg/kg) and 80% after intravenous administration.  The ratio between the dose 
and the quantity excreted in the bile was found to be linear and the minimum 
bioavailability based on the excretion data was found to be 45%.  Kinetic studies of 
biliary excretion indicated that, maximum excretion of metabolites in bile occurred 
within 1 hour after oral after oral administration, indicating rapid absorption of silybin. 
After intravenous administration of silybin-N-methylglucamine (100mg/kg), 
Bulles et al. reported considerable quantities of unconjugated silybin, in feces collected 
during 24 hours and intestinal contents 2 hours after administration.  Mennicke [161] 
evaluating the biliary excretion of silybin after rectal administration, reported detecting 3-
5% of the administered dose.  This along with the presence of silybin in the intestinal 
content as reported by Bulles, may indicate possible entero hepatic circulation. Thus, 
silybin or silymarin isomers exhibit entero hepatic circulation in the sequence: intestinal 
absorption, conjugation in the liver, excretion in the bile, hydrolysis by the intestinal flora 
and finally reuptake in the intestine. [56, 161]  
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Elimination half lives for silybin or silymarin after intravenous administration 
have not been reported.  Elimination half lives for Silybin after oral administration have 
been reported to be in the range from less than 1 hour up to six hours.  Weyhenmeyer et 
al. reported concentrations of unchanged silybin diastereomers in plasma from 4 hours to 
13 hours, with concentration of one isomer being three times higher than the second 
isomer.  A one compartment model was fit to the obtained plasma data which resulted in 
elimination half lives of less than 1 hour.  The actual half lives were not reported based 
on the one compartment model as it was suspected that another additional elimination 
phase existed which was at that time, hidden below the sensitivity of the analytical assay.  
The assay detected the beginning of a second elimination phase which was below the 
limit of detection.  They also found an irregular absorption pattern resulting in multiple 
concentration peaks. [79] Lorenz et al. reported an elimination half of 6 hours for silybin 
post oral administration. [158]  
Silymarin extract consists of six flavonolignans: Silycristin, Silydianin, Silybin A, 
Silybin B, Isosilybin A and Isosilybin B.  Silybin (the mixture of diastereomers Silybin A 
and B) has long been considered to be the most active component of the extract and 
hence early research has been focused on Silybin as a measure of silymarin.  Quantitative 
separation of all silymarin isomers or diastereomers was not possible during the earlier 
experiments-in vitro or in vivo, and thus silybin measured would be a measure of all the 
silymarin isomers collectively, unless specified.  This resulted in the incomplete 
pharmacokinetic profiling or evaluation of bioavailability of each isomer.  The overall 
bioavailability of silybin or silymarin from the extract is low mainly due to the low 
solubility of the extract.  Significant variation has been found in content, dissolution and 
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bioavailability of different formulations having the same label claim.  This indicates 
formulation differences resulting in lack of bioequivalence or variation in isomer content 
at source such as geographical location of the plant, time of harvest and method of 
processing to obtain the standardized extract.  Comparison of pharmacokinetic 
parameters determined from different in vivo studies should be done with caution, 
considering the differences in the analytical methods used, the types of isomers 
quantified and whether the level of free, conjugated or the total isomer is being reported.  
Systemic plasma concentrations of all detectable isomers should be measured even if the 
liver is the site of action as this provides an estimate on the quantity of the particular 
isomer being absorbed from the gastro intestinal tract.    
5.2:  EXPERIMENTAL METHODS AND DESIGN 
5.2.1:  Method of Analysis 
A reverse phase HPLC method was developed to detect the silymarin isomers in 
rat plasma. The development and complete validation of the method has been discussed 
in the Analytical Methodology Chapter of this dissertation.  A skeletal description of the 
method and a sample chromatogram are shown in Table 5.3 and Figure 5.1.  
Table 5.3: HPLC Specifications for Detection of Silymarin Isomers in Rat Plasma 
Method HPLC, Reverse Phase, Binary Gradient 
Column Type Phenomenex, Luna C-18(2) 
Column Dimensions 150 x 4.6mm, particle size: 5μ 
Mobile Phase Conditions Water (A): Methanol (B) 
%B: 20-50 in 28 minutes  
        50-55 in 36 minutes 
Total Flow: 2ml/min for10 minutes 
                   1ml/min for 10-38 minutes 
                   2ml/min for 38-41 minutes 
Internal Standard 1-naphthol (0.5µg/mL) 
Detection UV, 288nm 











                                                       Time (Minutes) 
Figure 5.1. Sample Chromatogram for Detection of Silymarin Isomers in Rat Plasma 
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The following limit of quantitation was set for the following isomers: silycristin: 
0.06µg/mL; silydianin: 0.08µg/mL; silybin A: 0.05µg/mL; silybin B: 0.05µg/mL; 
Isosilybin A: 0.05µg/mL; Isosilybin B: 0.06µg/mL. 
The concentration range for each silymarin isomer for the development of 
respective standard curves in rat plasma is illustrated in Table 5.4. 
Table 5.4:  Standard Curve Concentration Range for Each Silymarin Isomer in Rat 
Plasma 
Silymarin Isomer Concentration Range (µg/mL) 
Silycristin 0.24 - 15.32 
Silydianin 0.08-2.26 
Silybin A 0.47-11.81 
Silybin B 0.86-21.61 
Isosilybin A 0.20-5.13 
Isosilybin B 0.06-1.6 
5.2.2:  Animal Model Used 
Male Sprague Dawley rats weighing between 280-320g were purchased from 
Charles River (Wilmington, MA) and the Animal Resource Center (University of Texas 
at Austin, Austin, Tx).  The rats were housed individually in wired bottom cages, at 
22°C, 50% humidity and on a 12 hour light-dark cycle.  The rats were allowed free access 
to commercial rodent diet (Harlan, IN) and water was allowed ad libitum.  All amimal 
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research was carried out according to protocols pre-approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of Texas at Austin 
5.2.3:  Study Design and Dosing Regimen 
Thirty six rats were randomly divided into two groups, each group containing 
eighteen rats. One group was subjected to intravenous bolus dosing and the second group 
was subjected to oral dosing of silymarin extract. 
Silymarin extract obtained from Sigma Aldrich was used to prepare the dosing 
solutions.  The assay of the extract for isomer content is described in the Analytical 
Methodology section of this dissertation.  Dosing solutions were prepared by accurately 
weighing and dissolving the appropriate quantity of silymarin extract in a mixture of 
water: PEG 400: Ethanol in the ratio 50:40:10 respectively. 
5.2.3.1:  Intravenous Bolus Dosing 
Eighteen rats were divided into three groups of six rats each.  Three silymarin 
concentrations were selected for the intravenous bolus dose: (i) Treatment A: 25mg/Kg; 
(ii) Treatment B: 50mg/Kg; (iii) Treatment C: 100mg/Kg.   
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These silymarin concentrations yielded the corresponding isomer concentrations 
as per their proportion in the extract as shown in Table 5.5.   
Table 5.5:  Individual Isomer Assay and Concentrations in Silymarin I.V Bolus Doses   







Silycristin (Sc) 24.50 6.13 12.26 24.52 
Silydianin (Sd) 3.62 0.90 1.80 3.61 
Silybin A (SbA) 18.9 4.72 9.45 18.90 
Silybin B (SbB) 34.6 8.6 17.29 34.58 
Isosilybin A (ISbA) 8.22 2.05 4.11 8.22 
Isosilybin B (ISbB) 2.56 0.64 1.28 2.56 
Total 92.40    
 
Rats were dosed according to a cross over design as shown in Table 5.6 such that 
each rat received all the three treatments A, B & C during the three periods tested.  A 
wash out time of 10 days was maintained between any two periods.  Rats were fasted 12 
hours prior to dosing.  However, water was allowed ad libitum. 
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Table 5.6:  Intravenous Bolus Dosing Sequence 






1 ABC A B C 
2 BCA B C A 
3 CAB C A B 
4 ABC A B C 
5 BCA B C A 
6 CAB C A B 
 
Rats were fasted 12 hours prior to dosing and water was restricted from one hour 
before dosing up to four hours after dosing.  Food was restricted up to 12 hours after dose 
administration after which they had free access to food and water.  
 
5.2.3.2:  Oral Dosing 
Eighteen rats were divided into three groups of six rats each.  Three silymarin 
concentrations selected for oral administration were: (i) Treatment A1: 125 mg/Kg; (ii) 
Treatment B1:  250 mg/Kg; (iii) Treatment C1:  500 mg/Kg.  The silymarin 
concentrations yielded the corresponding isomer concentration in the dosing solutions as 
shown in Table 5.6. 
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Silycristin (Sc) 24.50 30.65 61.30 122.61 
Silydianin (Sd) 3.62 4.52 9.04 18.08 
Silybin A (SbA) 18.9 23.63 47.27 94.54 
Silybin B (SbB) 34.6 43.23 86.46 172.93 
Isosilybin A (ISbA) 8.22 10.27 20.55 41.11 
Isosilybin B (ISbB) 2.56 3.20 6.40 12.81 
Total 92.40    
 
Oral administration of silymarin was done using a cross over design over three 
periods such that each rat received all the treatments A1, B1 & C1 as shown in Table 5.7. 
Table 5.8: Oral Dosing Sequence 






1 A1B1C1 A1 B1 C1 
2 B1C1A1 B1 C1 A1 
3 C1A1B1 C1 A1 B1 
4 A1B1C1 A1 B1 C1 
5 B1C1A1 B1 C1 A1 
6 C1A1B1 C1 A1 B1 
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A wash out time of 10 days was maintained between any two periods.  Rats were 
fasted 12 hours prior to dosing and water was restricted from one hour before dosing up 
to four hours after dosing.  Food was restricted up to 12 hours after dose administration 
after which they had free access to food and water. 
5.2.4:  Catheterization of the Jugular Vein 
All rats were anesthetized and a cannula inserted into their jugular vein to enable 
the injection of drug solution during the intravenous study and sampling of blood post 
intravenous and oral drug administration. 
5.2.4.1:  Anesthesia  
Anesthesia was induced prior to surgery by an intraperitoneal injection of rodent 
anesthesia cocktail containing Ketamine HCl, Xylazine HCl and Acepromazine.  The 
anesthetic cocktail was prepared as follows:  
i. Ketamine HCl:  150mg, 100mg/mL, 1.5ml 
ii. Xylazine HCl:    30mg,   20mg/mL,   1.5mL 
iii. Acepromazine:  5mg,     10mg/mL,   0.5mL 
 
An initial dose of 0.6 mL/Kg of the cocktail was administered to induce 
anesthesia.  In the event that the animal regained consciousness during the surgical 
procedure, a 0.3 mL/Kg dose was administered again.  The anesthetic cocktail does not 
cause deep central respiratory depression.  Ketamine prevents the body temperature from 
dropping and Xylazine and Acepromazine provide muscle relaxation. 
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5.2.4.2:  Surgical Procedure  
Once an appropriate and stable plain of surgical anesthesia had been induced, the 
rat was moved to the surgical area.  The collar bone area near the chest was shaved in 
order to make the jugular vein roughly visible.  The head was also shaved to enable the 
mounting of the cannula on the head after the catheterization was complete.  Rimadyl 
(NSAID), 1% body weight was administered and the time of administration noted.  
Initially a one inch long incision was made over the head, between the eyes in order to 
expose the lambda/bregma.   
Catheterization of the jugular vein:  The animal was laid on its back its legs 
taped using a peach tape.  Then a 2-3 cm long incision was made in the collar bone area 
where the jugular vein could be roughly visible.  Precaution was observed not to damage 
the jugular vein during the making of the incision.  Once the jugular vein was exposed 
and isolated from the surrounding tissue, a tiny incision was made using a ball scissors.  
A catheter (6-7 cm polyethylene tubing, PE-50, trimmed to give a smooth beveled end) 
was attached to a syringe and its lumen filled with saline.  A bent blunt needle (used as a 
place holder) was inserted into the vein incision to make way for the catheter, and the 
catheter inserted in to the vein.  Once the catheter was inserted into the vein, the 
operation of the catheter was checked for free flow of blood by administering a small 
quantity of saline, from the syringe attached to it.  The catheter was then secured in place 
by 2 sutures, one at the farther end from the incision and one near the incision.  The 
catheter was checked for blood flow after each suture and then ensured that its lumen was 
filled with saline.  The syringe was detached, and the catheter was immediately capped to 
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prevent blood coagulation.  Gentamicin was applied to the incision cavity to prevent 
infection during recovery.   
Using a large forcep a subcutaneous pathway was created between the head and 
the chest.  The capped end of the catheter was then pulled gently through the 
subcutaneous pathway, such that the capped end of the catheter showed up on the head.   
The chest incision was then closed with sutures, and wound powder and 
Noesporin was applied to the sutures to prevent infection and aid recovery.   
 
Mounting of Catheter on the Head: The skull was cleaned with saline, and 4 tiny 
shallow holes were drilled into the skull to form four vertices of a square.  The holes were 
drilled such that they were not more than 0.25 cm apart from each other and roughly 0.15 
cm deep.  Care was taken to ensure that the holes were shallow enough so as not to 
expose the brain to the screws.  Tiny screws were inserted into these holes and slightly 
tightened half way through.  The catheter was positioned between these screws and put in 
place with the help of cyanoacrylate (SuperGlu®) glue.  The catheter was then further 
reinforced into place by filling the space between the screws with dental cement.  The 
cement was allowed to dry and the catheter was again finally checked for free blood flow.  
Care was taken to prevent the cement from sticking to the exposed skin around the head, 
by filling the gap between the skin and the cement by wound powder.  The rat was then 
placed on a heating pad to recover and gain consciousness.   
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5.2.4.2:  Recovery Period 
The rats were allowed to recover from surgery and regain the lost weight for 
approximately two weeks prior to the start of the pharmacokinetic study.  As the weight 
of each rat approached 300 g only then were they assumed fit for drug administration. 
  
5.2.4.3:  Anticoagulant and Catheter Flushing 
Heparin, 20units/mL was used as an anti coagulant throughout the experiments.  
Catheter flushing solution was composed of 0.9% NaCl injectable solution containing 
20units/mL of Heparin.  Catheters were flushed daily, during intravenous drug 
administration and during blood sampling with 0.3 mL of flushing solution in order to 
prevent clotting of blood inside the catheter.   
5.2.5:  Dose Administration 
Dosing solutions were prepared fresh prior to dosing.  Preparation of dosing 
solutions has already been described in the previous sections of this chapter.  The volume 
of the administered dose was adjusted according to the weight of the animal such that the 
required concentration of drug was administered.  The injection volume ranged from 0.1 
to 0.4 ml. 
5.2.5.1:  Intravenous Dosing   
During intravenous dosing, the appropriate quantity of drug solution was filled in 
a syringe and kept ready for administration.  Prior to dosing, the catheter was flushed 
with Heparin/Saline solution (Flushing solution) to ensure that it had a free flow.  With 
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the lumen of the catheter filled with the flushing solution, the syringe filled with drug 
solution was attached to the catheter and the drug solution pushed through the catheter.  
The empty drug syringe was then detached and 0.15 ml of flushing solution pushed 
through the catheter to ensure that there was no drug solution remaining in the catheter 
after administration.   
5.2.5.2:  Oral Administration 
Silymarin was administered to the rats orally by using a rodent feeding needle.  
The feeding needle was pre-filled with the respective drug solution to ensure accurate 
administration of the drug concentration.   
5.2.6:  Blood Sampling Plasma Collection and Storage 
Blood samples were drawn at 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 16, 18 and 24 
hours time points.  400 µL of blood was drawn using a pre heparinised syringe and 
collected into a pre heparinised micro centrifuge tube.  The tubes were centrifuged 
immediately at 4000 rpm for 10 minutes.  The plasma which was transferred to a 
centrifuge tube and stored at -4°C until assayed. 
5.2.8:  Analysis of Plasma 
Rat plasma was analyzed for the quantitation of silymarin isomers using the 
HPLC method described in the Analytical Methodology section of this dissertation. 
Calibration curve concentrations were injected thrice and a new calibration curve was 
prepared every 48 hours during the analysis of the plasma samples.  The ratio of the 
isomer peak area to the internal standard peak area was used in the calculation of the 
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signal response and quantitative determination of each isomer in plasma.  A linear 
relationship was obtained when the area ratio was plotted against the concentration of 
each of the isomers. 
5.2.9:  Pharmacokinetics Following Intravenous Bolus Dose 
The plasma concentration-time data for each quantifiable isomer per rat was 
tabulated and their mean and standard deviation calculated. 
5.2.9.1:  Non Compartmental Analysis 
Non compartmental pharmacokinetic parameters were calculated from the plasma 
concentration time profile, by using WinNonlin Professional Edition Version 2.1.  The 
means and the standard deviations of the pharmacokinetic parameters were calculated.  
The AUC from time of dosing to the last measurable concentration (AUC0-t) was 
calculated using the Linear Trapezoidal Rule and extrapolated to infinity by the addition 
of the term CLast/λZ where CLast is the last observable and λZ is the terminal rate constant 
determined by log linear regression analysis. 
The pharmacokinetic parameter and the respective equations used to calculate 
them are listed below: 
AUC0-t:  Area under the curve from time of dosing to time of last measurable 
concentration, determined by the linear trapezoidal rule. 




+= −∞− 00          Equation 5.1 




DoseCL       Equation 5.2 






       Equation 5.3 
Volume of Distribution at Steady State (Vss): = MRTinf * CL     Equation 5.4 
 where, MRTinf is the Mean Residence Time extrapolated to infinity 
5.2.9.2:  Two-Compartmental Analysis 
The plasma concentration-time profile was fitted to a two compartment model 
following an intravenous bolus dose with no lag time and a 1st order elimination rate to 
yield macro constants (A, B, α, β).  The model is illustrated in figure 5.2 and can be 
described by Equation 5.2. 
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tt eBeACp βα −− += **                         Equation 5.5 
 where,  
Cp is the plasma concentration at time a particular time ‘t’ on the plasma 
concentration- time curve. 
A and B are intercepts on the Y-axis for each exponential segment of the curve 
described by equation 5.5. 
α and β are the hybrid rate constants for the distribution and elimination phase 
respectively.   
A, B, α and β were obtained using the method of residuals.  
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Pharmacokinetic parameters were calculated using the same equations described 
in the non compartmental analysis Section 5.2.9.1, except for the calculation of volume 
of distribution at steady state (Vss) and Volume of distribution (Vd) which were 





12+=          Equation 5.6 
            where, Vp = Dose/(A+B) = Volume of distribution of the central   
                                                          compartment 
                        K12 = First order intercompartmental rate constant of the drug 
going into the tissue compartment 
                        K21= First order intercompartmental rate constant of the drug 





DoseVD           Equation 5.7 
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5.2.10:  Determination of Bioavailability 
Determination of pharmacokinetic parameters for the silymarin isomers post oral 
administration was done using WinNonlin Professional Version 2.1.  Absolute 
bioavailability for the detected isomers was calculated using Equation 5.8 
       














            F = Absolute Bioavailability  
OralAUC inf0− = Area under the plasma concentration-time curve from time zero to 
time infinity for a particular isomer X, after oral administration (µg-hr/mL) 
VIAUC . inf0− = Area under the plasma concentration-time curve from time zero to 
time infinity for a particular isomer X, after an intravenous bolus administration (µg-
hr/mL) 
 = Oral administered Dose of Isomer X (µg/Kg) OralDose
VIDose .  = Intravenous Bolus Dose administered of Isomer X (µg/Kg) 
VIAUC . inf0−  for the particular isomer, in the above equation was the mean of the 
individual AUC’s obtained by non compartmental analysis after intravenous bolus 
treatment C for the particular isomer. The dose used was the corresponding 
concentration of the isomer in the intravenous treatment C dose, in micrograms.  
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Calculation of Hepatic Extraction Ratio and Maximum Oral Bioavailability: 
The most direct quantitative measure of the liver’s ability to eliminate a drug is hepatic 
clearance which includes biliary excretory clearance.  Hepatic extraction ratio can be 
estimated if the hepatic clearance and the hepatic blood flow are approximated.  
Maximum oral bioavailability (1-EH) dependent on physiologic factors, implies that no 
amount of pharmaceutical manipulation can improve this bioavailability value for an oral 
dosage formulation.  Thus, any drug that has a high hepatic extraction ratio (EH) will 
have low bioavailability and vice versa.  But even if the drug has a low hepatic extraction 
ratio (i.e. a high maximum oral bioavailability) there can be other factors such as low 
dissolution, that limit the drug from reaching the portal vein further decreasing the 
bioavailability.   
Previous pharmacokinetic studies measuring silybin after the administration of 
silymarin have indicated that silybin is excreted in urine in minimum quantities, 
following oral (2-5%) and intravenous (~8%) administration.  There have been 
contradictory reports on the biliary excretion of silybin or silymarin as silybin following 
oral/rectal administration, with values ranging between 5%-80%. [58] This high degree 
of variation can be attributed to the limited solubility of silymarin isomers.   
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Based on these observations, the value of total clearance (CLT, mean calculated 
from individual PK parameters) reported here following intravenous administration, was 
used to calculate the hepatic extraction ratio (EH) in the following equation: 
EH=CLH/QH        Equation 5.9 
where, 
EH =hepatic extraction ratio 
CLH=Hepatic Clearance= CLT 
QH=Hepatic Blood Flow in Rat =25.6 mL/min ~5100 mL/Kg-hr for a 0.3 Kg Rat. 
The value for QH was obtained from experiments done by Sato et. al. [164] 
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5.3:  RESULTS AND DISCUSSION  
Individual rat plasma concentration-time profiles and individual pharmacokinetic 
parameters obtained using non-compartmental (NCA) and two-compartmental analysis, 
for each silymarin isomer following intravenous bolus and oral administration (NCA 
only) are presented in the Appendix (A1-A5) at the end of this dissertation. 
In this section, the mean plasma concentrations after intravenous bolus 
administration (Treatments A, B&C) and oral administration (Treatments A1, B1&C1) 
for a particular silymarin isomer are presented.  A Comparison of the mean of the 
individual pharmacokinetic parameters obtained after intravenous administration, using 
non-compartmental analysis (NCA) and two-compartmental analysis is presented 
followed by the non compartmental analysis and the calculation of absolute 
bioavailability for each silymarin isomer.  The data for each isomer is followed by a 
discussion on the pharmacokinetics and the bioavailability of that isomer. 
Plasma concentrations for Silydianin (Sd) following treatment A, B, C were either 
not detected or below the limit of quantitation.  Plasma levels for Silybin A (SbA) after 
Treatment A were also not detected. Isosilybin B was detected in only two rats for each 
of the Treatments A, B&C. 
Post oral administration, quantifiable levels could only be detected for  silycristin, 
silybin A and silybin B in plasma.   
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The final number of rats ‘n’ per treatment per isomer following intravenous 
administration was as follows:  
• Silycristin: Treatments A, C (n=6) B (n=7) 
• Silydianin: Treatments A, B&C (n=0) 
• Silybin A: Treatment A (n=0), Treatment B (n=5), Treatment C (n=6) 
• Silybin B: Treatments A (n=6), B (n=8) & C (n=6) 
• Isosilybin A: Treatments A&C (n=5), Treatment B (n=7) 
• Isosilybin B: Treatments A, B&C (n=2) 
 
The final number of rats ‘n’ per treatment per isomer following oral 
administration was as follows:  
• Silycristin: Treatments A1 (n=5), B1 (n=3) C1 (n=4) 
• Silydianin, Isosilybin A, Isosilybin B: Treatments A1, B1&C1 (n=0) 
• Silybin A: Treatment A1 (n=3), Treatment B1 (n=2), Treatment C1 (n=4) 
• Silybin B: Treatments A1 (n=2), B1 (n=5) & C1 (n=4) 
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5.3.1:  Results for Silycristin 
Table 5.9:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 6.13 mg/Kg, 12.26 mg/Kg, 24.52 mg/Kg of Silycristin 
respectively, to Male Sprague Dawley Rats-Treatment A, B, C 
 Mean Silycristin Plasma Concentration (µg/mL) 










0 0 0 0 0 0 0 
0.25 5.12 2.05 15.85 7.24 33.96 13.32 
0.5 1.25 0.64 6.07 5.03 13.52 7.65 
0.75 0.47 0.17 2.00 1.47 7.03 3.47 
1 0.40 0.16 0.89 0.43 3.95 1.83 
2 0.14 0.09 0.54 0.63 0.95 0.32 
4 0.07 0.02 0.13 0.04 0.28 0.16 
6 -- -- 0.07 0 0.08 0 
Weight (Kg) 0.29 0.017 0.30 0.01 0.30 0.01 
 
 
Figure 5.3. Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 6.13 mg/Kg, 12.26 mg/Kg, 24.52 mg/Kg of Silycristin 
respectively, to Male Sprague Dawley Rats-Treatment A, B, C 
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Table 5.10:Mean Plasma Concentrations (µg/mL) Time Profile after Oral Administration 
of 125 mg/Kg (A1), 250 mg/Kg (B1), 500 mg/Kg (C1) Silymarin equivalent 
to 30.65 mg/Kg, 61.30 mg/Kg, 122.61 mg/Kg of Silycristin respectively, to 
Male Sprague Dawley Rats-Treatment A1, B1, C1 
 Mean Silycristin Plasma Concentration (µg/mL) 















0 0 0 0 0 0 0 
0.25 0.52 0 0.35 0.32 0.51 0.11 
0.5 0.29 0.06 0.21 0.15 0.38 0.22 
0.75 0.24 0.17 0.28 0.05 0.37 0.10 
1 0.31 0.33 0.14 0.08 0.45 0.17 
2 0.37 0.28 0.28 0.36 0.40 0.23 
4 0.54 0.55 0.43 0.48 0.43 0.28 
6 0.52 0.11 0.53 0.12 0.92 0.83 
8 0.42 0.23 0.30 0.19 0.93 0.29 
12 0.29 0.16 0.22 0.11 0.38 0.05 
16 0.27 0.04     
Weight (Kg) 0.27 0.03 0.27 0.03 0.27 0.03 
 
 
Figure 5.4:Mean Plasma Concentrations (µg/mL) Time Profile after Oral Administration 
of 125 mg/Kg (A1), 250 mg/Kg (B1), 500 mg/Kg (C1) Silymarin equivalent 
to 30.65 mg/Kg, 61.30 mg/Kg, 122.61 mg/Kg of Silycristin respectively, to 
Male Sprague Dawley Rats-Treatment A1, B1, C1 
 228
 229
Table 5.11: Comparison of Pharmacokinetic Parameters for Silycristin- (I.V Bolus 
Administration, Treatments A, B, C) from Mean Plasma Concentration-
Time Data and Mean of Individual Pharmacokinetic Parameters 
Non Compartmental Analysis (Cp= Plasma Conc.) 
Parameter Treatment A Parameters n=6 
Treatment B Parameters 
n=7 
Treatment C Parameters 
n=6 
 Mean Cp* 








Mean of Ind. 
PK Param§∏ 
AUC0-t 
(mcg-hr/ml) 4.65 5.45 12.84 13.66 28.82 29.04 
AUC0-∞ 
(mcg-hr/ml) 4.79 5.58 12.99 13.77 28.95 29.65 
Clearance 
(ml/Kg-hr) 1281.09 1351.81 944.02 1062.14 847.07 908.86 
Vd (ml/kg) 1262.79 1726.07 1883.06 1007.75 1370.80 1134.76 
Vss (ml/kg) 718.19 566.53 502.42 464.85 413.84 422.51 
t1/2 (hr) 0.68 0.86 1.38 0.65 1.12 0.90 
EH  0.26  0.18  0.18 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 4.87 6.49 12.57 13.98 26.05 28.71 
Clearance 
(ml/Kg-hr) 1258.88 1192.22 975.69 1110.58 941.24 1007.84 
Vd (ml/kg) 1234.23 1500.78 1840.94 1058.22 1518.58 1308.42 
Vss (ml/kg) 378.18 474.34 568.19 470.68 514.46 559.25 
t1/2 (hr) 0.68 0.86 1.31 0.65 1.12 0.93 
A (mcg/mL) 30.15 55.36 42.70 69.92 76.00 106.25 
Alfa (hr-1) 7.75 8.93 4.31 6.32 3.67 4.75 
B (mcg/mL) 1.00 1.11 1.41 5.36 3.30 5.48 
Beta (hr-1) 1.02 0.97 0.53 1.33 0.62 0.81 
* Mean of plasma concentration time profile;  § Mean of individual pharmacokinetic parameters 
∏ Standard deviations for the means are listed in the Addendum at the end of this chapter. 
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Table 5.12:Mean of the Individual Non-Compartmental Pharmacokinetic Parameters 
obtained for Silycristin following Oral Administration of Silymarin 
(Treatments A1, B1, C1) 
 Mean Non Compartmental Pharmacokinetic Parameters 
















(mcg-hr/ml) 4.17 0.03 3.55 3.34 4.82 4.61 
AUC0-∞ 
(mcg-hr/ml) 5.55 2.70 4.69 4.41 6.09 5.54 
Cmax (µg/mL) 0.73 3.62 0.61 0.47 0.94 0.58 
Tmax (Hr) 4.85 0.35 3.58 2.65 3.38 3.04 
F 0.15 0.10 0.06 0.06 0.04 0.04 
 
 
Figure 5.5: Representative Two-Compartmental Fit for Silycristin Following Intravenous 




Figure 5.6: Representative Two-Compartmental Fit for Silycristin Following Intravenous 




Figure 5.7: Representative Two-Compartmental Fit for Silycristin Following Intravenous 
Bolus Treatment C   (Sc= Silycristin) 
 233
Table 5.13:  Silycristin I.V Bolus Dose and Mean AUC0-inf   






A 6130.63 5.58 
B 12261.25 13.77 
C 24522.51 29.65 
 
 
Sc AUC vs Dose






























Figure 5.8:  Dose Proportionality Plot for Silycristin AUC 0-inf 






5.3.2:  Pharmacokinetics of Silycristin 
A comparison of the mean pharmacokinetic parameters obtained for silycristin 
following intravenous administration, using non compartmental analysis and 2-
compartment modeling, are presented in the following Table 5.11.  The plasma 
concentration-time data post intravenous administration fit a two compartment model, 
representative graphs of which are shown in Figures 5.5-5.7.  A plot of the mean of the 
individual AUC0-inf obtained using non compartmental analysis for each I.V treatment 
(A,B&C) plotted against the silycristin dose equivalent of silymarin, indicated dose 
proportionality (Figure 5.8). 
The values of AUC0-inf, CLT, Vd, and half life calculated from the mean plasma 
concentration-time profile and the means obtained from the individual pharmacokinetic 
parameters, using NCA do not differ significantly from those calculated using a two-
compartment model confirming the assumption that the silycristin plasma data fits a two 
compartmental model.  The mean half life for the three treatments (A,B,C) following 
intravenous administration ranges between 0.65-0.9 hour indicating no significant change 
in elimination with increasing dose.   
Table 5.12 shows the absolute bioavailability for silycristin after oral 
administration of treatments (A1, B1 and C1).  It is clearly seen that the bioavailability 
(F) decreases with the increasing dose (FA1= 0.15±0.1, FB1=0.06±0.06, FC1=0.04±0.04) 
indicating dose dependency.  This is possible mainly due to the overall low aqueous 
solubility of the silymarin extract.  Low dissolution can cause dose dependency in 
bioavailability due to the fixed transit time through the gastrointestinal tract and thus 
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amount of silycristin absorbed is unlikely to increase in proportion with the dose 
administered. 
Figure 5.4 shows the plot of silycristin mean plasma concentration versus time 
after oral administration of three treatments A1, B1 and C1.  Though the highest plasma 
levels are observed for the lowest dose A1, all the three treatments show slight 
indications of an entero-hepatic cycle for silycristin.  The silycristin mean plasma levels 
for the three doses, show a distinct rise between 0.25-0.5 hours followed by a decrease 
and then a Tmax between 3-6 hours before dropping to a minimum or below LOQ. 
The hepatic extraction ratio (EH) calculated from the CLT for silycristin ranges 
between 0.18-0.26 indicating low clearance by the liver (<0.3). [165] This further 
supports the assumption that the low value of F calculated for silycristin is mainly due to 
dissolution limited absorption.  The value of CLT is used in the calculation of EH instead 
of the CLH based on previous reports about minimal amounts of silybin/silymarin being 
excreted from the urine. [58] 
The mean Vd values (Table 5.11:Mean of Ind PK.Param), obtained either by NCA 
or 2-compartmental analysis for silycristin shows a distinct decrease when going from 
treatment A to B as compared to from B to C.  This drop in the Vd from treatment A to B 
signifies possible saturability in binding to tissues.   
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 5.3.3:  Results for Silydianin 
No detectable levels of silydianin were obtained following intravenous or oral 
administration.  This could probably be due to the very low proportion of silydianin in the 
extract (~3.6%).  After intravenous administration, traces of silydianin could be detected 
for the 0.25 hour and 0.5 hour time points respectively, after which the levels dropped 
below the limit of quantitation (0.08µg/mL).  Thus, due to lack of sufficient data points 
for the determination of an elimination phase, pharmacokinetic parameters for silydianin 
could not be determined.  Following oral administration, absolutely no traces of 
silydianin were detected in plasma.  Along the low proportion of silydianin in the extract 
the low intestinal permeability of silydianin, as predicted by the high minimal cross 
sectional area (157.10 Ǻ2) and a low lipophilicity as predicted by the CLogP (-0.39), 
could be the most probable reasons for the absence of silydianin in plasma. 
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5.3.4:  Results for Silybin A 
Table 5.14:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 4.72 mg/Kg, 9.45 mg/Kg, 18.90 mg/Kg of Silybin A 
respectively, to Male Sprague Dawley Rats-Treatment A, B, C 
 Mean Silybin A Plasma Concentration (µg/mL) 















0 ND -- 0 0 0 0 
0.25 ND -- 9.29 3.30 17.19 5.15 
0.5 ND -- 3.19 1.92 5.08 1.83 
0.75 ND -- 0.88 0.73 2.31 1.45 
1 ND -- 0.63 0.43 1.35 0.63 
2 ND -- 0.28 0.33 0.40 0.26 
4 ND -- -- -- 0.16 0.13 
6 ND -- -- -- 0.07 0 





Figure 5.9:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 50 mg/Kg (B), 100 mg/Kg (C) Silymarin equivalent to 
9.45 mg/Kg, 18.90 mg/Kg of Silybin A respectively, to Male Sprague 
Dawley Rats-Treatment B, C 
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Table 5.15:Mean Plasma Concentrations (µg/mL) Time Profile after Oral Administration 
of 125 mg/Kg (A1), 250 mg/Kg (B1), 500 mg/Kg (C1) Silymarin equivalent 
to 23.63 mg/Kg, 47.27 mg/Kg, 94.54 mg/Kg of Silybin A respectively, to 
Male Sprague Dawley Rats-Treatment A1, B1, C1 
 Mean Silybin A Plasma Concentration (µg/mL) 















0 0 0 0 0 0 0 
0.25 0.50 0.26 0.31 0 0.50 0.20 
0.5 0.48 0 0.18 0.06 0.39 0.19 
0.75 0.17 0.12 0.24 0 0.40 0.18 
1 0.19 0.07 0.22 0.08 0.25 0.09 
2 0.25 0.06 0.22 0.03 0.19 0.04 
4 0.21 0.08 0.34 0.20 0.27 0.24 
6 0.27 0.14 0.16 0.01 0.24 0.08 
8 0.16 0.02 0.13 0 0.17 0.05 
12 0.13 0 -- -- 0.12 0 
Weight (Kg) 0.26 0.02 0.29 0.03 0.27 0.03 
 
  
Figure 5.10: Mean Plasma Concentrations (µg/mL) Time Profile after Oral 
Administration of 125 mg/Kg (A1), 250 mg/Kg (B1), 500 mg/Kg (C1) 
Silymarin equivalent to 23.63 mg/Kg, 47.27 mg/Kg, 94.54 mg/Kg of Silybin 
A respectively, to Male Sprague Dawley Rats-Treatment A1, B1, C1 
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Table 5.16:  Comparison of Pharmacokinetic Parameters for Silybin A-(I.V Bolus 
Administration, Treatments A, B, C) from Mean Plasma Concentration-
Time Data and Mean of Individual Pharmacokinetic Parameters 
Non Compartmental Analysis (Cp= Plasma Conc.) 
Parameter Treatment A Parameters 
n=0 
Treatment B Parameters 
n=4 
Treatment C Parameters 
n=6 
 Mean Cp* Mean of Ind. 
PK Param§∏ 
Mean Cp* Mean of Ind. 
PK Param§∏ 









N/A 7.59 7.93 15.34 15.36 
Clearance 
(ml/Kg-hr) 
N/A N/A 1245.58 1279.19 1232.95 1316.52 
Vd (ml/kg) N/A N/A 1509.41 1561.42 1804.01 1768.92 
Vss (ml/kg) N/A N/A 474.11 602.03 526.22 484.38 
t1/2 (hr) N/A N/A 0.84 0.87 1.01 0.95 




N/A N/A 7.73 8.33 13.88 14.71 
Clearance 
(ml/Kg-hr) 
N/A N/A 1223.68 1192.37 1361.97 1429.35 
Vd (ml/kg) N/A N/A 1474.31 1473.66 1974.12 1849.47 
Vss (ml/kg) N/A N/A 509.43 569.56 641.95 634.39 
t1/2 (hr) N/A N/A 0.84 0.90 1.00 0.90 
A (mcg/mL) N/A N/A 30.80 36.90 58.00 73.13 
Alfa (hr-1) N/A N/A 1.40 5.84 2.17 5.63 
B (mcg/mL) N/A N/A 5.10 1.31 5.40 2.47 
Beta (hr-1) N/A N/A 0.83 0.88 0.69 0.94 
* Mean of plasma concentration time profile;  § Mean of individual pharmacokinetic parameters 
∏ Standard deviations for the means are listed in the Addendum at the end of this chapter. 
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Table 5.17:  Mean of the Individual Non-Compartmental Pharmacokinetic Parameters 
obtained for Silybin A following Oral Administration of Silymarin 
(Treatments A1, B1, C1) 
 Mean Non Compartmental Pharmacokinetic Parameters 
















(mcg-hr/ml) 1.98 0.26 1.55 0.63 1.66 0.51 
AUC0-∞ 
(mcg-hr/ml) 3.92 0.77 2.53 0.16 2.54 0.47 
Cmax (µg/mL) 0.46 0.23 0.36 0.17 0.57 0.16 
Tmax (Hr) 2.25 3.25 2.38 2.30 1.31 1.81 
F 0.20 0.04 0.12 0.01 0.03 0.01 
 
Figure 5.11: Representative Two-Compartmental Fit for Silybin A (Treatment B: 





Figure 5.12: Representative Two-Compartmental Fit for Silybin A (Treatment C: 
18.90mg/Kg) Following Intravenous Bolus Administration 
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5.3.5:  Pharmacokinetics of Silybin A 
Plasma levels for Silybin A, after I.V bolus administration of silymarin 
(Treatment A: 25 mg/Kg~4.72 mg/Kg silybin A) were not detected or were below LOQ 
(0.05µg/mL).  Pharmacokinetic parameters were determined for silybin A: Treatment B 
(9.45 mg/Kg~50 mg/Kg silymarin) and Treatment C (18.90mg/Kg~100 mg/Kg 
silymarin), post I.V bolus administration using non-compartmental and two-
compartmental analysis. 
Dose proportionality for Silybin A could not be determined due to absence of  
plasma levels for Treatment A (4.72 mg/Kg).  AUC0-inf after Treatment B (9.45 
mg/Kg~50 mg/Kg silymarin) was calculated to be 7.93µg.hr/mL and after Treatment C 
(18.90mg/Kg~100 mg/Kg silymarin) was calculated as 15.36µg.hr/mL.  Thus, the AUC0-
inf increased approximately two fold with the doubling of dose, indicating a trend in dose 
proportionality but a regression analysis could not be done due to the presence of only 2 
data points. 
A comparison of the mean pharmacokinetic parameters obtained for silybin A 
following intravenous administration, using non compartmental analysis and 2-
compartment modeling, are presented in the following Table 5.16.  The plasma 
concentration-time data post intravenous administration fit a two compartment model, 
representative graphs of which are shown in Figures 5.11-5.12. 
The values of AUC0-inf, CLT, Vd, and half life calculated from the mean plasma 
concentration-time profile and the means obtained from the individual pharmacokinetic 
parameters, using non compartmental analysis do not differ significantly from those 
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calculated using a two-compartment model confirming the assumption that the silybin A 
plasma data confidently fits a two compartmental model.  The mean half life for each of 
the three treatments calculated from the individual plasma data ranges between 0.84-1.01 
hour indicating no significant change in elimination of the drug with increasing dose. 
Table 5.17 shows the absolute bioavailability for silybin A after oral 
administration of Treatments (B1=47.27 mg/Kg SbA~250 mg/Kg silymarin and 
C1=94.54 mg/Kg SbA~500 mg/Kg silymarin).  The (F) values indicate that the 
bioavailability decreases with the increasing dose (FA1=0.20±0.4, FB1=0.12±0.01, 
FC1=0.03±0.01) indicating dose dependency.  The reason for the low bioavailability is 
probably the same as that for silycristin which is low aqueous solubility.  Low dissolution 
can cause dose dependency in bioavailability due to the fixed transit time through the 
gastrointestinal tract thus making it unlikely for the increase in the absorption of silybin 
A with the increasing dose.   
Figure 5.10 shows the plot of silybin A mean plasma concentration versus time 
after oral administration of three treatments A1, B1 and C1.  The silybin A plasma 
concentration time profile shows signs of an entero-hepatic cycle with the plasma levels 
showing an initial increase between 0.25-0.5 hours and then another increase between 4-6 
hours before finally dropping below LOQ.  This trend is more prominent in silybin A as 
compared to the plot of silycristin (Figure 5.4). 
The hepatic extraction ratio (EH) calculated from the CLT for silybin A ranges 
between 0.25-0.26 indicating low clearance by the liver (EH<0.3). [165] This further 
supports the assumption that the decreasing value of F calculated for silybin A is mainly 
due to dissolution limited absorption with the increase in dose.  The value of CLT is used 
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in the calculation of EH instead of the CLH based on previous reports about minimal 
amounts of silybin/silymarin being excreted from the urine. [58] 
The Vd values as calculated by two compartmental analysis, shows an 
approximate 33% increase between intravenous dose B and C.  This increase in Vd with 
the increasing dose indicates saturable binding to plasma proteins.  It should be noted 
that, Vd of silycristin as discussed earlier indicated saturable binding to tissues. 
5.3.6:  Results for Silybin B 
Table 5.18: Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 8.64 mg/Kg, 17.29 mg/Kg, 34.58 mg/Kg of Silybin B 
respectively, to Male Sprague Dawley Rats-Treatment A, B, C 
 Mean Silybin B Plasma Concentration (µg/mL) 










0 0 0 0 0 0 0 
0.25 4.62 1.53 12.06 6.23 25.37 9.46 
0.5 2.18 1.97 4.34 2.44 7.93 4.14 
0.75 0.87 0.34 1.79 0.88 4.34 3.18 
1 0.76 0.39 1.22 0.60 2.44 1.01 
2 0.54 0.38 0.80 0.45 1.04 0.61 
4 0.20 0 0.65 0.45 0.82 0.35 
6 -- -- -- -- 0.63 0.56 
8 -- -- -- -- 0.13 0 
Weight (Kg) 0.303 0.026 0.298 0.008 0.30 0.01 
 
Figure 5.13:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 8.64 mg/Kg, 17.29 mg/Kg, 34.58 mg/Kg of Silybin B (SbB) 




Table 5.19:Mean Plasma Concentrations (µg/mL) Time Profile after Oral Administration 
of 125 mg/Kg (A1), 250 mg/Kg (B1), 500 mg/Kg (C1) Silymarin equivalent 
to 43.23 mg/Kg, 86.46 mg/Kg, 172.93 mg/Kg of Silybin B respectively, to 
Male Sprague Dawley Rats-Treatment A1, B1, C1 
 Mean Silybin B Plasma Concentration (µg/mL) 















0 0 0 0 0 0 0 
0.25 0.19 0 0.25 0.12 0.63 0.14 
0.5 0.11 0 0.19 0.13 0.49 0.30 
0.75 0.17 0 0.24 0.09 0.43 0.19 
1 0.19 0 0.18 0.12 0.21 0.07 
2 0.30 0.23 0.22 0.15 0.34 0.26 
4 0.81 0.81 0.51 0.47 0.80 0.84 
6 0.22 0.04 0.23 0.17 0.80 0.74 
8 0.14 0.02 0.15 0.04 0.43 0.19 
12 0.12 0.02 0.24 0.19 0.12 0.01 
16 -- -- 0.16 0 -- -- 
Weight (Kg) 0.29 0.03 0.27 0.03 0.28 0.03 
 
Figure 5.14: Mean Plasma Concentrations (µg/mL) Time Profile after Oral 
Administration of 125 mg/Kg (A1), 250 mg/Kg (B1), 500 mg/Kg (C1) 
Silymarin equivalent to 43.23 mg/Kg, 86.46 mg/Kg, 172.93 mg/Kg of 




Table 5.20:  Comparison of Pharmacokinetic Parameters for Silybin B-(I.V Bolus 
Administration, Treatment A, B, C) from Mean Plasma Concentration-Time 
Data and Mean of Individual Pharmacokinetic Parameters 
Non Compartmental Analysis (Cp= Plasma Conc.) 
Parameter Treatment A Parameters n=5 
Treatment B Parameters 
n=8 
Treatment C Parameters 
n=6 
 Mean Cp* Mean of Ind. PK Param§∏ Mean Cp* 
Mean of Ind. 
PK Param§∏ Mean Cp* 
Mean of Ind. 
PK Param§∏ 
AUC0-t 
(µg-hr/ml) 4.62 4.57 11.35 11.56 25.68 24.07 
AUC0-∞ 
(µg-hr/ml) 5.16 7.17 13.77 14.08 26.07 26.48 
Clearance 
(ml/Kg-hr) 1674.71 1314.30 1255.64 1272.04 1326.60 1381.00 
Vd (ml/kg) 4577.14 3837.18 4645.06 3565.72 3837.02 4538.23 
Vss (ml/kg) 2347.63 2469.51 2372.96 2459.83 1400.49 1818.23 
t1/2 (hr) 1.89 2.30 2.56 2.27 2.00 2.24 
EH -- 0.26 -- 0.25 -- 0.27 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 5.42 7.71 13.67 13.94 23.40 24.39 
Clearance 
(ml/Kg-hr) 1595.77 1217.57 1265.33 1275.31 1478.08 1553.70 
Vd (ml/kg) 4312.89 3545.23 4601.73 3997.97 4223.12 5169.78 
Vss (ml/kg) 2553.48 2161.34 2259.48 2365.02 1765.69 2212.85 
t1/2 (hr) 1.87 2.27 2.52 2.25 1.98 2.22 
A (mcg/mL) 10.40 25.70 38.70 48.59 70.50 89.12 
Alfa (hr-1) 4.30 7.38 5.27 6.02 4.80 5.14 
B (mcg/mL) 1.11 1.20 1.74 2.06 3.05 3.63 
Beta (hr-1) 0.37 0.42 0.27 0.55 0.35 0.59 
* Mean of plasma concentration time profile;  § Mean of individual pharmacokinetic parameters 
∏ Standard deviations for the means are listed in the Addendum at the end of this chapter. 
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Table 5.21:  Mean of the Individual Non-Compartmental Pharmacokinetic Parameters 
obtained for Silybin B following Oral Administration of Silymarin 
(Treatments A1, B1, C1) 
 Mean Non Compartmental Pharmacokinetic Parameters 
















(mcg-hr/ml) 3.29 2.09 2.62 1.12 4.07 2.98 
AUC0-∞ 
(mcg-hr/ml) 5.17 0.68 3.13 1.25 4.56 3.09 
Cmax (µg/mL) 0.81 0.81 0.62 0.38 1.27 0.65 
Tmax (Hr) 4.00 0.00 5.40 4.10 2.69 2.79 
F 0.62 0.08 0.09 0.04 0.03 0.02 
 
 
Figure 5.15: Representative Two-Compartmental Fit for Silybin B (SbB; Treatment A: 




Figure 5.16: Representative Two-Compartmental Fit for Silybin B (SbB; Treatment B: 




Figure 5.17: Representative Two-Compartmental Fit for Silybin B (SbB; Treatment C: 
34.58 mg/Kg) Following Intravenous Bolus Administration 
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Table 5.22:  Silybin B I.V Bolus Dose and Mean AUC0-inf   





A 8646.82 7.17 
B 17293.63 14.08 
C 34587.27 26.48 
 
 
SbB AUC vs Dose




























Figure 5.18:  Dose Proportionality Plot for Silybin B AUC 0-inf 







5.3.7:  Pharmacokinetics of Silybin B 
A comparison of the mean pharmacokinetic parameters obtained for silybin B 
following intravenous administration, using non compartmental analysis and 2-
compartment modeling, are presented in Table 5.20.  The plasma concentration-time data 
post intravenous administration fits a two compartment model, representative graphs of 
which are shown in Figures 5.15-5.17.  A plot of the mean of the individual AUC0-inf 
obtained using non compartmental analysis for each I.V treatment (A,B&C) plotted 
against the silybin B dose equivalent of silymarin, indicated dose proportionality (Figure 
5.18).   
The respective values of AUC0-inf, CLT, Vd, and half life calculated from the mean 
plasma concentration-time profile and the means obtained from the individual 
pharmacokinetic parameters, using NCA are in close approximation with those calculated 
using two-compartmental analysis confirming the assumption that the silybin B plasma 
data confidently fits a two compartmental model.  The mean half life for each of the three 
treatments calculated from the individual plasma data ranges between 2.2-2.3 hours 
indicating no significant change in elimination with increasing dose. 
Table 5.21 shows the absolute bioavailability for silybin B after oral 
administration of treatments (A1=43.23 mg/Kg SbB~125 mg/Kg silymarin, B1=86.46 
mg/Kg SbB~250 mg/Kg silymarin, and C1=172.93 mg/Kg SbB~500 mg/Kg silymarin).  
It is observed that the bioavailability (F) decreases with the increasing dose (FA1= 
0.62±0.08, FB1=0.09±0.04, FC1=0.03±0.02) indicating dose dependency.  This is due to 
the overall low aqueous solubility of the silymarin extract.  Low dissolution can cause 
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dose dependency in bioavailability due to the fixed transit time through the 
gastrointestinal tract and thus amount of silybin B absorbed is unlikely to increase in 
proportion with the dose administered.   
It should be noted that even if the bioavailability decreased with the increasing 
dose for silycristin, silybin A and silybin B, FA1 for silycristin (0.15±0.1) was the lowest 
followed by silybin A (0.20±0.04) and then silybin B (0.62±0.08) in the increasing order.  
Figure 5.14 shows the plot of silybin B mean plasma concentration versus time 
after oral administration of three treatments A1, B1 and C1.  The oral plasma 
concentration-time profile weakly indicates an eneterohepatic cycle, but not as prominent 
as that for silybin A. 
The hepatic extraction ratio (EH) for silybin B ranges between 0.25-0.27 
indicating low clearance by the liver (<0.3). [165] The value of F decreases with the 
increase in dose, but the value of EH stays constant over the three treatments, indicating 
that maximum oral bioavailability (1-EH) for silybin B could be in the range of 0.73-0.75 
indicating that the decrease in the value of bioavailability is mainly due to absorption 
factors such as limited dissolution rather than hepatic metabolism. 
The mean Vd values (Table 5.15:Mean of Ind PK.Param), obtained by NCA 
remain constant with the increasing intravenous doses.  But when the intravenous data is 
treated as a two-compartment model, the Vd between Treatment A (3.5 L/Kg) and 
Treatment C (5.16 L/Kg) increases by 62% indicating extensive plasma protein binding. 
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5.3.8: Results for Isosilybin A 
Table 5.23:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 2.05 mg/Kg, 4.11 mg/Kg, 8.22 mg/Kg of Isosilybin A 
respectively, to Male Sprague Dawley Rats-Treatment A, B, C 


















0 0 0 0 0 0 0 
0.25 1.66 1.24 2.60 0.81 5.71 1.73 
0.5 0.45 0.26 0.89 0.44 1.67 0.65 
0.75 0.23 0.07 0.37 0.10 0.97 0.28 
1 0.18 0.06 0.26 0.06 0.59 0.19 
2 0.07 0.03 0.10 0.03 0.22 0.09 
4 0.08 0 0.10 0.03 0.14 0.04 
6 -- -- -- -- 0.11 0.00 
Weight (Kg) 0.30 0.02 0.30 0.008 0.31 0.01 
 
Figure 5.19:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 2.05 mg/Kg, 4.11 mg/Kg, 8.22 mg/Kg of Isosilybin A 




Table 5.24:  Comparison of Pharmacokinetic Parameters for Isosilybin A-(I.V Bolus 
Administration, Treatment A, B, C) from Mean Plasma Concentration-Time 
Data and Mean of Individual Pharmacokinetic 
Non Compartmental Analysis (Cp= Plasma Conc.) 
Parameter Treatment A Parameters n=4 
Treatment B Parameters 
n= 7 
Treatment C Parameters 
n= 5 
 Mean Cp* Mean of Ind. PK Param§∏ Mean Cp* 
Mean of Ind. 
PK Param§∏ Mean Cp* 
Mean of Ind. 
PK Param§∏ 
AUC0-t 
(mcg-hr/ml) 1.65 1.04 2.32 2.33 5.36 5.47 
AUC0-∞        
(mcg-hr/ml) 1.93 1.17 2.56 2.51 5.70 5.77 
Clearance 
(ml/Kg-hr) 1067.07 1918.90 1603.56 1780.37 1443.66 1518.61 
Vd (ml/kg) 3643.66 3375.78 4128.04 3011.19 3344.82 2780.47 
Vss (ml/kg) 1611.72 1824.19 1750.12 1294.44 1125.93 1100.04 
t1/2 (hr) 2.37 1.32 1.78 1.28 1.61 1.27 
EH -- 0.37 -- 0.35 -- 0.30 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 2.06 1.38 2.54 2.40 4.82 5.54 
Clearance 
(ml/Kg-hr) 997.50 1671.09 1618.76 1797.01 1705.87 1578.40 
Vd (ml/kg) 3381.39 3253.49 4150.67 3112.39 3876.98 2900.06 
Vss (ml/kg) 1470.86 1775.52 1700.02 1368.77 1565.56 1298.48 
t1/2 (hr) 2.35 1.33 1.78 1.27 1.58 1.26 
A (mcg/mL) 8.87 6.32 8.70 8.87 15.30 22.95 
Alfa (hr-1) 7.31 6.40 5.38 5.83 4.84 5.70 
B (mcg/mL) 0.25 0.34 0.36 0.51 0.73 1.33 
Beta (hr-1) 0.37 0.42 0.27 0.55 0.35 0.59 
* Mean of plasma concentration time profile;  § Mean of individual pharmacokinetic parameters 
∏ Standard deviations for the means are listed in the Addendum at the end of this chapter. 
 
Figure 5.20: Representative Two-Compartmental Fit for Isosilybin A (ISbA; Treatment 





Figure 5.21: Representative Two-Compartmental Fit for Isosilybin A (ISbA; Treatment 




Figure 5.22: Representative Two-Compartmental Fit for Isosilybin A (ISbA; Treatment 
C: 8.22 mg/Kg) Following Intravenous Bolus Administration 
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Table 5.25:  Isosilybin A I.V Bolus Dose and Mean AUC0-inf  





A 2055.68 1.17 
B 4111.35 2.51 





ISbA AUC vs Dose


























Figure 5.23:  Dose Proportionality Plot for Isosilybin A (ISbA): AUC0-inf (µg.hr/mL) vs. 
Dose (µg/Kg) (ISbA = Isosilybin A) 
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5.3.9:  Pharmacokinetics of Isosilybin A  
A comparison of the mean pharmacokinetic parameters obtained for isosilybin A 
following intravenous administration, using non compartmental and 2-compartmental 
analysis, are presented in the following Table 5.24.  The plasma concentration-time data 
post intravenous administration fit a two compartment model, representative graphs of 
which are shown in Figures 5.20-5.22.  A plot of the mean of the individual AUC0-inf 
obtained using non compartmental analysis for each I.V treatment (A,B&C) plotted 
against the isosilybin A dose equivalent of silymarin, indicated dose proportionality 
(Figure 5.23).   
The respective values of AUC0-inf, CLT, Vd, and half life calculated from the mean 
plasma concentration-time profile and the means obtained from the individual 
pharmacokinetic parameters, using NCA do are in close approximation with those 
calculated using a two-compartment model confirming the assumption that the isosilybin 
A plasma data confidently fits a two compartmental model.  The mean half life for each 
of the three treatments calculated from the individual plasma data ranges between 1.27-
1.32 hours indicating no significant change in elimination with increasing dose.   
No levels of isosilybin A were detected in plasma after oral administration of 
silymarin Treatments A1, B1 and C1. 
The hepatic extraction ratio (EH) for isosilybin A was found to be in the range of 
0.30-0.37 indicating a maximum oral bioavailability between 0.63-0.70.  After oral 
administration, no quantitative levels of isosilybin A were detected in plasma.  Hence 
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bioavailability of isosilybin A can be improved with modified formulations as 
approximately 70% of the administered dose escapes hepatic metabolism. 
The mean Vd values (Table 5.23:Mean of Ind PK.Param), obtained by NCA 
indicates a 18% decrease from Treatment A to Treatment C whereas the Vd obtained by 
2-compartmental analysis shows a 11 % decrease from Treatment A to Treatment C.  
Thus, it is not clear about the extent of binding of isosilybin A to tissues or plasma 
proteins. 
5.3.10:  Results for Isosilybin B 
Table 5.26:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 0.64 mg/Kg, 1.28 mg/Kg, 2.56 mg/Kg of Isosilybin B 
respectively, to Male Sprague Dawley Rats-Treatment A, B, C 
 Mean Isosilybin B Plasma Concentration (µg/mL) 










0 0 0 0 0 0 0 
0.25 0.62 0.24 1.14 0.11 3.26 0.62 
0.5 0.37 0.23 0.47 0.18 0.96 0.23 
0.75 0.11 0.06 0.38 0.20 0.60 0.25 
1 0.20 0.14 0.17 0.08 0.28 0.05 
2 0.13 0.07 0.12 0.09 0.17 0.05 
Weight (Kg) 0.28 0.01 0.29 0.01 0.31 0.00 
Figure 5.24:  Mean Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg (A), 50 mg/Kg (B), 100 mg/Kg (C) Silymarin 
equivalent to 0.64 mg/Kg, 1.28 mg/Kg, 2.56 mg/Kg of Isosilybin B 





Table 5.27: Comparison of Pharmacokinetic Parameters for Isosilybin B-(I.V Bolus 
Administration) from Mean Plasma Concentration-Time Data and Mean of 
Individual Pharmacokinetic Parameters 
Non Compartmental Analysis (Cp= Plasma Conc.) 
Parameter Treatment A Parameters n=2 
Treatment B Parameters 
n= 2 
Treatment C Parameters 
n= 2 
 Mean Cp* 








Mean of Ind. 
PK Param§∏ 
AUC0-t 
(mcg-hr/ml) 0.59 0.60 1.01 1.03 2.86 2.99 
AUC0-∞       
(mcg-hr/ml) 0.92 1.03 1.17 1.29 3.21 3.24 
Clearance 
(ml/Kg-hr) 693.39 629.54 1097.47 1031.64 797.88 844.83 
Vd (ml/kg) 1744.58 2128.87 1458.84 1486.47 1631.63 1050.65 
Vss (ml/kg) 1399.06 2688.90 897.34 984.10 552.62 422.05 
t1/2 (hr) 1.74 2.80 0.92 1.06 1.42 0.95 
EH -- 0.12 -- 0.20 -- 0.16 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 0.96 1.05 1.28 2.78 3.29 3.45 
Clearance 
(ml/Kg-hr) 668.75 624.74 1000.95 573.88 779.25 802.89 
Vd (ml/kg) 1671.87 2671.86 1334.59 984.15 916.84 979.25 
Vss (ml/kg) 1306.57 2032.84 774.25 625.61 358.22 397.88 
t1/2 (hr) 1.73 2.75 0.92 1.05 0.82 0.93 
A (mcg/mL) 0.91 0.95 4.30 33.41 18.08 19.00 
Alfa (hr-1) 3.90 3.96 7.16 11.42 17.20 7.45 
B (mcg/mL) 0.29 0.30 0.51 0.52 7.63 0.92 
Beta (hr-1) 0.40 0.33 0.75 0.72 0.88 0.84 
* Mean of plasma concentration time profile;  § Mean of individual pharmacokinetic parameters 
∏ Standard deviations for the means are listed in the Addendum at the end of this chapter. 
 
Figure 5.25: Representative Two-Compartmental Fit for Isosilybin B (ISbB; Treatment 





Figure 5.26: Representative Two-Compartmental Fit for Isosilybin B (ISbB; Treatment 




Figure 5.27: Representative Two-Compartmental Fit for Isosilybin B (ISbB; Treatment 
C: 2.56 mg/Kg) Following Intravenous Bolus Administration 
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5.3.11:  Pharmacokinetics of Isosilybin B 
A comparison of the mean pharmacokinetic parameters obtained for isosilybin B 
following intravenous administration, using non compartmental and 2-compartmental 
analysis, are presented in the following Table 5.27.  The plasma concentration-time data 
post intravenous administration fit a two compartment model, representative graphs of 
which are shown in Figures 5.25-5.27.  Mean AUC0-inf for Isosilybin B did not increase 
proportionally with the increasing intravenous dose (Treatment A: AUC0-
inf=1.03µg.hr/mL; Treatment B: AUC0-inf=1.29µg.hr/mL; Treatment C AUC0-
inf=3.24µg.hr/mL). 
Plasma levels of Isosilybin B were observed only in two rats out of the minimum 
six tested, leading to a significant degree of variation observed between pharmacokinetic 
parameters obtained using non compartmental analysis and a two-compartment model. 
The respective values of AUC0-inf and half life calculated from the mean plasma 
concentration-time profile and the means obtained from the individual pharmacokinetic 
parameters, using NCA are in fair approximation with those calculated using a two-
compartment model indicating a two-compartment fit for the isosilybin B plasma data 
following intravenous administration.  The mean half life for the three treatments 
calculated from the individual plasma data ranges between 0.92-2.80 hours.   
No levels of isosilybin B were detected in plasma after oral administration of 
silymarin treatments A1, B1 and C1. 
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The hepatic extraction ratio (EH) for isosilybin B was found to be in the range 
0.12-0.2 indicating very low elimination by the liver.  This also implies that the 
maximum oral bioavailability for isosilybin B is in the range of 0.78-0.8.   
The mean Vd values (Table 5.27:Mean of Ind PK.Param), obtained by NCA and 
2-compartmental analysis, indicated a ~50% decrease from Treatment A to Treatment C, 
indicating a decrease in the Vd with increasing dose.  Thus, based on this observation, 
isosilybin B shows probable saturability in binding to tissues. 
The clearance obtained for treatment B using NCA shows a higher value (1031.64 
ml/Kg-hr) which could be attributed to the low n=2 sample size.  Using the equation 
Dose=CLT x AUC0-inf, the value of the dose calculated is within 2-10% of the 
administered dose for Treatments A and C and within 25% of the administered dose for 
Treatment B, indicating the uniformity of clearance with the increasing dose. 
5.3.12:  Comparison of Pharmacokinetic Parameters 
The comparison of pharmacokinetic parameters calculated using non 
compartmental analysis and 2-compartmental analysis, for the different silymarin isomers 
is presented in Table 5.28 and 5.29 respectively.  The parameters presented are the mean 
of the individual pharmacokinetic parameters calculated from the individual plasma 
concentration-time profile. 
Table 5.30 represents the comparison of absolute bioavailability for the different 
silymarin isomers.   
It is interesting to note that, even though all the active components in silymarin 
are isomers and diastereomers there are significant differences observed between their 
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pharmacokinetic parameters.  Based on non compartmental analysis, diastereomer silybin 
B is found to have the longest elimination half life (~2.2 hours) compared to silybin A 
(~0.9 hour).  Silybin B also has the highest volume of distribution among all the isomers.  
Thus, previous and current studies, in vitro and in vivo which are conducted based on the 
measure of silybin as a single component, should not neglect the differences found 
between these major diastereomers of silymarin.  Similarly significant differences are 
also found between diastereomers isosilybin A and isosilybin B. 
The values of absolute bioavailability (F) for silycristin, silybin A and silybin B 
indicate dissolution limited absorption due to the very low solubility of the silymarin 
isomers.  This is evident from the decrease in the F values for the isomers with the 
increasing dose and significantly differing values of F obtained for Treatment A1, which 
is the lowest oral dose.  Thus considering the values of F obtained for Treatment A1, 
silycristin (FA1= 0.15) is the least bioavailable, followed silybin A (FA1=0.20) and then 
silybin B (FA1=0.62) being the most bioavailable.  Thus, considering the values of 
maximum oral bioavailability calculated from EH, the observations made in this study for 
Treatment A1 and from previous related studies about increasing F by modification of 
formulations, the overall bioavailability of silymarin isomers can be increased to give 
meaningful therapeutic levels.  
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Table 5.28:  Non-Compartmental Pharmacokinetic Parameters for Silymarin Isomers 
Treatment A 
Parameter Silycristin Silydianin Silybin A Silybin B Isosilybin A Isosilybin B
AUC0-t (µg-hr/ml) 5.45 ND ND 4.57 1.04 0.60 
AUC0-∞ (µg-hr/ml) 5.58 ND ND 7.17 1.17 1.03 
Clearance 
(ml/Kg-hr) 1351.81 ND ND 1314.30 1918.90 629.54 
Vd (ml/kg) 1726.07 ND ND 3837.18 3375.78 2128.87 
Vss (ml/kg) 566.53 ND ND 2469.51 1824.19 2688.90 
t1/2 (hr) 0.86 ND ND 2.30 1.32 2.80 
EH 0.26 ND ND 0.26 0.37 0.12 
Treatment B 
 Silycristin Silydianin Silybin A Silybin B Isosilybin A Isosilybin B
AUC0-t (µg-hr/ml) 13.66 ND 7.39 11.56 2.33 1.03 
AUC0-∞ (µg-hr/ml) 13.77 ND 7.93 14.08 2.51 1.29 
Clearance 
(ml/Kg-hr) 1062.14 ND 1279.19 1272.04 1780.37 1031.64 
Vd (ml/kg) 1007.75 ND 1561.42 3565.72 3011.19 1486.47 
Vss (ml/kg) 464.85 ND 602.03 2459.83 1294.44 984.10 
t1/2 (hr) 0.65 ND 0.87 2.27 1.28 1.06 
EH 0.18 ND 0.25 0.25 0.35 0.20 
Treatment C 
 Silycristin Silydianin Silybin A Silybin B Isosilybin A Isosilybin B
AUC0-t (µg-hr/ml) 29.04 ND 15.14 24.07 5.47 2.99 
AUC0-∞ (µg-hr/ml) 29.65 ND 15.36 26.48 5.77 3.24 
Clearance 
(ml/Kg-hr) 908.86 ND 1316.52 1381.00 1518.61 844.83 
Vd (ml/kg) 1134.76 ND 1768.92 4538.23 2780.47 1050.65 
Vss (ml/kg) 422.51 ND 484.38 1818.23 1100.04 422.05 
t1/2 (hr) 0.90 ND 0.95 2.24 1.27 0.95 
EH 0.18 ND 0.26 0.27 0.30 0.16 
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Table 5.29:  Two-Compartmental Pharmacokinetic Parameters for Silymarin Isomers 
Treatment A 
Parameter Silycristin Silydianin Silybin A Silybin B Isosilybin A Isosilybin B 
AUC0-∞ (µg-hr/ml) 6.49 ND ND 7.71 1.38 1.05 
Clearance (ml/Kg-hr) 1192.22 ND ND 1217.57 1671.09 624.74 
Vd (ml/kg) 1500.78 ND ND 3545.23 3253.49 2671.86 
Vss (ml/kg) 474.34 ND ND 2161.34 1775.52 2032.84 
t1/2 (hr) 0.86 ND ND 2.27 1.33 2.75 
A (mcg/mL) 55.36 ND ND 25.70 6.32 0.95 
Alfa (hr-1) 8.93 ND ND 7.38 6.40 3.96 
B (mcg/mL) 1.11 ND ND 1.20 0.34 0.30 
Beta (hr-1) 0.97 ND ND 0.42 0.70 0.33 
Treatment B 
 Silycristin Silydianin Silybin A Silybin B Isosilybin A Isosilybin B 
AUC0-∞ (µg-hr/ml) 13.98 ND 8.33 13.94 2.40 2.78 
Clearance (ml/Kg-hr) 1110.58 ND 1192.37 1275.31 1797.01 573.88 
Vd (ml/kg) 1058.22 ND 1473.66 3997.97 3112.39 984.15 
Vss (ml/kg) 470.68 ND 569.56 2365.02 1368.77 625.61 
t1/2 (hr) 0.65 ND 0.90 2.25 1.27 1.05 
A (mcg/mL) 69.92 ND 36.90 48.59 8.87 33.41 
Alfa (hr-1) 6.32 ND 5.84 6.02 5.83 11.42 
B (mcg/mL) 5.36 ND 1.31 2.06 0.51 0.52 
Beta (hr-1) 1.33 ND 0.88 0.55 0.71 0.72 
Treatment C 
 Silycristin Silydianin Silybin A Silybin B Isosilybin A Isosilybin B 
AUC0-∞ (µg-hr/ml) 28.71 ND 14.71 24.39 5.54 3.45 
Clearance (ml/Kg-hr) 1007.84 ND 1429.35 1553.70 1578.40 802.89 
Vd (ml/kg) 1308.42 ND 1849.47 5169.78 2900.06 979.25 
Vss (ml/kg) 559.25 ND 634.39 2212.85 1298.48 397.88 
t1/2 (hr) 0.93 ND 0.90 2.22 1.26 0.93 
A (mcg/mL) 106.25 ND 73.13 89.12 22.95 19.00 
Alfa (hr-1) 4.75 ND 5.63 5.14 5.70 7.45 
B (mcg/mL) 5.48 ND 2.47 3.63 1.33 0.92 
Beta (hr-1) 0.81 ND 0.94 0.59 0.73 0.84 
 279
































F 0.15 0.06 0.04 ND 0.20 0.12 0.03 0.62 0.09 0.03 ND 
 
5.3.13:  Selection of a Bioavailability and Bioequivalence Marker 
As discussed previously in Chapter II of this dissertation we set three main 
criteria that need to be fulfilled when selecting a bioavailability and bioequivalence 
marker for an herbal extract.  These criteria are: 
1.  The selected marker should have one of the least permeability among its active 
components in the extract. 
2.  The proportion of the selected marker in the extract should be sufficient for its 
precise and quantitative determination in biological fluids after oral administration (e.g. 
silycristin in Milk thistle, kawain in Kava) 
3.  The selected marker should be easily available as a reference standard, at a 
reasonable cost and acceptable purity for routine analysis.  
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Based on these criteria, and the inter parameter relationships observed between 
the in silico descriptors and the in vitro permeability, the following markers were selected 
for Kava, Ginkgo biloba and Milk thistle (Chapter II) 
I:  Kawain as a marker for Kava 
II:  Ginkgolide B as a marker for the ginkgo terpenes, and quercetin as a marker 
for the flavonol glycosides. 
III:  Silycristin as a marker for Milk thistle (silymarin). 
 
Milk thistle (silymarin) was selected as a representative extract for the verification 
of marker prediction and further experiments with regards to solubility, partition 
coefficient, in vitro dissolution and in vivo pharmacokinetic studies were conducted.  The 
presence of isomers and diastereomers in silymarin further presented a challenge in the 
analytical separation and quantitation of these components in chemical and biological 
matrices.  Further most previous related studies concerning silymarin were always done 
with a measure for silybin as a single component representing the extract, and not as 
separate diastereomers or even as separate isomers of silymarin.   
Silycristin was predicted as a bioavailability marker for Milk thistle (silymarin) 
based on its low permeability, low lipophilicity and a relatively high minimal cross-
sectional area.  Further, the proportion of silycristin in silymarin is high enough for its 
quantitation in biological fluids.  Based on the correlations between in silico descriptors 
and in vitro permeability, silydianin can also be selected as a marker for silymarin, but 
the proportion of silydianin in the extract is significantly low for its quantitation in 
biological matrices.  Thus, not selecting silydianin as a marker for silymarin proved to be 
true as no levels of silydianin were detected in plasma after intravenous and oral 
administration of any of the doses.  Hence, silydianin may be considered as a ‘false 
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positive’ during marker selection, leading to a wrong bioavailability/bioequivalence 
marker. 
Post oral administration, plasma levels were observed only for silycristin, silybin 
A and silybin B.  Table 5.28 shows the average absolute bioavailability for silycristin, 
silybin A and silybin B following three oral treatments of silymarin.  The value of F is 
seen to decrease for each isomer with the increasing dose, indicating dissolution limited 
absorption.  Based on the values of F for the lowest oral dose, silycristin is found to have 
the lowest bioavailability (F=0.15±0.1) followed by silybin A (F=0.20±0.04) followed by 
silybin B (F=0.62±0.08).  Thus, even though the value of F decreases with the increasing 
dose, based on the lowest oral dose administered, silycristin is found to have the least 
bioavailability among the detected isomers.  
Table 4.3 in Chapter IV of this dissertation, presents the Biopharmaceutic 
Classification of isomers of silymarin based on their experimental and calculated 
partition coefficient, experimentally determined solubility and its comparison to the 
partition coefficient values of metoprolol as a model reference drug.  Silymarin isomers 
having a CLogP and experimental LogP value less than that of Metoprolol were 
classified as low permeability drugs and vice versa.  Based on this classification, silybin 
A, silybin B, Isosilybin A and Isosilybin B were classified as High Permeability-Low 
Solubility (Class II drugs), silydianin was classified as a Low Permeability-Low 
Solubility (Class IV drug) and only silycristin due to its intermediate CLogP and 
experimental LogP shuffled between the High-Permeability-Low Solubility class and 
Low Permeability-Low Solubility class.  Thus, silycristin is a good choice for a 
bioavailability marker, as it can be safely assumed that it has a permeability nature which 
is intermediate between High Permeability and the Low Permeability Class.  Thus, being 
in a low permeability class like silydianin, during prediction, silycristin would pose as a 
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risk towards marker selection (posing as a false negative) for being so less permeable, 
that it would not be detected in biological fluids at all.  But its simultaneous placement 
into the Low Permeability and High Permeability class indicates that silycristin can be 
one of the least permeable compounds, having a low permeability than most of the other 
isomers but at the same time permeable enough to be detected in biological fluids as a 
representative marker for the Milk thistle extract.  
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CHAPTER 6:CONCLUSIONS 
Due to their rising popularity, herbal supplements have created a specific niche 
for themselves between the food and the drug industry.  Due to their categorization as 
dietary supplements, they lack scientific seriousness where as on the other hand they act 
like unregulated drugs with potential therapeutic effects.  Development of bioavailability 
marker compounds is necessary for the quality control and therapeutic efficacy of herbal 
supplements.  Solubility, partition coefficient and intestinal permeability are the 
fundamental factors that affect bioavailability of a drug after oral administration.  Though 
accurate quantitative predictions of human intestinal permeability or bioavailability are 
difficult, an effort has been made to get a qualitative idea about these parameters with the 
aid of in silico descriptors such as the polar surface area (PSA), minimal cross-sectional 
area (MCSA) and the predicted log of octanol-water partition coefficient (CLogP).  Eight 
herbal extracts comprising of 37 active components were selected for this investigation.  
Conclusions based on the various experiments conducted on some or all of these 37 
active components are listed below: 
 
1. The main objective of this dissertation was to select the least permeable 
compound as a performance and bioavailability marker, which is the most 
conservative approach to ensure the bioavailability of a herbal extract or 
supplement.  The estimation of in silico descriptors and their correlation with in 
vitro permeability enables the selection of a performance marker for establishing 
the bioavailability and bioequivalence of herbal extracts. 
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2. In silico descriptors like the MCSA, CLogP and polar surface area (PSA) 
were estimated for 37 active compounds in 8 herbal extract.  The MCSA gives an 
idea of the permeability of the compound based on its size and orientation, while 
permeating the lipid bilayer. The PSA and CLogP relate to the (size and polar 
nature) and the lipophilicity of the compound respectively all of which are direct 
predictors of permeability.  Hence, the use of in silico descriptors to predict the 
intestinal permeability of the compounds gives a certain directional focus in the 
selection of bioavailability/bioequivalence markers. 
3. In vitro permeability data for the compounds in each herbal extract was 
obtained using SimBioDAS®, an in vitro epithelial cell based assay developed by 
Kinetana Inc.  Permeability coefficients for two diastereomers, silybin A and 
silybin B present in Milk thistle were estimated using the CaCo-2 cell model 
where in silybin B (Peff = 2.62 x 10-6 cm/sec) was found to have a higher 
permeability than silybin A (Peff = 1.6 x 10-6 cm/sec). 
4. Plots (CLogP vs PSA and Peff vs PSA) indicate that the increase in the 
PSA leads to a decrease in the lipophilicity of the compounds indicating lower 
permeability values.  The MCSA (Peff vs MCSA) and the PSA (Peff vs PSA) 
combined, provide a good estimate towards the selection of the least permeable 
compound in selected herbal extracts, thus enabling us to differentiate between 
isomers and diastereomers.  The qualitative predictions are valid for compounds 
with molecular weight less than 500.  Based on conservative limits of CLogP (-
1.5 to +2.2), MCSA (100 Ǻ2 to 160 Ǻ2) and permeability (<5 x 10-6 cm/sec) a 
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rectangular box could be drawn containing an observed cluster of compounds that 
included the selected markers.  
5. Though intestinal permeability and bioavailability are two different 
processes, the extent of intestinal permeability is a primary predictor of the 
bioavailability of that compound.  Based on the inter parameter relationships 
between PSA, MCSA, CLogP and in vitro permeability the following markers 
were selected: 
• Kawain selected as a bioavailability marker for the active kava 
lactones in Kava extract. 
• In Ginkgo biloba, Ginkgolide B is selected as a bioavailability 
marker for the ginkgo terpenes and quercetin as a marker for the 
flavonol glycosides. 
• In Milk thistle silycristin is selected as a bioavailability marker for 
the silymarin isomers. 
Due to the presence of isomers and diastereomers as active components of Milk 
thistle (silymarin), lack of sufficient bioavailability data on the isomers in 
literature, Milk thistle (silymarin) was selected as a representative extract for 
further verification of the hypothesis through experimental techniques. 
6. A reproducible, sensitive and accurate, binary gradient reverse phase 
HPLC method was developed and validated for the complete separation and 
quantitative determination of silymarin isomers in chemical matrices and rat 
plasma (LOD: 0.02-0.03µg/mL; LOQ: 0.05-0.08µg/mL). 
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7. Solubility of the silymarin isomers was determined at pH 7.2.  All isomers 
were found to be practically insoluble with values of solubility <0.1 mg/mL.  
Silydianin (0.019 mg/mL) and silycristin (0.015 mg/mL) had relatively highest 
solubilies and isosilybin B (0.00045 mg/mL) had the lowest solubility among the 
isomers. 
8. Apparent octanol-water partition coefficient values indicated that all the 
isomers were moderately lipophilic with values between the range 1.05 to 2.19.  
The correlation coefficient (r2)obtained between the predicted CLogP and the 
apparent LogP was 0.835. 
9. Classification of the isomers based on the BCS (Biopharmaceutic 
Classification System) indicated that silybin A, silybin B, isosilybin A and 
isosilybin B were Class II (High Permeability-Low Solubility) compounds, 
silydianin was a Class IV (Low Permeability-Low Solubility) compound and 
silycristin was classified as an intermediate between Class II and Class IV 
10. Assay for content of isomers in three commercially available products 
having the same label claim indicated a high degree of variability between 
formulations.  Content of silybin A and silybin B in one commercial product 
(Company C) was more than twice when compared to the other two commercial 
products (Company A and Company B).  Such variation in isomer content for 
formulations with the same label claim is questionable and may arise due to many 
factors ranging from geographical location of the plant and the time of harvest, to 
the type and efficiency of the extraction method used obtain the standardized 
silymarin extract. 
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11. In vitro dissolution of one commercial product (Company A) for the 
release (%) of silybin A (32.09±1.18), silybin B (46.91±1.57)and silydianin 
(50.26±1.5) indicated incomplete dissolution of the dosage form.  Considering 
that the formulation did not have any solubility enhancers and wettability was not 
a limiting factor towards dissolution, these results are in agreement with the 
results obtained from the solubility experiments for silybin A, silybin B and 
silydianin, where silydianin was the most soluble isomer, followed by silybin B 
ad silybin A. 
The pharmacokinetics of silymarin isomers was studied in male Sprague Dawley 
rats after intravenous and oral administration.  Quantitative levels of silydianin could not 
be detected post intravenous or oral administration.  Intravenous plasma concentration 
time profiles for each detected isomer fit a two-compartment model.  The half lives for 
the silymarin isomers ranged from 0.8-2.27 hours, and the apparent volume of 
distribution was in the range from 1.55-4.55 L/Kg.  Following intravenous 
administration, the area under the plasma concentration-time curve was found to increase 
proportionally with the increasing dose for all the isomers (except isosilybin B) indicating 
dose proportionality (r2=0.99).  Post oral administration, plasma levels were detected only 
for silycristin, silybin A and silybin B with a high degree of variation.  Silycristin was 
found to have the lowest bioavailability among the three isomers, indicating solubility 
limited absorption.  Silybin A was found to be less bioavailable than silybin B indicating 
a significant difference between the two diastereomers. 
Thus, based on the most conservative approach that selection of the least 
bioavailable compound from the extract as a marker, will ensure the bioavailability of the 
rest of the extract, silycristin was selected as a bioavailability and bioequivalence marker.  
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Hence, bioavailability testing of silycristin will ensure the bioavailability of silybin A and 
silybin B, which are considered as the most active components of Milk thistle. 
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Appendix  
A1:  INDIVIDUAL PHARMACOKINETIC DATA FOR SILYCRISTIN 
Table 5.31:Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg Silymarin equivalent to 6.13 mg/Kg of 
Silycristin to Male Sprague Dawley Rats-Treatment A 
Time 
(Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
0 0 0 0 0 0 0 0 0 
0.25 4.13 7.64 4.83 7.65 3.12 3.33 5.12 2.05 
0.5 2.27 1.65 1.37 0.84 0.62 0.74 1.25 0.64 
0.75 0.58 0.73 0.42 0.33 0.28 0.51 0.47 0.17 
1 0.46 0.61 0.32 0.28 0.19 0.53 0.40 0.16 
2 0.22 0.08 0.08 0.11 0.06 0.27 0.14 0.09 
4 0.00 0.00 0.06 0.00 0.00 0.09 0.07 0.02 
Weight 
(Kg) 0.274 0.295 0.290 0.288 0.324 0.288 0.293 0.017 
 
Figure 5.28:  Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 25 mg/Kg Silymarin equivalent to 6.13 mg/Kg of 










Table 5.32:  Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 50 mg/Kg Silymarin equivalent to 12.26 mg/Kg of 
Silycristin to Male Sprague Dawley Rats-Treatment B 
Time 
(Hrs) 
Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7 Mean SD 
0 0 0 0 0 0 0 0 0 0 
0.25 25.98 16.34 17.80 22.06 8.07 15.26 5.44 15.85 7.24 
0.5 13.08 2.62 4.50 13.42 2.20 4.82 1.86 6.07 5.03 
0.75 4.13 1.28 1.42 1.10 0.87 4.13 1.04 2.00 1.47 
1 0.44 0.72 1.15 0.98 0.32 1.55 1.07 0.89 0.43 
2 0.29 0.16 0.33 0.18 0.06 1.80 0.97 0.54 0.63 
4 0 0 0.10 0 0 0.18 0.10 0.13 0.04 
6 0 0 0 0 0 0.07 0 0.07 0 
Weight 
(Kg) 0.29 0.31 0.29 0.30 0.31 0.30 0.30 0.30 0.01 
 
Figure 5.33:  Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 50 mg/Kg Silymarin equivalent to 12.26 mg/Kg of 











Table 5.33:Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 100 mg/Kg Silymarin equivalent to 24.52 mg/Kg of 
Silycristin to Male Sprague Dawley Rats-Treatment C  
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
0 0 0 0 0 0 0 0 0 
0.25 15.47 35.64 23.99 33.06 13.32 53.25 33.96 13.32 
0.5 3.23 9.61 9.89 17.72 7.65 25.22 13.52 7.65 
0.75 4.10 8.51 6.98 4.56 3.47 13.23 7.03 3.47 
1 2.39 6.06 1.74 5.88 1.83 6.06 3.95 1.83 
2 1.24 1.34 0.57 0.67 0.32 1.34 0.95 0.32 
4 0 0.41 0 0.07 0.16 0.41 0.28 0.16 
6 0 0.08 0 0 0 0.08 0.08 0 
Weight 
(Kg) 0.32 0.31 0.29 0.31 0.32 0.29 0.30 0.01 
 
Figure 5.30: Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 100 mg/Kg Silymarin equivalent to 24.52 mg/Kg of 









Table 5.34:  Pharmacokinetic Parameters for Silycristin (6.13 mg/Kg) equivalent to 
Silymarin (25 mg/Kg) after Intravenous Administration (Treatment A ) 
using Non-Compartmental and 2-Compartmental Analysis 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
AUC0-t 
(mcg-hr/ml) 
3.08 7.35 4.16 11.17 3.10 3.86 5.45 3.22 
AUC0-∞ 
(mcg-hr/ml) 
3.36 7.39 4.27 11.31 3.15 4.00 5.58 3.20 
Clearance 
(ml/Kg-hr) 
1823.25 829.26 1436.77 542.24 1946.45 1532.89 1351.81 555.76 
Vd 
(ml/kg) 
2363.73 459.40 2761.06 630.21 1562.36 2579.67 1726.07 1003.85
Vss 
(ml/kg) 
1131.03 157.21 622.51 64.79 386.78 1036.86 566.53 446.00 
t1/2 (hr) 0.90 0.38 1.33 0.81 0.56 1.17 0.86 0.36 
2-Compartmental Analysis 
AUCo-inf       
(mcg-hr/ml) 
3.49 9.74 3.97 11.40 3.41 6.90 6.49 3.45 
Clearance 
(ml/Kg-hr) 
1756.71 629.64 1543.19 537.64 1797.64 888.51 1192.22 573.68 
Vd 
(ml/kg) 
2196.01 346.71 2805.87 640.12 1382.82 1633.16 1500.78 926.35 
Vss (ml/kg) 1162.47 108.87 697.80 85.42 377.67 413.81 474.34 405.29 
t1/2 (hr) 0.87 0.38 1.26 0.83 0.53 1.27 0.86 0.37 
A (mcg/mL) 6.72 88.00 19.00 120.62 26.80 71.01 55.36 44.88 
Alfa (hr-1) 3.00 11.00 5.76 11.30 9.30 13.22 8.93 3.84 
B (mcg/mL) 1.00 3.15 0.37 0.61 0.69 0.83 1.11 1.02 
Beta (hr-1) 0.80 1.82 0.55 0.84 1.30 0.54 0.97 0.50 
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Table 5.35:Pharmacokinetic Parameters for Silycristin (12.26 mg/Kg) equivalent to 
Silymarin (50 mg/Kg) after Intravenous Administration (Treatment B ) 
using Non-Compartmental and 2-Compartmental Analysis 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7 Mean SD 
AUC0-t 
(mcg-hr/ml) 17.66 18.32 16.05 14.38 6.71 16.18 6.29 13.66 5.05 
AUC0-∞ 
(mcg-hr/ml) 17.80 18.42 16.18 14.50 6.75 16.30 6.43 13.77 5.06 
Clearance 
(ml/Kg-hr) 688.85 665.79 757.88 845.70 1817.22 752.30 1907.21 1062.14 550.17
Vd 
(ml/kg) 323.40 411.27 972.91 555.76 1045.14 1213.00 2532.73 1007.75 752.63
Vss 
(ml/kg) 190.86 88.90 222.55 254.96 345.75 528.08 1622.88 464.85 528.90
t1/2 (hr) 0.33 0.43 0.89 0.46 0.40 1.12 0.92 0.65 0.32 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 18.42 22.37 15.24 15.07 6.02 14.21 6.52 13.98 5.94 
Clearance 
(ml/Kg-hr) 671.60 593.92 780.60 755.78 1953.45 997.04 2021.68 1110.58 612.08
Vd 
(ml/kg) 302.52 336.34 1005.63 508.56 1132.05 1437.92 2684.56 1058.22 835.83
Vss 
(ml/kg) 243.08 80.68 266.97 343.34 487.79 553.56 1319.37 470.68 406.01
t1/2 (hr) 0.32 0.43 0.87 0.43 0.39 1.16 0.99 0.65 0.34 
A (mcg/mL) 32.99 222.00 84.00 33.00 28.80 58.27 30.40 69.92 70.05 
Alfa (hr-1) 3.71 11.15 6.59 2.61 5.80 6.00 8.40 6.32 2.85 
B (mcg/mL) 20.97 4.00 2.00 3.90 1.89 2.70 2.03 5.36 6.94 
Beta (hr-1) 2.20 1.63 0.80 1.60 1.80 0.60 0.70 1.33 0.63 
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Table 5.36: Pharmacokinetic Parameters for Silycristin (24.52 mg/Kg) equivalent to 
Silymarin (100 mg/Kg) after Intravenous Administration (Treatment C) 
using Non-Compartmental and 2-Compartmental Analysis 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
AUC0-t 
(mcg-hr/ml) 17.09 36.65 41.86 18.87 33.48 26.29 29.04 9.96 
AUC0-∞ 
(mcg-hr/ml) 19.03 36.74 42.59 19.38 33.83 26.34 29.65 9.64 
Clearance 
(ml/Kg-hr) 1288.92 667.37 575.78 1265.36 724.87 930.85 908.86 308.26
Vd (ml/kg) 2014.55 817.32 1098.14 1134.10 940.99 803.44 1134.76 452.43
Vss (ml/kg) 798.66 313.52 282.82 469.30 269.85 400.91 422.51 199.42
t1/2 (hr) 1.08 0.85 1.32 0.62 0.90 0.60 0.90 0.28 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 13.50 42.42 40.55 18.72 31.47 25.58 28.71 11.63 
Clearance 
(ml/Kg-hr) 1816.18 578.08 604.80 1310.30 779.17 958.53 1007.84 478.90
Vd (ml/kg) 2595.26 722.59 1099.69 1191.16 1443.03 798.78 1308.42 683.28
Vss (ml/kg) 1428.36 276.89 322.77 542.52 342.99 441.95 559.25 436.30
t1/2 (hr) 0.99 0.87 1.26 0.63 1.28 0.58 0.93 0.30 
A (mcg/mL) 35.00 262.48 107.00 58.00 119.00 56.00 106.25 83.07 
Alfa (hr-1) 4.95 9.15 3.07 4.20 4.34 2.80 4.75 2.30 
B (mcg/mL) 4.50 11.00 3.10 5.40 2.20 6.70 5.48 3.14 
Beta (hr-1) 0.70 0.80 0.55 1.10 0.54 1.20 0.81 0.28 
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Table 5.37:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 125 
mg/Kg Silymarin equivalent to 30.65 mg/Kg of Silycristin to Male Sprague 
Dawley Rats-Treatment A1 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
0 0 0 0 0 0 0 0 
0.25 0 0 0.52 0 0 0.52 0 
0.5 0 0.25 0.33 0 0 0.29 0.06 
0.75 0 0.37 0.12 0 0 0.24 0.17 
1 0.18 0.69 0.08 0 0 0.31 0.33 
2 0.29 0.83 0.08 0.33 0.31 0.37 0.28 
4 0.08 1.34 0 0.44 0.31 0.54 0.55 
6 0.47 0.55 0 0.65 0.39 0.52 0.11 
8 0.15 0.36 0 0.48 0.70 0.42 0.23 
12 0.11 0 0 0.39 0.38 0.29 0.16 
16 0 0 0 0.25 0.30 0.27 0.04 
Weight(Kg) 0.285 0.308 0.24 0.264 0.242 0.27 0.03 
 
 
Figure 5.31: Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
125 mg/Kg Silymarin equivalent to 30.65 mg/Kg of Silycristin to Male 
Sprague Dawley Rats-Treatment A1 
1 2 3 4 5
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Table 5.38:  Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
250 mg/Kg Silymarin equivalent to 61.30 mg/Kg of Silycristin to Male 
Sprague Dawley Rats-Treatment B1 
Time (Hrs) Rat 1 Rat 2 Rat 3 Mean SD 
0 0 0 0 0 0 
0.25 0.12 0 0.58 0.35 0.32 
0.5 0.15 0.13 0.43 0.21 0.15 
0.75 0 0.25 0.25 0.28 0.05 
1 0.10 0.23 0.00 0.14 0.08 
2 0.08 0.12 0.82 0.28 0.36 
4 0.35 0.09 1.14 0.43 0.48 
6 0.45 0 0.62 0.53 0.12 
8 0.29 0 0.49 0.30 0.19 
12 0.14 0 0.29 0.22 0.11 





Figure 5.32: Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
250 mg/Kg Silymarin equivalent to 61.30 mg/Kg of Silycristin to Male 
Sprague Dawley Rats-Treatment B1 
1 2 3 4
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Table 5.39: Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
500 mg/Kg Silymarin equivalent to 122.61 mg/Kg of Silycristin to Male 
Sprague Dawley Rats-Treatment C1 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Mean SD 
0 0 0 0 0 0 0 
0.25 0 0.59 0 0.43 0.51 0.11 
0.5 0 0.36 0.18 0.61 0.38 0.22 
0.75 0 0.44 0.25 0.41 0.37 0.10 
1 0.62 0.46 0.49 0.22 0.45 0.17 
2 0.66 0.37 0.45 0.11 0.40 0.23 
4 0.74 0.32 0.22 0 0.43 0.28 
6 1.78 0.86 0.12 0 0.92 0.83 
8 1.13 0.73 0 0 0.93 0.29 
12 0.34 0.41 0 0 0.38 0.05 




Figure 5.33:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
500 mg/Kg Silymarin equivalent to 122.61 mg/Kg of Silycristin to Male 
Sprague Dawley Rats-Treatment C1 
1 2 3 4
 303
 304
Table 5.40:Non Compartmental Pharmacokinetic Parameters for Silycristin (30.65 
mg/Kg) following Oral Administration of Silymarin (125 mg/Kg) Treatment 
A1 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC0-t 
(mcg-hr/ml) 
2.31 5.97 0.33 6.17 6.08 4.17 0.03 
AUC0-∞ 
(mcg-hr/ml) 
2.82 7.10 0.64 8.31 8.86 5.55 2.70 
Cmax 
(µg/mL) 
0.47 1.34 0.52 0.65 0.70 0.73 3.62 
Tmax (Hr) 6 4 0.25 6 8 4.85 0.35 
F 0.08 0.19 0.02 0.22 0.24 0.15 0.10 
Table 5.41: Non Compartmental Pharmacokinetic Parameters for Silycristin (61.30 
mg/Kg) following Oral Administration of Silymarin (250 mg/Kg) Treatment 
B1 
Parameter Rat 1 Rat 2 Rat 3 Mean SD 
AUC0-t 
(mcg-hr/ml) 
3.00 0.51 7.13 3.55 3.34 
AUC0-∞ 
(mcg-hr/ml) 
3.74 0.83 9.50 4.69 4.41 
Cmax (µg/mL) 0.45 0.25 1.14 0.61 0.47 
Tmax (Hr) 6.00 0.75 4.00 3.58 2.65 
F 0.05 0.01 0.13 0.06 0.06 
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Table 5.42:Non Compartmental Pharmacokinetic Parameters for Silycristin (122.61 
mg/Kg) following Oral Administration of Silymarin (500 mg/Kg) Treatment 
C1 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Mean SD 
AUC0-t 
(mcg-hr/ml) 
10.52 6.57 1.65 0.56 4.82 4.61 
AUC0-∞ 
(mcg-hr/ml) 
11.76 9.89 2.00 0.71 6.09 5.54 
Cmax (µg/mL) 1.78 0.86 0.49 0.61 0.94 0.58 
Tmax (Hr) 6.00 6.00 1.00 0.50 3.38 3.04 
F 0.08 0.07 0.01 0.005 0.04 0.04 
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A2:  INDIVIDUAL PHARMACOKINETIC DATA FOR SILYBIN A 
 
Table 5.43:Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 50 mg/Kg Silymarin equivalent to 9.45 mg/Kg of Silybin 
A to Male Sprague Dawley Rats-Treatment B 
 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
0 0 0 0 0 0 0 0 
0.25 9.23 8.09 14.95 7.68 6.53 9.29 3.30 
0.5 1.13 2.89 5.71 4.53 1.69 3.19 1.92 
0.75 0.64 0.56 0.49 2.18 0.53 0.88 0.73 
1 0.52 0.28 0.48 1.39 0.48 0.63 0.43 
2 0.12 0.11 0.17 0.86 0.12 0.28 0.33 
Weight 








Figure 5.34: Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 50 mg/Kg Silymarin equivalent to 9.45 mg/Kg of Silybin 
A to Male Sprague Dawley Rats-Treatment B  
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Table 5.44:Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 100 mg/Kg Silymarin equivalent to 18.90 mg/Kg of 
Silybin A to Male Sprague Dawley Rats-Treatment C 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
0 0 0 0 0 0 0 0 0 
0.25 15.39 12.17 24.90 11.84 17.66 21.20 17.19 5.15 
0.5 3.12 4.36 8.12 3.57 5.25 6.05 5.08 1.83 
0.75 1.10 3.98 4.33 1.77 1.35 1.33 2.31 1.45 
1 1.19 2.49 1.51 0.62 1.04 1.24 1.35 0.63 
2 0.75 0.38 0.70 0.17 0.21 0.19 0.40 0.26 
4 0.07 0.12 0.34 0 0.09 0 0.16 0.13 
6 0 0.07 0 0 0 0 0.07 0 
Weight (Kg) 0.315 0.308 0.286 0.312 0.317 0.29 0.305 0.013 
 
Figure 5.35:Plasma Concentrations (µg/mL) Time Profile after Intravenous Bolus 
Administration of 100 mg/Kg Silymarin equivalent to 18.90 mg/Kg of 










Table 5.45:Pharmacokinetic Parameters for Silybin A (9.45 mg/Kg) equivalent to 
Silymarin (50 mg/Kg) after Intravenous Administration (Treatment B) using 
Non-Compartmental and 2-Compartmental Analysis 
Non Compartmental Analysis 
Parameter Rat 1* Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC0-t (mcg-hr/ml) 12.57 5.94 10.56 6.52 5.70 7.39 2.28 
AUC0-∞ (mcg-hr/ml) 12.65 6.07 10.74 8.32 5.80 7.93 2.30 
Clearance (ml/Kg-hr) 747.39 1557.78 880.33 1136.73 1630.55 1279.19 355.20
Vd (ml/kg) 534.91 1767.20 948.12 2377.70 1323.74 1561.42 614.81
Vss (ml/kg) 89.39 427.02 226.06 1440.43 400.07 602.03 551.92
t1/2 (hr) 0.50 0.79 0.75 1.45 0.56 0.87 0.39 
2-Compartmental Analysis 
AUCo-inf (mcg-hr/ml) 26.57 8.22 10.46 8.96 5.70 8.33 1.99 
Clearance (ml/Kg-hr) 355.80 1150.39 904.06 1055.09 1659.93 1192.37 327.79
Vd (ml/kg) 260.92 1437.98 951.64 2228.10 1276.91 1473.66 542.12
Vss (ml/kg) 35.22 270.85 289.38 1288.63 429.37 569.56 484.58
t1/2 (hr) 0.51 0.87 0.73 1.46 0.53 0.90 0.40 
A (mcg/mL) 394.03 56.00 39.50 19.00 33.08 36.90 15.35 
Alfa (hr-1) 15.65 7.50 4.20 4.50 7.16 5.84 1.73 
B (mcg/mL) 1.90 0.60 1.00 2.24 1.40 1.31 0.70 
Beta (hr-1) 1.36 0.80 0.95 0.47 1.30 0.88 0.34 
* Rat 1 considered as an outlier, not included in the calculation of the Mean and SD.  
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Table 5.46:Pharmacokinetic Parameters for Silybin A (18.90 mg/Kg) equivalent to 
Silymarin (100 mg/Kg) after Intravenous Administration (Treatment C) 
using Non-Compartmental and 2-Compartmental Analysis 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
AUC0-t 
(mcg-hr/ml) 
16.31 11.80 21.21 9.67 14.54 17.3016 15.14 4.11 
AUC0-∞ 
(mcg-hr/ml) 
16.39 11.95 21.94 9.81 14.66 17.4216 15.36 4.28 
Clearance 
(ml/Kg-hr) 
1153.51 1582.00 861.82 1927.02 1289.44 1085.33 1316.52 382.28 
Vd 
(ml/kg) 
1299.89 3602.25 1820.98 1518.35 1704.10 667.926 1768.92 986.20 
Vss 
(ml/kg) 
367.17 971.04 480.95 484.41 377.51 225.208 484.38 256.59 




17.48 9.28 18.90 8.44 17.54 16.62 14.71 4.60 
Clearance 
(ml/Kg-hr) 
1081.71 2037.23 1000.20 2241.40 1077.99 1137.60 1429.35 555.43 
Vd 
(ml/kg) 
1201.91 4074.84 2000.42 1724.16 1426.31 669.18 1849.47 1181.71
Vss 
(ml/kg) 
309.99 1567.85 632.42 730.63 294.17 271.28 634.39 496.68 
t1/2 (hr) 0.77 1.39 1.39 0.53 0.92 0.41 0.90 0.42 
A (mcg/mL) 133.00 15.80 61.00 32.00 112.00 84.99 73.13 45.52 
Alfa (hr-1) 9.26 2.11 4.15 4.80 7.20 6.27 5.63 2.50 
B (mcg/mL) 2.80 0.90 2.10 2.30 1.50 5.20 2.47 1.49 
Beta (hr-1) 0.90 0.50 0.50 1.30 0.76 1.70 0.94 0.48 
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Table 5.47:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 125 
mg/Kg Silymarin equivalent to 23.63 mg/Kg of Silybin A to Male Sprague 
Dawley Rats-Treatment A1 
Time (Hrs) Rat 1 Rat 2 Rat 3 Mean SD 
0 0 0 0 0 0 
0.25 0 0.69 0.32 0.50 0.26 
0.5 0 0.48 0.48 0.48 0 
0.75 0 0.25 0.08 0.17 0.12 
1 0 0.24 0.14 0.19 0.07 
2 0.21 0.23 0.32 0.25 0.06 
4 0.14 0.20 0.30 0.21 0.08 
6 0.22 0.43 0.17 0.27 0.14 
8 0.15 0.16 0.18 0.16 0.02 
12 0.13 0 0 0.13 0 
Weight (Kg) 0.285 0.240 0.247 0.26 0.02 
 
Figure 5.36: Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
125 mg/Kg Silymarin equivalent to 23.63 mg/Kg of Silybin A to Male 





Table 5.48:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 250 
mg/Kg Silymarin equivalent to 47.27 mg/Kg of Silybin A to Male Sprague 
Dawley Rats-Treatment B1 
Time (Hrs) Rat 1 Rat 2 Mean SD 
0 0 0 0 0 
0.25 0.31 0 0.31 0 
0.5 0.14 0.22 0.18 0.06 
0.75 0 0.24 0.24 0 
1 0.28 0.16 0.22 0.08 
2 0.19 0.24 0.22 0.03 
4 0.48 0.19 0.34 0.20 
6 0.17 0.16 0.16 0.01 
8 0.13 0 0.13 0 




Figure 5.37:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
250 mg/Kg Silymarin equivalent to 47.27 mg/Kg of Silybin A to Male 




Table 5.49:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 500 
mg/Kg Silymarin equivalent to 94.54 mg/Kg of Silybin A to Male Sprague 
Dawley Rats-Treatment C1 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Mean SD 
0 0 0 0 0 0 0 
0.25 0.27 0.60 0.72 0.41 0.50 0.20 
0.5 0 0.37 0.60 0.22 0.39 0.19 
0.75 0.34 0.27 0.68 0.33 0.40 0.18 
1 0.18 0.31 0.35 0.18 0.25 0.09 
2 0.19 0.19 0.25 0.15 0.19 0.04 
4 0.14 0.17 0.15 0.63 0.27 0.24 
6 0.29 0 0 0.18 0.24 0.08 
8 0.13 0 0.20 0 0.17 0.05 
12 0.12 0 0 0 0.12 0 




Figure 5.38: Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
500 mg/Kg Silymarin equivalent to 94.54 mg/Kg of Silybin A to Male 
Sprague Dawley Rats-Treatment C1 
 1 2 3 4
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Table 5.50: Non Compartmental Pharmacokinetic Parameters for Silybin A (23.63 
mg/Kg) following Oral Administration of Silymarin (125 mg/Kg) Treatment 
A1 
Parameter Rat 1 Rat 2 Rat 3 Mean SD 
AUC0-t 
(mcg-hr/ml) 
1.76 2.26 1.91 1.98 0.26 
AUC0-∞ 
(mcg-hr/ml) 
3.55 4.80 3.40 3.92 0.77 
Cmax (µg/mL) 0.22 0.69 0.48 0.46 0.23 
Tmax (Hr) 6.00 0.25 0.50 2.25 3.25 
F 0.19 0.25 0.18 0.20 0.04 
 319
Table 5.51:  Non Compartmental Pharmacokinetic Parameters for Silybin A (47.27 
mg/Kg) following Oral Administration of Silymarin (250 mg/Kg) Treatment 
B1 
Parameter Rat 1 Rat 2 Mean SD 
AUC0-t 
(mcg-hr/ml) 
2.00 1.11 1.55 0.63 
AUC0-∞ 
(mcg-hr/ml) 
2.42 2.64 2.53 0.16 
Cmax (µg/mL) 0.48 0.24 0.36 0.17 
Tmax (Hr) 4.00 0.75 2.38 2.30 
F 0.11 0.12 0.12 0.01 
Table 5.52:  Non Compartmental Pharmacokinetic Parameters for Silybin A (94.54 
mg/Kg)following Oral Administration of Silymarin (500 mg/Kg) Treatment 
C1 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Mean SD 
AUC0-t 
(mcg-hr/ml) 
2.05 0.96 1.59 2.02 1.66 0.51 
AUC0-∞ 
(mcg-hr/ml) 
3.04 1.99 2.32 2.80 2.54 0.47 
Cmax (µg/mL) 0.34 0.60 0.72 0.63 0.57 0.16 
Tmax (Hr) 0.75 0.25 0.25 4.00 1.31 1.81 
F 0.04 0.03 0.03 0.04 0.03 0.01 
 320
A3:  INDIVIDUAL PHARMACOKINETIC DATA FOR SILYBIN B 
Table 5.53:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 25 mg/Kg Silymarin equivalent to 8.64 mg/Kg of Silybin 
B to Male Sprague Dawley Rats-Treatment 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
0 0 0 0 0 0 0 0 0 
0.25 6.98 5.90 4.40 3.77 3.84 2.84 4.62 1.53 
0.5 6.15 1.25 1.72 1.30 1.84 0.85 2.18 1.97 
0.75 0.91 0.47 1.23 0.74 1.30 0.57 0.87 0.34 
1 0.63 0.46 1.25 0.65 1.23 0.32 0.76 0.39 
2 0.39 0.17 1.00 0.45 1.02 0.21 0.54 0.38 
4 0 0 0 0 0 0.20 0.20 0 
Weight 
(Kg) 
0.274 0.295 0.344 0.29 0.324 0.288 0.303 0.026 
 
Figure 5.39: Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 25 mg/Kg Silymarin equivalent to 8.64 mg/Kg of Silybin 
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Table 5.54:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 50 mg/Kg Silymarin equivalent to 17.29 mg/Kg of 
Silybin B to Male Sprague Dawley Rats-Treatment 
Time 
(Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7 Rat 8 Mean SD 
0 0 0 0 0 0 0 0 0 0 0 
0.25 15.76 9.53 11.46 25.74 6.70 9.38 11.11 6.79 12.06 6.23 
0.5 5.91 2.49 3.82 8.97 2.67 6.13 2.06 2.65 4.34 2.44 
0.75 2.66 1.57 1.00 0.65 1.91 3.10 1.06 2.39 1.79 0.88 
1 0.50 1.37 0.77 0.92 1.86 1.91 0.57 1.86 1.22 0.60 
2 0.20 1.17 0.68 0.19 1.16 1.19 0.55 1.27 0.80 0.45 
4 0 1.02 0.53 0 1.05 0.20 0.07 1.04 0.65 0.45 
Weight 
(Kg) 0.293 0.305 0.293 0.295 0.307 0.304 0.304 0.284 0.298 0.008 
 
 
Figure 5.40:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 50 mg/Kg Silymarin equivalent to 17.29 mg/Kg of 





















Table 5.55:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 100 mg/Kg Silymarin equivalent to 34.58 mg/Kg of 
Silybin B to Male Sprague Dawley Rats-Treatment 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
0 0 0 0 0 0 0 0 0 
0.25 19.07 17.29 38.01 17.29 24.40 36.17 25.37 9.46 
0.5 5.12 5.28 15.94 6.42 6.02 8.81 7.93 4.14 
0.75 2.78 4.68 10.33 4.47 1.79 1.98 4.34 3.18 
1 1.88 2.48 4.31 2.51 1.38 2.09 2.44 1.01 
2 1.64 0.58 1.38 1.71 0.73 0.23 1.04 0.61 
4 1.10 0.33 0.80 1.04 0 0 0.82 0.35 
6 1.03 0.24 0 0 0 0 0.63 0.56 
8 0 0.13 0 0 0 0 0.13 0 
Weight (Kg) 0.32 0.31 0.29 0.31 0.32 0.29 0.30 0.01 
 
Figure 5.41: Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 100 mg/Kg Silymarin equivalent to 34.58 mg/Kg of 













Table 5.56:Pharmacokinetic Parameters for Silybin B (8.64 mg/Kg) after Intravenous 
Administration of Silymarin (25 mg/Kg) using Non-Compartmental and 2-
Compartmental Analysis-Treatment A 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6* Mean SD 
AUC0-t 
(mcg-hr/ml) 5.09 5.75 4.53 3.45 4.03 2.98 4.57 0.90 
AUC0-∞ 
(mcg-hr/ml) 5.92 5.94 10.12 4.64 9.24 4.34 7.17 2.37 
Clearance 
(ml/Kg-hr) 1461.86 1455.13 854.58 1864.36 935.56 1993.17 1314.30 418.02 
Vd (ml/kg) 3089.44 1665.37 4759.85 4878.96 4792.30 13747.83 3837.18 1425.20
Vss (ml/kg) 1375.62 410.14 3785.45 2764.57 4011.78 7735.68 2469.51 1552.01
t1/2 (hr) 1.46 0.79 3.86 1.81 3.55 4.78 2.30 1.34 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 7.34 6.13 10.84 4.85 9.42 3.78 7.71 2.43 
Clearance 
(ml/Kg-hr) 1178.02 1411.70 797.72 1782.31 918.12 2286.06 1217.57 395.01 
Vd 
(ml/kg) 2506.16 1604.21 4432.04 4570.01 4613.73 15247.53 3545.23 1398.71
Vss 
(ml/kg) 917.02 428.19 3296.96 2443.64 3720.91 9229.80 2161.34 1445.14
t1/2 (hr) 1.47 0.79 3.85 1.78 3.48 4.62 2.27 1.33 
A 
(mcg/mL) 34.00 42.40 23.10 16.80 12.20 6.80 25.70 12.41 
Alfa (hr-1) 6.80 8.46 8.14 7.03 6.49 4.40 7.38 0.86 
B 
(mcg/mL) 1.10 0.98 1.44 0.96 1.50 0.34 1.20 0.26 
Beta (hr-1) 0.47 0.88 0.18 0.39 0.20 0.15 0.42 0.28 
*Rat 6 considered as an outlier, not included in the calculation of the Mean 
and SD.  
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Table 5.57:Pharmacokinetic Parameters for Silybin B (17.29 mg/Kg) after Intravenous 
Administration of Silymarin (50 mg/Kg) using Non-Compartmental and 2-
Compartmental Analysis- Treatment B 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7 Rat 8 Mean SD 
AUC0-t     
(µg-hr/ml) 
11.75 11.58 10.40 18.74 8.87 9.63 12.30 9.24 11.56 3.16 
AUC0-∞     
(µg-hr/ml) 
11.97 16.34 13.66 18.91 14.40 9.89 12.40 15.05 14.08 2.79 
Clearance 
(ml/Kg-hr) 
1444.50 1058.16 1265.98 914.59 1200.99 1747.87 1394.87 1149.33 1272.04 257.71 
Vd 
(ml/kg) 
1573.22 1573.22 7742.07 803.39 6330.46 2284.49 1825.78 6393.09 3565.72 2759.90 
Vss   
(ml/kg) 
411.87 3296.29 3616.36 198.59 5106.01 1576.16 444.99 5028.36 2459.83 2062.75 
t1/2 (hr) 0.75 3.24 4.24 0.61 3.65 0.91 0.91 3.86 2.27 1.60 
2-Compartmental Analysis 
AUCo-inf   
(µg-hr/ml) 
11.19 16.37 13.15 17.97 14.72 10.55 13.35 14.25 13.94 2.48 
Clearance 
(ml/Kg-hr) 
1545.76 1056.35 1315.05 962.31 1174.72 1639.83 1295.12 1213.33 1275.31 229.24 
Vd 
(ml/kg) 
1680.21 5030.08 7735.62 801.92 6182.81 2129.84 1681.97 6741.30 3997.97 2719.64 
Vss 
(ml/kg) 
547.20 2653.93 3566.52 264.17 4570.69 1351.67 393.75 5572.19 2365.02 2046.21 
t1/2 (hr) 0.75 3.30 4.08 0.58 3.65 0.90 0.90 3.85 2.25 1.59 
A 
(mcg/mL) 
39.00 68.88 38.10 75.00 28.00 22.40 106.71 10.60 48.59 32.16 
Alfa (hr-1) 3.97 8.69 5.20 4.60 7.10 4.90 9.60 4.10 6.02 2.17 
B (µg/mL) 1.26 1.77 0.99 2.00 2.05 4.60 1.72 2.10 2.06 1.10 
Beta (hr-1) 0.92 0.21 0.17 1.20 0.19 0.77 0.77 0.18 0.55 0.41 
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Table 5.58:  Pharmacokinetic Parameters for Silybin B (34.58 mg/Kg) after Intravenous 
Administration of Silymarin (100 mg/Kg) using Non-Compartmental and 2-
Compartmental Analysis- Treatment C 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean SD 
AUC0-t 
(mcg-hr/ml) 22.48 17.57 32.97 18.03 21.63 31.72 24.07 6.71 
AUC0-∞ 
(mcg-hr/ml) 
28.64 18.15 35.93 21.64 22.67 31.84 26.48 6.78 
Clearance 
(ml/Kg-hr) 
1207.49 1906.07 962.53 1598.14 1525.56 1086.22 1381.00 356.61 
Vd (ml/kg) 7217.54 8127.38 3557.32 5559.95 2182.57 584.62 4538.23 2940.99
Vss   
(ml/kg) 
4101.12 2049.98 1049.19 2995.75 522.71 190.61 1818.23 1521.24
t1/2 (hr) 4.14 2.96 2.56 2.41 0.99 0.37 2.24 1.36 
2-Compartmental Analysis 
AUCo-inf 
(mcg-hr/ml) 28.03 13.46 32.41 19.83 21.88 30.72 24.39 7.27 
Clearance 
(ml/Kg-hr) 
1234.08 2570.07 1067.28 1743.78 1581.06 1125.93 1553.70 564.21 
Vd 
(ml/kg) 
7259.27 10951.84 3930.18 6013.40 2258.67 605.34 5169.78 3724.38
Vss 
(ml/kg) 
3743.29 3812.02 1326.57 3545.89 616.13 233.19 2212.85 1669.17
t1/2 (hr) 4.08 2.95 2.55 2.39 0.99 0.37 2.22 1.35 
A 
(mcg/mL) 
98.30 26.20 68.70 35.10 121.40 185.00 89.12 59.35 
Alfa (hr-1) 7.07 2.73 2.90 4.00 6.85 7.30 5.14 2.16 
B 
(mcg/mL) 
2.40 0.91 2.37 3.21 2.91 10.00 3.63 3.22 
Beta (hr-1) 0.17 0.23 0.27 0.29 0.70 1.86 0.59 0.65 
 329
Table 5.59:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 125 
mg/Kg Silymarin equivalent to 43.23 mg/Kg of Silybin B to Male Sprague 
Dawley Rats-Treatment A1 
Time (Hrs) Rat 1 Rat 2 Mean SD 
0 0 0 0 0 
0.25 0.19 0 0.19 0 
0.5 0.11 0 0.11 0 
0.75 0.17 0 0.17 0 
1 0.19 0 0.19 0 
2 0.46 0.13 0.30 0.23 
4 1.38 0.24 0.81 0.81 
6 0.25 0.19 0.22 0.04 
8 0.12 0.16 0.14 0.02 
12 0.11 0.14 0.12 0.02 




Figure 5.42: Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
125 mg/Kg Silymarin equivalent to 43.23 mg/Kg of Silybin B to Male 





Table 5.60:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 250 
mg/Kg Silymarin equivalent to 86.46 mg/Kg of Silybin B to Male Sprague 
Dawley Rats-Treatment B1  
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
0 0 0 0 0 0 0 0 
0.25 0 0.17 0.39 0 0.19 0.25 0.12 
0.5 0 0.07 0.36 0.22 0.11 0.19 0.13 
0.75 0 0 0.27 0.32 0.13 0.24 0.09 
1 0 0.11 0.11 0.33 0 0.18 0.12 
2 0.10 0.26 0.08 0.19 0.46 0.22 0.15 
4 0.14 1.24 0.33 0.12 0.71 0.51 0.47 
6 0.07 0.36 0.44 0.08 0.19 0.23 0.17 
8 0.20 0.10 0.15 0 0.14 0.15 0.04 
12 0.38 0 0 0 0.10 0.24 0.19 
16 0.16 0 0 0 0 0.16 0 





1 2 3 4 5
Figure 5.43:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
250 mg/Kg Silymarin equivalent to 86.46 mg/Kg of Silybin B to Male 
Sprague Dawley Rats-Treatment B1 
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Table 5.61:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 500 
mg/Kg Silymarin equivalent to 172.93 mg/Kg of Silybin B to Male Sprague 
Dawley Rats-Treatment C1  
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Mean SD 
0 0 0 0 0 0 0 
0.25 0.46 0.50 0.67 0.81 0.63 0.14 
0.5 0.19 0.77 0.52 0.19 0.49 0.30 
0.75 0.19 0.34 0.33 0.38 0.43 0.19 
1 0.22 0.15 0.15 0.21 0.21 0.07 
2 0.29 0 0.23 0 0.34 0.26 
4 0.48 0.07 0.12 1.98 0.80 0.84 
6 1.66 0 0.34 0.41 0.80 0.74 
8 0.65 0 0.28 0.35 0.43 0.19 
12 0.13 0 0.11 0 0.12 0.01 




Figure 5.44:Plasma Concentrations (µg/mL) Time Profile after Oral Administration of 
500 mg/Kg Silymarin equivalent to 172.93 mg/Kg of Silybin B to Male 
Sprague Dawley Rats-Treatment C1 
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Table 5.62:Non Compartmental Pharmacokinetic Parameters for Silybin B (43.23 
mg/Kg) following Oral Administration of Silymarin (125 mg/Kg) Treatment 
A1 
Parameter Rat 1 Rat 2 Mean SD 
AUC0-t 
(mcg-hr/ml) 
4.76 1.81 3.29 2.09 
AUC0-∞ 
(mcg-hr/ml) 
5.65 4.69 5.17 0.68 
Cmax (µg/mL) 1.38 0.24 0.81 0.81 
Tmax (Hr) 4.00 4.00 4.00 0.00 
F 0.67 0.56 0.62 0.08 
Table 5.63:Non Compartmental Pharmacokinetic Parameters for Silybin B (86.46 
mg/Kg) following Oral Administration of Silymarin (250 mg/Kg) Treatment 
B1 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC0-t 
(mcg-hr/ml) 
2.98 3.83 2.13 0.94 3.20 2.62 1.12 
AUC0-∞ 
(mcg-hr/ml) 
3.71 3.98 2.40 1.28 4.26 3.13 1.25 
Cmax (µg/mL) 0.38 1.24 0.44 0.33 0.71 0.62 0.38 
Tmax (Hr) 12.00 4.00 6.00 1.00 4.00 5.40 4.10 
F 0.11 0.11 0.07 0.04 0.12 0.09 0.04 
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Table 5.64:Non Compartmental Pharmacokinetic Parameters for Silybin B (172.93 
mg/Kg) following Oral Administration of Silymarin (500 mg/Kg) Treatment 
C1 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Mean SD 
AUC0-t 
(mcg-hr/ml) 
7.29 0.57 2.81 5.61 4.07 2.98 
AUC0-∞ 
(mcg-hr/ml) 
7.62 0.75 3.43 6.43 4.56 3.09 
Cmax (µg/mL) 1.66 0.77 0.67 1.98 1.27 0.65 
Tmax (Hr) 6.00 0.50 0.25 4.00 2.69 2.79 
F 0.06 0.01 0.03 0.05 0.03 0.02 
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A4:  INDIVIDUAL PHARMACOKINETIC DATA FOR ISOSILYBIN A 
Table 5.65:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 25 mg/Kg Silymarin equivalent to 2.05 mg/Kg of 
Isosilybin A to Male Sprague Dawley Rats-Treatment-Treatment A 
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
0 0 0 0 0 0 0 0 
0.25 1.10 1.64 3.81 0.79 0.96 1.66 1.24 
0.5 0.89 0.47 0.31 0.29 0.29 0.45 0.26 
0.75 0.19 0.28 0.17 0.17 0.32 0.23 0.07 
1 0.13 0.21 0.25 0.11 0.17 0.18 0.06 
2 0.06 0.07 0.06 0.06 0.12 0.07 0.03 
4 0 0 0 0 0.08 0.08 0 
Weight (Kg) 0.274 0.295 0.258 0.324 0.288 0.30 0.02 
 
Figure 5.45:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 25 mg/Kg Silymarin equivalent to 2.05 mg/Kg of 














Table 5.66:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 50 mg/Kg Silymarin equivalent to 4.11 mg/Kg of 
Isosilybin A to Male Sprague Dawley Rats-Treatment B  
Time 
(Hrs) 
Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7 Mean SD 
0 0 0 0 0 0 0 0 0 0 
0.25 3.72 2.98 2.43 3.38 1.52 2.41 1.77 2.60 0.81 
0.5 1.58 0.79 0.90 1.38 0.57 0.37 0.66 0.89 0.44 
0.75 0.33 0.46 0.50 0.18 0.35 0.36 0.41 0.37 0.10 
1 0.21 0.29 0.27 0.25 0.27 0.17 0.35 0.26 0.06 
2 0.12 0.11 0.15 0.07 0.06 0.10 0.08 0.10 0.03 
4 0.00 0.10 0.12 0.00 0.00 0.00 0.07 0.10 0.03 
Weight 
(Kg) 
0.293 0.305 0.293 0.295 0.307 0.304 0.284 0.30 0.008 
 
2 3 4 5 6 71 
Figure 5.46:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 50 mg/Kg Silymarin equivalent to 4.11 mg/Kg of 
Isosilybin A to Male Sprague Dawley Rats-Treatment B 
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Table 5.67:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 100 mg/Kg Silymarin equivalent to 8.22 mg/Kg of 
Isosilybin A to Male Sprague Dawley Rats-Treatment C  
Time (Hrs) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
0 0 0 0 0 0 0 0 
0.25 5.20 4.46 8.08 3.95 6.89 5.71 1.73 
0.5 1.18 1.60 2.81 1.46 1.31 1.67 0.65 
0.75 0.82 1.45 0.83 0.98 0.78 0.97 0.28 
1 0.43 0.92 0.55 0.51 0.51 0.59 0.19 
2 0.34 0.22 0.10 0.15 0.27 0.22 0.09 
4 0 0.18 0 0.09 0.16 0.14 0.04 
6 0 0.11 0 0 0 0.11 0.00 
Weight (Kg) 0.32 0.31 0.29 0.31 0.32 0.31 0.01 
 
Figure 5.47: Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 100 mg/Kg Silymarin equivalent to 8.22 mg/Kg of 
Isosilybin A to Male Sprague Dawley Rats-Treatment C 
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Table 5.68:  Pharmacokinetic Parameters for Isosilybin A (2.05 mg/Kg) following 
Intravenous Administration of Silymarin (25 mg/Kg) using Non-
Compartmental and 2-Compartmental Analysis- Treatment A 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3* Rat 4 Rat 5 Mean SD 
AUC0-t (mcg-hr/ml) 0.83 1.48 7.15 0.68 1.16 1.04 0.36 
AUC0-∞ (mcg-hr/ml) 0.89 1.54 7.21 0.78 1.49 1.17 0.40 
Clearance 
(ml/Kg-hr) 
2307.15 1334.14 284.74 2650.00 1384.29 1918.90 661.57 
Vd (ml/kg) 2563.08 1197.34 300.23 4168.34 5574.35 3375.78 1903.33 
Vss (ml/kg) 1443.78 520.55 28.77 2004.40 3328.04 1824.19 1174.48 
t1/2 (hr) 0.77 0.62 0.73 1.09 2.79 1.32 1.00 
2-Compartmental Analysis 
AUC0-∞ (mcg-hr/ml) 1.49 1.95 24.03 0.76 1.35 1.38 0.49 
Clearance 
(ml/Kg-hr) 
1380.02 1055.00 85.54 2722.04 1527.32 1671.09 727.89 
Vd (ml/kg) 1709.16 941.97 91.00 4253.19 6109.62 3253.49 2372.41 
Vss (ml/kg) 563.89 355.64 6.10 2200.47 3982.11 1775.52 1686.59 
t1/2 (hr) 0.86 0.62 0.74 1.08 2.77 1.33 0.98 
A (mcg/mL) 7.80 13.50 461.13 2.24 1.72 6.32 5.52 
Alfa (hr-1) 6.90 9.87 19.58 5.42 3.40 6.40 2.72 
B (mcg/mL) 0.29 0.65 0.45 0.22 0.21 0.34 0.21 
Beta (hr-1) 0.81 1.12 0.94 0.64 0.25 0.70 0.36 
* Rat 3 considered as an outlier, not included in the calculation of the Mean and SD. 
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Table 5.69:Pharmacokinetic Parameters for Isosilybin A (4.11 mg/Kg) following 
Intravenous Administration of Silymarin (50 mg/Kg) using Non-
Compartmental and 2-Compartmental Analysis-Treatment B 
Non-Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Rat 7 Mean SD 
AUC0-t      
(µg-hr/ml) 2.70 2.92 2.30 2.45 1.31 2.90 1.72 2.33 0.61 
AUC0-∞ 
(µg-hr/ml) 2.85 3.14 2.80 2.52 1.36 3.07 1.84 2.51 0.67 
Clearance 








(ml/kg) 641.06 1111.91 2901.24 543.88 1318.44 472.57 2071.97 1294.44
902.4
0 
t1/2 (hr) 0.92 1.58 2.84 0.71 0.51 1.19 1.23 1.28 0.77 
2-Compartmental Analysis 
AUCo-inf   
(µg-hr/ml) 2.88 3.21 2.62 2.49 1.68 2.01 1.90 2.40 0.56 
Clearance 








(ml/kg) 716.53 1060.40 3075.83 653.21 906.25 1200.58 1968.56 1368.77
870.6
9 
t1/2 (hr) 0.91 1.58 2.77 0.71 0.50 1.17 1.22 1.27 0.75 
A 
(mcg/mL) 8.80 15.70 6.10 8.22 9.38 7.70 6.20 8.87 3.25 
Alfa (hr-1) 4.00 7.23 4.30 4.10 9.80 5.20 6.15 5.83 2.12 
B 
(mcg/mL) 0.52 0.46 0.30 0.48 1.00 0.31 0.51 0.51 0.23 
Beta (hr-1) 0.76 0.44 0.25 0.98 1.38 0.59 0.57 0.71 0.37 
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Table 5.70:Pharmacokinetic Parameters for Isosilybin A (8.22 mg/Kg) after Intravenous 
Administration of Silymarin (100 mg/Kg) using Non-Compartmental and 2-
Compartmental Analysis- Treatment C 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
AUC0-t 
(mcg-hr/ml) 
5.10 4.81 6.23 3.57 7.64 5.47 1.54 
AUC0-∞ 
(mcg-hr/ml) 
5.69 5.06 6.29 3.75 8.05 5.77 1.59 
Clearance (ml/Kg-hr) 1444.72 1626.51 1307.98 2192.21 1021.61 1518.61 436.52 
Vd (ml/kg) 2517.25 3706.48 769.27 4225.23 2684.12 2780.47 1329.32
Vss (ml/kg) 871.69 1972.32 334.73 1660.49 660.98 1100.04 690.21 




6.49 5.21 6.16 3.36 6.50 5.54 1.33 
Clearance (ml/Kg-hr) 1266.33 1579.09 1335.94 2446.38 1264.25 1578.40 502.06 
Vd (ml/kg) 2183.88 3588.86 781.25 4704.64 3241.68 2900.06 1487.44
Vss (ml/kg) 685.47 2232.77 393.96 2176.53 1003.68 1298.48 855.09 
t1/2 (hr) 1.20 1.58 0.41 1.33 1.78 1.26 0.53 
A (mcg/mL) 44.11 8.34 24.50 7.60 30.20 22.95 15.43 
Alfa (hr-1) 9.28 3.74 5.56 3.60 6.31 5.70 2.32 
B (mcg/mL) 1.01 1.31 2.99 0.65 0.67 1.33 0.97 
Beta (hr-1) 0.58 0.44 1.71 0.52 0.39 0.73 0.55 
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A5:  INDIVIDUAL PHARMACOKINETIC DATA FOR ISOSILYBIN B 
Table 5.71:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 25 mg/Kg Silymarin equivalent to 0.64 mg/Kg of 
Isosilybin B to Male Sprague Dawley Rats-Treatment A  
Time (Hrs) Rat 1 Rat 2 Mean SD 
0 0 0 0 0 
0.25 0.78 0.45 0.62 0.24 
0.5 0.54 0.21 0.37 0.23 
0.75 0.15 0.07 0.11 0.06 
1 0.30 0.10 0.20 0.14 
2 0.18 0.08 0.13 0.07 




Figure 5.48:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 25 mg/Kg Silymarin equivalent to 0.64 mg/Kg of 




Table 5.72:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 50 mg/Kg Silymarin equivalent to 1.28 mg/Kg of 
Isosilybin B to Male Sprague Dawley Rats-Treatment B  
Time (Hrs) Rat 1 Rat 2 Mean SD 
0 0 0 0 0 
0.25 1.18 1.01 1.14 0.11 
0.5 0.67 0.31 0.47 0.18 
0.75 0.52 0.24 0.38 0.20 
1 0.23 0.19 0.17 0.08 
2 0.22 0.08 0.12 0.09 
Weight (Kg) 0.304 0.284 0.29 0.01 
 
Figure 5.49:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 50 mg/Kg Silymarin equivalent to 1.28 mg/Kg of 





Table 5.73:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 100 mg/Kg Silymarin equivalent to 2.56 mg/Kg of 
Isosilybin B to Male Sprague Dawley Rats-Treatment C  
Time (Hrs) Rat 1 Rat 2 Mean SD 
0 0 0 0 0 
0.25 3.70 2.82 3.26 0.62 
0.5 0.80 1.12 0.96 0.23 
0.75 0.43 0.77 0.60 0.25 
1 0.32 0.25 0.28 0.05 
2 0.21 0.14 0.17 0.05 
Weight (Kg) 0.315 0.312 0.31 0.00 
 
Figure 5.50:Plasma Concentrations (µg/mL) Time Profile after Intravenous 
Administration of 100 mg/Kg Silymarin equivalent to 2.56 mg/Kg of 




Table 5.74:Pharmacokinetic Parameters for Isosilybin B (0.640 mg/Kg) following 
Intravenous Administration of Silymarin (25 mg/Kg) using Non-
Compartmental and 2-Compartmental Analysis- Treatment A 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Mean SD 
AUC0-t (mcg-hr/ml) 0.79 0.41 0.60 0.27 
AUC0-∞ (mcg-hr/ml) 1.16 0.91 1.03 0.17 
Clearance (ml/Kg-hr) 554.45 704.63 629.54 106.20 
Vd (ml/kg) 963.81 3293.92 2128.87 1647.64 
Vss (ml/kg) 1134.78 4243.02 2688.90 2197.86 
t1/2 (hr) 1.42 4.17 2.80 1.95 
2-Compartmental Analysis 
AUC0-∞ (mcg-hr/ml) 1.23 0.88 1.05 0.24 
Clearance 
(ml/Kg-hr) 522.21 727.26 624.74 144.99 
Vd (ml/kg) 1065.74 4277.98 2671.86 2271.40 
Vss (ml/kg) 883.72 3181.96 2032.84 1625.10 
t1/2 (hr) 1.41 4.08 2.75 1.88 
A (mcg/mL) 0.79 1.11 0.95 0.23 
Alfa (hr-1) 3.19 4.74 3.96 1.10 
B (mcg/mL) 0.48 0.11 0.30 0.26 
Beta (hr-1) 0.49 0.17 0.33 0.23 
 353
Table 5.75:Pharmacokinetic Parameters for Isosilybin B (1.28 mg/Kg) following 
Intravenous Administration of Silymarin (50 mg/Kg) using Non-
Compartmental and 2-Compartmental Analysis- Treatment B 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Mean SD 
AUC0-t (mcg-hr/ml) 1.10 0.96 1.03 0.10 
AUC0-∞ (mcg-hr/ml) 1.53 1.05 1.29 0.34 
Clearance 
(ml/Kg-hr) 
837.00 1226.28 1031.64 275.26 
Vd (ml/kg) 1648.39 1324.55 1486.47 228.99 
Vss (ml/kg) 1268.12 700.09 984.10 401.66 
t1/2 (hr) 1.37 0.75 1.06 0.44 
2-Compartmental Analysis 
AUC0-∞ (mcg-hr/ml) 1.23 0.88 1.05 0.24 
Clearance 
(ml/Kg-hr) 
522.21 727.26 624.74 144.99 
Vd (ml/kg) 1065.74 4277.98 2671.86 2271.40 
Vss (ml/kg) 883.72 3181.96 2032.84 1625.10 
t1/2 (hr) 1.41 4.08 2.75 1.88 
A (mcg/mL) 0.79 1.11 0.95 0.23 
Alfa (hr-1) 3.19 4.74 3.96 1.10 
B (mcg/mL) 0.48 0.11 0.30 0.26 
Beta (hr-1) 0.49 0.17 0.33 0.23 
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Table 5.76:Pharmacokinetic Parameters for Isosilybin B (2.56 mg/Kg) following 
Intravenous Administration of Silymarin (100 mg/Kg) using Non-
Compartmental and 2-Compartmental Analysis- Treatment C 
Non Compartmental Analysis 
Parameter Rat 1 Rat 2 Mean SD 
AUC0-t (mcg-hr/ml) 3.68 2.30 2.99 0.98 
AUC0-∞ (mcg-hr/ml) 4.06 2.42 3.24 1.16 
Clearance 
(ml/Kg-hr) 631.24 1058.42 844.83 302.06 
Vd (ml/kg) 1167.83 933.47 1050.65 165.72 
Vss (ml/kg) 354.89 489.21 422.05 94.97 
t1/2 (hr) 1.28 0.61 0.95 0.47 
2-Compartmental Analysis 
AUC0-∞ (mcg-hr/ml) 4.39 2.51 3.45 1.33 
Clearance 
(ml/Kg-hr) 
584.39 1021.39 802.89 309.00 
Vd (ml/kg) 1062.54 895.97 979.25 117.78 
Vss (ml/kg) 309.43 486.33 397.88 125.09 
t1/2 (hr) 1.26 0.61 0.93 0.46 
A (mcg/mL) 29.50 8.50 19.00 14.85 
Alfa (hr-1) 8.90 6.00 7.45 2.05 
B (mcg/mL) 0.59 1.25 0.92 0.46 
Beta (hr-1) 0.55 1.14 0.84 0.42 
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